0001376339-16-000213.txt : 20161108 0001376339-16-000213.hdr.sgml : 20161108 20161108161458 ACCESSION NUMBER: 0001376339-16-000213 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 71 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161108 DATE AS OF CHANGE: 20161108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MIMEDX GROUP, INC. CENTRAL INDEX KEY: 0001376339 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 900300868 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35887 FILM NUMBER: 161981444 BUSINESS ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 BUSINESS PHONE: 678-384-6720 MAIL ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 FORMER COMPANY: FORMER CONFORMED NAME: Alynx, Co. DATE OF NAME CHANGE: 20060922 10-Q 1 mdxg-2016930x10xq.htm 10-Q Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended September 30, 2016
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____________________to______________________

Commission file number 001-35887

MIMEDX GROUP, INC.
(Exact name of registrant as specified in its charter)

Florida
 
26-2792552
(State or other jurisdiction of incorporation)
 
(I.R.S. Employer Identification Number)
1775 West Oak Commons Ct NE
Marietta, GA
 
30062
(Address of principal executive offices)
 
(Zip Code)

(770) 651-9100
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes x No ¨
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x     No ¨
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer x
Accelerated filer ¨
Non-accelerated filer ¨
(Do not check if a smaller reporting company)
Smaller reporting company ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ¨ No x
 
As of October 15, 2016, there were 109,514,557 shares of the registrant’s common stock outstanding.



Table of Contents
 
Part I     FINANCIAL INFORMATION
 
Item 1
Condensed Consolidated Financial Statements
 
 
Condensed Consolidated Balance Sheets (unaudited) September 30, 2016 and December 31, 2015

 
Condensed Consolidated Statements of Operations (unaudited) Three and Nine Months Ended September 30, 2016 and 2015

 
Condensed Consolidated Statements of Stockholders' Equity (unaudited) for Nine Months Ended September 30, 2016

 
Condensed Consolidated Statements of Cash Flows (unaudited) Nine Months Ended September 30, 2016 and 2015

 
Notes to the Unaudited Condensed Consolidated Financial Statements Three and Nine Months Ended September 30, 2016 and 2015
8

Item 2
Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 3
Quantitative and Qualitative Disclosures About Market Risk

Item 4
Controls and Procedures

Part II   OTHER INFORMATION
Item 1
Legal Proceedings

Item 1A
Risk Factors

Item 2
Unregistered Sales of Equity Securities and Use of Proceeds

Item 3
Defaults upon Senior Securities

Item 4
Mine Safety Disclosures

Item 5
Other Information

Item 6
Exhibits

Signatures
 


2


Forward-Looking Statements
 
This Form 10-Q and certain information incorporated herein by reference contain forward-looking statements and information within the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934.  This information includes assumptions made by, and information currently available to management, including statements regarding future economic performance and financial condition, liquidity and capital resources, acceptance of our products by the market, and management’s plans and objectives. In addition, certain statements included in this and our future filings with the Securities and Exchange Commission (“SEC”), in press releases, and in oral and written statements made by us or with our approval, which are not statements of historical fact, are forward-looking statements. Words such as “may,” “could,” “should,” “would,” “believe,” “expect,” “expectation,” “anticipate,” “estimate,” “intend,” “seeks,” “plan,” “project,” “continue,” “predict,” “will,” “should,” and other words or expressions of similar meaning are intended by us to identify forward-looking statements, although not all forward-looking statements contain these identifying words.  These forward-looking statements are found at various places throughout this report and in the documents incorporated herein by reference.  These statements are based on our current expectations about future events or results and information that is currently available to us, involve assumptions, risks, and uncertainties, and speak only as of the date on which such statements are made.
Our actual results may differ materially from those expressed or implied in these forward-looking statements.  Factors that may cause such a difference include, but are not limited to, those discussed in Part II, Item 1A, “Risk Factors,” below and in our most recent Annual Report on Form 10-K, as well as other reports we file with the SEC.  Except as expressly required by the federal securities laws, we undertake no obligation to update any such factors, or to publicly announce the results of, or changes to any of the forward-looking statements contained herein to reflect future events, developments, changed circumstances, or for any other reason.
As used herein, the terms “MiMedx,” “the Company,” “we,” “our” and “us” refer to MiMedx Group, Inc., a Florida corporation, and its consolidated subsidiaries as a combined entity, except where it is clear that the terms mean only MiMedx Group, Inc.



3



Part I - FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements


MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
 
September 30, 2016
(unaudited)
 
December 31, 2015
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
18,338

 
$
28,486

Short term investments
—

 
3,000

Accounts receivable, net
63,427

 
53,755

Inventory, net
18,313

 
7,460

Prepaid expenses and other current assets
6,212

 
3,609

Total current assets
106,290

 
96,310

Property and equipment, net of accumulated depreciation
13,757

 
9,475

Goodwill
26,951

 
4,040

Intangible assets, net of accumulated amortization
27,249

 
10,763

Deferred tax asset, net
7,019

 
14,838

Deferred financing costs and other assets
399

 
487

Total assets
$
181,665

 
$
135,913

LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
11,162

 
$
6,633

Accrued compensation
10,812

 
15,034

Accrued expenses
6,664

 
4,644

Current portion of earn out liability
9,642

 
—

Other current liabilities
3,298

 
466

Total current liabilities
41,578

 
26,777

Earn out liability
15,978

 
—

Other liabilities
832

 
1,148

Total liabilities
58,388

 
27,925

Commitments and contingencies (Note 14)


 


Stockholders' equity:
 
 
 
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding
—

 
—

Common stock; $.001 par value; 150,000,000 shares authorized;
110,212,547 issued and 109,512,781 outstanding at September 30, 2016 and 109,467,416 issued and 107,361,471 outstanding at December 31, 2015
110

 
109

Additional paid-in capital
159,940

 
163,133

Treasury stock at cost:
699,766 shares at September 30, 2016 and 2,105,945 shares at December 31, 2015
(5,136
)
 
(17,124
)
Accumulated deficit
(31,637
)
 
(38,130
)
Total stockholders' equity
123,277

 
107,988

Total liabilities and stockholders' equity
$
181,665

 
$
135,913

See notes to condensed consolidated financial statements

4


MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(unaudited)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015

 
 
 
 
 
 
 
Net sales
$
64,429

 
$
49,015

 
$
175,139

 
$
135,461

Cost of sales
7,997

 
4,979

 
23,338

 
15,217

Gross margin
56,432

 
44,036

 
151,801

 
120,244

 
 
 
 
 
 
 
 
Operating expenses:
 
 
 
 
 
 
 
Research and development expenses
2,919

 
2,187

 
8,582

 
6,072

Selling, general and administrative expenses
48,179

 
34,901

 
131,599

 
96,860

Amortization of intangible assets
631

 
234

 
1,889

 
699

Operating income
4,703

 
6,714

 
9,731

 
16,613

 
 
 
 
 
 
 
 
Other income (expense), net
 
 
 
 
 
 
 
Interest income (expense), net
(87
)
 
(5
)
 
(254
)
 
(18
)
 
 
 
 
 
 
 
 
Income before income tax provision
4,616

 
6,709

 
9,477

 
16,595

Income tax provision
(1,295
)
 
(158
)
 
(2,984
)
 
(527
)
 
 
 
 
 
 
 
 
Net income
$
3,321

 
$
6,551

 
$
6,493

 
$
16,068

 
 
 
 
 
 
 
 
Net income per common share - basic
$
0.03

 
$
0.06

 
$
0.06

 
$
0.15

 
 
 
 
 
 
 
 
Net income per common share - diluted
$
0.03

 
$
0.06

 
$
0.06

 
$
0.14

 
 
 
 
 
 
 
 
Weighted average shares outstanding - basic
105,991,990

 
106,511,294

 
105,927,890

 
106,178,136

 
 
 
 
 
 
 
 
Weighted average shares outstanding - diluted
112,361,179

 
114,556,036

 
112,193,701

 
114,110,120

See notes to condensed consolidated financial statements

5



MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(in thousands, except share data)
(unaudited)



 
 
Common Stock Issued

Treasury Stock
 
 
 
 
Shares
Amount
Additional Paid - in Capital
Shares
Amount
Accumulated Deficit
Total
Balance December 31, 2015
 
109,467,416

$
109

$
163,133

2,105,945

$
(17,124
)
$
(38,130
)
$
107,988

Share-based compensation expense
 
—

—

13,826

—

—

—

13,826

Exercise of stock options
 
243,928

—

(2,957
)
(682,082
)
5,505

—

2,548

Issuance of restricted stock
 
501,203

1

(14,676
)
(1,825,329
)
14,675

—

—

Restricted stock shares cancelled/forfeited
 
—

—

1,070

137,575

(1,070
)
—

—

Shares issued for services performed
 

—

6

(43,344
)
340

—

346

Stock repurchase
 
—

—

—

1,338,616

(10,378
)
—

(10,378
)
Shares repurchased for tax withholding
 
—

—

—

109,394

(892
)
 
(892
)
Shares issued in conjunction with acquisition
 
—

—

(462
)
(441,009
)
3,808

 
3,346

Net income
 
—

—

—

—

—

6,493

6,493

Balance September 30, 2016
 
110,212,547

$
110

$
159,940

699,766

$
(5,136
)
$
(31,637
)
$
123,277


See notes to condensed consolidated financial statements

6


MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
 
Nine Months Ended September 30,
 
2016
 
2015
Cash flows from operating activities:
 
 
 
Net income
$
6,493

 
$
16,068

Adjustments to reconcile net income to net cash from operating activities:
 
 
 
Depreciation
2,394

 
1,247

Amortization of intangible assets
1,889

 
699

Amortization of inventory fair value step-up
1,471

 
—

Amortization of deferred financing costs
136

 
—

Share-based compensation
13,826

 
12,564

Increase (decrease) in cash, net of effects of acquisition, resulting from changes in:
 
 
 
  Accounts receivable
(7,671
)
 
(20,106
)
  Inventory
(3,599
)
 
(520
)
  Prepaid expenses and other current assets
(2,023
)
 
(1,201
)
  Other assets
(163
)
 
(26
)
  Accounts payable
(3,941
)
 
3,747

  Accrued compensation
(4,223
)
 
1,474

  Accrued expenses
2,020

 
1,592

  Other liabilities
2,539

 
(1,087
)
Net cash flows from operating activities
9,148

 
14,451

 
 
 
 
Cash flows from investing activities:
 
 
 
 Purchases of equipment
(5,301
)
 
(4,176
)
 Purchase of Stability Inc., net of cash acquired
(7,631
)
 
—

 Fixed maturity securities redemption
3,000

 
2,500

 Patent application costs
(515
)
 
(594
)
Net cash flows from investing activities
(10,447
)
 
(2,270
)
 
 
 
 
Cash flows from financing activities:
 
 
 
 Proceeds from exercise of stock options
2,548

 
3,465

 Stock repurchase under repurchase plan
(10,378
)
 
(21,068
)
 Stock repurchase for tax withholdings on vesting of restricted stock
(892
)
 
—

 Deferred financing costs
(106
)
 
—

 Payments under capital lease obligations
(21
)
 
(87
)
Net cash flows from financing activities
(8,849
)
 
(17,690
)
 
 
 
 
Net change in cash
(10,148
)
 
(5,509
)
 
 
 
 
Cash and cash equivalents, beginning of period
28,486

 
46,582

Cash and cash equivalents, end of period
$
18,338

 
$
41,073

See notes to condensed consolidated financial statements

7


MIMEDX GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2016 AND 2015
1.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASU’’) to the FASB’s Accounting Standards Codification (“ASC”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the nine months ended September 30, 2016 and 2015, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at December 31, 2015, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. 
You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2015, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on February 29, 2016. 
The Company operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The MiMedx allograft product families include our: dHACM family with AmnioFix®, EpiFix® and EpiBurn® brands; Amniotic Fluid family with OrthoFlo brand; Umbilical family with EpiCord™ and AmnioCord™ brands; Placental Collagen family with CollaFix™ and AmnioFill™ brands; Bone family with Physio® brand; and Skin family with AlloBurn™ brand. AmnioFix,  EpiFix, and EpiBurn are our tissue technologies processed from human amniotic membrane; OrthoFlo is an amniotic fluid derived allograft;  EpiCord™ and AmnioCord™ are derived from the umbilical cord; Physio is a bone grafting material comprised of 100% bone tissue with no added carrier; AlloBurn is a skin product derived from human skin designed for the treatment of burns; and CollaFix, our next brand we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair. 
2.
Significant Accounting Policies
Please see Note 2 to the Company's Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2015, for a description of all significant accounting policies. 
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. 
Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay. 
Inventories
Inventory is valued at the lower of cost or market value. The Company assesses the valuation of its inventory on a periodic basis and makes adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for the Company's excess inventory charge. The Company's excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory. The value of inventory as of September 30, 2016 includes a fair value step - up connected with the January 2016 acquisition of Stability Inc. of approximately $600,000, which is comprised of approximately $2.1 million as of the date of the acquisition less amortization of approximately $1.5 million during the nine months ended September 30, 2016. Please see Note 4 contained herein.

8




Revenue Recognition
The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all other revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals, clinics and doctor's offices. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.  
Acquisitions
Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.

Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of an earn out based on sales less direct production costs, and are valued using discounted cash flow techniques. The fair value of these payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.
Patent Costs
The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company and are included in Intangible Assets in the Condensed Consolidated Balance Sheets. The Company capitalized approximately $515,000 of patent costs during the first nine months of 2016. The Company capitalized approximately $594,000 of patent costs during the first nine months of 2015.
Treasury Stock
The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a first - in first - out (FIFO) basis.
Recent Accounting Pronouncements 
The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued, both effective and
not yet effective. In May 2014, the FASB issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with
Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when
companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting
periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company
is currently assessing the impact the adoption of ASU 2014-09 will have on our condensed consolidated financial statements.

In November 2015, the FASB issued ASU No. 2015-17, "Balance Sheet Classification of Deferred Taxes". ASU 2015-17
simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the
balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016,
and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption
is permitted. The Company adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify
reporting with the release of the valuation allowance as disclosed in Note 12. Prior periods were not retrospectively adjusted.

In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)". The core principle of Topic 842 is that a lessee
should recognize the assets and liabilities that arise from both capital and operating leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.

9



In March 2016, the FASB issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718)". The standard is
intended to simplify several areas of accounting for share - based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. This ASU is effective for fiscal years beginning after December 15, 2016. The Company is currently assessing the impact the adoption of ASU 2016-09 will have on its consolidated financial statements.

In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments”. The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company is currently assessing the impact of the adoption of ASU 2016-15 will have on its consolidated financial statements.
All other ASUs issued and not yet effective for the nine months ended September 30, 2016, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.

3.
Liquidity and Management’s Plans
As of September 30, 2016, the Company had approximately $18,338,000 of cash and cash equivalents.  The Company reported total current assets of approximately $106,290,000 and current liabilities of approximately $41,578,000 as of September 30, 2016.  The Company believes that its anticipated cash from operating and financing activities, existing cash and cash equivalents, and availability under its line of credit will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next year.

4. Acquisition of Stability Inc.

On January 13, 2016, the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics ("Stability"), a provider of human tissue products to surgeons, facilities, and distributors serving the surgical, spine, and orthopedic sectors of the healthcare
industry. As a result of this transaction, the Company acquired all of the outstanding shares of Stability in exchange for
$6,000,000 cash, $3,346,000 in stock, represented by 441,009 shares of our common stock, and assumed debt of $1,771,000. Additional one time costs incurred in connection with the transaction totaled $1,088,000 and are included within selling, general and administrative expenses on the condensed consolidated statements of operations. Contingent consideration may be payable in a formula determined by sales less certain expenses for the years 2016 and 2017. As of September 30, 2016, the contingent consideration was valued at $25,620,000 and is shown in the schedule below as fair value of earn-out. The Company used a third party specialist to assist us with the valuation. The contingent consideration was classified as a liability.

The Company has evaluated the contingent consideration for accounting purposes under GAAP and has determined that the
contingent consideration is within the scope of ASC 480 "Distinguishing Liabilities from Equity" whereby a financial instrument,
other than an outstanding share, that embodies a conditional obligation that the issuer may settle by issuing a variable number
of its equity shares shall be classified as a liability if, at inception, the monetary value of the obligation is based solely or
predominantly on variations in something other than the fair value of the issuer’s equity shares.

The actual purchase price was based on cash paid, the fair value of our stock on the date of the acquisition, and direct costs
associated with the combination. The actual purchase price has been preliminarily allocated as of September 30, 2016 (in
thousands) and is subject to change:


10


Cash paid at closing
 
$
6,000

Working capital adjustment
 
(480
)
Common stock issued (441,009 shares valued at $9.07 per share)
 
3,346

Assumed debt
 
1,771

Fair value of earn-out
 
25,620

Total fair value of purchase price
 
$
36,257

 
 
 
Net assets acquired:
 

Debt-free working capital
 
$
2,179

Other assets, net
 
199

Property, plant and equipment
 
1,375

Deferred tax liability
 
(8,268
)
Subtotal
 
(4,515
)
Intangible assets:
 
 
Customer relationships
 
6,090

Patents and know-how
 
9,170

Trade names and trademarks
 
830

Non compete agreements
 
1,080

Licenses and permits
 
690

Subtotal
 
17,860

Goodwill
 
22,912

Total Assets Purchased
 
$
36,257

 
 
 
Working capital and other assets were composed of the following (in thousands):
 
 
Working capital
 
 
Cash
 
$
140

Prepaid Expenses and other current assets
 
100

Accounts receivable
 
2,001

Federal and state taxes receivable
 
28

Inventory
 
8,725

Accounts payable and accrued expenses
 
(8,815
)
Debt-free working capital
 
$
2,179

 
 
 
Current portion of long term debt
 
$
(194
)
Long-term debt
 
(560
)
Line of Credit
 
(932
)
Shareholder loan
 
(85
)
Net working capital
 
$
408

 
 

Other assets:
 
 
Other long term assets
 
$
199


The acquisition was accounted for as a purchase business combination as defined by FASB Topic 805 - "Business Combinations". The fair value of the contingent consideration is measured as a Level 3 instrument. The contingent consideration liability is recorded at fair value on the acquisition date and will be remeasured quarterly until purchase accounting is completed based on the assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measured is based on significant inputs that are not observable in the market, they are categorized as

11


Level 3. The income valuation approach was applied in determining the fair value of the contingent consideration using a discounted cash flow valuation technique with significant unobservable inputs comprised of projected sales and certain expenses. The values assigned to intangible assets are subject to amortization. The intangible assets were assigned the following lives for amortization purposes:

 
 
Estimated useful life (in years)
Intangible asset:
 
 
Customer relationships
 
12
Patents and know-how
 
20
Trade name and Trademarks
 
Indefinite
Non compete agreements
 
4
Licenses and permits
 
2

Goodwill consists of the excess of the purchase price paid over the identifiable net assets and liabilities acquired at fair value.
Goodwill was determined using the residual method based on an independent appraisal of the assets and liabilities acquired in
the transaction and is preliminary as of September 30, 2016 and is subject to change. Goodwill is tested for impairment on an annual basis as defined by FASB Topic 350 - "Intangibles - Goodwill and Other".

The following unaudited pro forma summary financial information presents the consolidated results of operations for the Company as if the acquisition had occurred on January 1, 2015. The pro forma results are shown for illustrative purposes only and do not purport to be indicative of the results that would have been reported if the acquisition had occurred on the date indicated or indicative of the results that may occur in the future.

Unaudited pro forma information for the three and nine months ended September 30, 2016 and 2015 (in thousands) is as follows:

 
 
Three months ended September 30,
 
Nine Months Ended September 30,
 
 
2016
2015
 
2016
2015
Revenue
 
$
64,429

$
52,108

 
$
175,687

$
148,521

 
 
 
 
 
 
 
Net income
 
$
3,406

$
4,253

 
$
7,074

$
12,227

 
 
 
 
 
 
 
Income per share, fully diluted
 
$
0.03

$
0.04

 
$
0.06

$
0.11


The 2016 supplemental pro forma earnings were adjusted to exclude $1,088,000 of acquisition-related legal, audit and other
costs, net of tax. The 2015 supplemental pro forma earnings were adjusted to include $1,186,000 of amortization costs related to recorded intangible assets with defined useful lives, and $1,471,000 of inventory step-up charges as a result of the acquisition for comparability to 2016. The number of shares outstanding used in calculating the income per share for 2015 was adjusted to include 441,009 shares issued as part of the purchase price and assumed to be issued on January 1, 2015.


5. Short Term Investments
Short term investments consisted of approximately $3,000,000 of FDIC insured certificates of deposit held with various financial institutions as of December 31, 2015. The cost of these instruments approximated their fair market value at December 31, 2015.

6. Inventories
Inventories consisted of the following items as of September 30, 2016, and December 31, 2015 (in thousands):

12


 
September 30, 2016
 
December 31, 2015
Raw materials
$
1,193

 
$
602

Work in process
6,710

 
3,850

Finished goods
11,118

 
3,405

 Inventory, gross
19,021

 
7,857

Reserve for obsolescence
(708
)
 
(397
)
 Inventory, net
$
18,313

 
$
7,460


7.
Property and Equipment 
Property and equipment consisted of the following as of September 30, 2016, and December 31, 2015 (in thousands):
 
September 30,
2016
 
December 31,
2015
Leasehold improvements
$
3,259

 
$
2,684

Lab and clean room equipment
7,971

 
4,564

Furniture and office equipment
6,271

 
4,577

Construction in progress
3,629

 
2,629

   Property and equipment, gross
21,130

 
14,454

Less accumulated depreciation
(7,373
)
 
(4,979
)
   Property and equipment, net
$
13,757

 
$
9,475

Included in net property and equipment is approximately $427,000 of equipment covered under capital leases. The corresponding liability of approximately $41,000 is included in other liabilities in the accompanying Condensed Consolidated Balance Sheets. Interest rates for these leases range from approximately 3% to 12% with maturity dates to January 2018.
Also included in net property and equipment is approximately $1.0 million in leasehold improvements paid for by the landlord of the Company's main facility with a corresponding liability included in other liabilities which is amortized over the term of the lease.
Depreciation expense for the nine months ended September 30, 2016 and 2015, was approximately $2,394,000 and $1,247,000, respectively, and approximately $838,000 and $470,000 for the three months ended September 30, 2016 and 2015, respectively.

8.
Intangible Assets and Royalty Agreement
Intangible assets are summarized as follows (in thousands):
 
Weighted
Average
Amortization
Lives
 
September 30, 2016
 
December 31, 2015
 
 
 
Cost
 
Cost
Licenses (a) (b) (c) (d)
7 years
 
$
1,699

 
$
1,009

Patents & Know How (b) (d)
19 years
 
17,211

 
8,001

Customer & Supplier Relationships (b) (d)
13 years
 
9,851

 
3,761

Tradenames & Trademarks (b) (d)
indefinite
 
1,838

 
1,008

Non-compete agreements (d)
4 years
 
1,080

 
—

In Process Research & Development (b)
n/a
 
25

 
25

Patents in Process (c)
n/a
 
2,298

 
1,823

Total
 
 
34,002

 
15,627

Less Accumulated amortization and impairment charges
 
 
(6,753
)
 
(4,864
)
Net
 
 
$
27,249

 
$
10,763


13


(a)
On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000.  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license.
(b)
On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Tradenames & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the nine months ended September 30, 2016, approximately $40,000 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization.
(c)
Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
(d)
On January 13, 2016, the Company acquired Stability. As a result, the Company recorded intangible assets for Patents & Know - How of $9,170,000, Customer Relationships of $6,090,000, Non - compete agreements of $1,080,000, Tradenames & Trademarks of $830,000 and Licenses of $690,000.
Amortization expense for the nine months ended September 30, 2016 and 2015, was approximately $1,889,000 and $699,000, respectively, and $631,000 and $234,000 for three months ended September 30, 2016 and 2015, respectively.
Expected future amortization of intangible assets as of September 30, 2016, is as follows (in thousands):
Year ending December 31,
Estimated
Amortization
Expense
2016 (a)
$
630

2017
2,430

2018
2,075

2019
2,075

2020
1,805

Thereafter
16,396

 
$
25,411

(a) Estimated amortization expense for the year ending December 31, 2016, includes only amortization to be recorded after September 30, 2016.

9. Credit Facility

On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain
lenders and Bank of America, N.A., as administrative agent. The Credit Agreement establishes a senior secured revolving
credit facility in favor of the Company with a maturity date of October 12, 2018 and an aggregate lender commitment of up to
$50 million. The Credit Agreement also provides for an uncommitted incremental facility of up to $35 million, which can be
exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and
conditions set forth in the Credit Agreement. Borrowings under the facility will bear interest at LIBOR plus 1.5% to 2.25%.
Fees paid in connection with the initiation of the credit facility totaled approximately $500,000. These deferred financing costs
are being amortized to interest expense over the three-year life of the facility. The Credit Agreement contains customary
representations, warranties, covenants, and events of default. As of September 30, 2016, there were no outstanding revolving loans under the credit facility.





14



10. Net Income (Loss) Per Share
Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, restricted stock, and warrants using the treasury stock method. 
The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except share data):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Net income
$
3,321

 
$
6,551

 
$
6,493

 
$
16,068

Denominator for basic earnings per share - weighted average shares
105,991,990

 
106,511,294

 
105,927,890

 
106,178,136

Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)
6,369,189

 
8,044,742

 
6,265,811

 
7,931,984

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
112,361,179

 
114,556,036

 
112,193,701

 
114,110,120

Income per common share - basic
$
0.03

 
$
0.06

 
$
0.06

 
$
0.15

Income per common share - diluted
$
0.03

 
$
0.06


$
0.06


$
0.14

(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Outstanding Stock Options
5,704,112

 
7,320,155

 
5,767,469

 
7,366,426

Outstanding Warrants
—

 
38,023

 
—

 
37,820

Restricted Stock Awards
665,077

 
686,564

 
498,342

 
527,738

 
6,369,189

 
8,044,742

 
6,265,811

 
7,931,984



11. Equity
Stock Incentive Plans 
The Company has four share-based compensation plans which provide for the granting of equity awards, including qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors: the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan (the "2016 Plan"), which was approved by shareholders on May 18, 2016; the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “Assumed 2006 Plan”); the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”); and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”). The awards are subject to a vesting schedule as set forth in each individual agreement. The Company currently intends to use only the 2016 Plan to make future grants.


15


Activity with respect to the stock options is summarized as follows:
 
Number
 of
Shares
 
Weighted-
Average
Exercise
Price
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic
Value
Outstanding at January 1, 2016
14,019,629

 
$
3.62

 
 
 
 
Granted
—

 
$
—

 
 
 
 
Exercised
(926,010
)
 
$
2.76

 
 
 
 
Unvested options forfeited
(93,097
)
 
$
6.52

 
 
 
 
Vested options expired
(38,354
)
 
$
6.77

 
 
 
 

Outstanding at September 30, 2016
12,962,168

 
$
3.65

 
5.77
 
$
64,153,271

Vested at September 30, 2016
11,818,559

 
$
3.30

 
5.62
 
$
62,449,678

Vested or expected to vest at September 30, 2016 (a)
12,937,248

 
$
3.30

 
5.62
 
$
64,120,370

(a)
Includes forfeiture adjusted unvested shares.
The intrinsic value of the options exercised during the nine months ended September 30, 2016, was approximately $5,283,449. 
Following is a summary of stock options outstanding and exercisable at September 30, 2016:
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
Number outstanding
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Weighted-
Average
Exercise
Price
 
Number Exercisable
 
Weighted-
Average
Exercise Price
$0.50 - $0.76
441,429

 
2.6
 
$
0.72

 
441,429

 
$
0.72

$0.87 - $1.35
4,397,970

 
4.9
 
1.19

 
4,397,970

 
1.19

$1.40 - $2.45
1,442,424

 
4.2
 
1.92

 
1,442,424

 
1.92

$2.66 - $3.99
889,430

 
6.1
 
3.06

 
889,430

 
3.06

$4.19 - $6.38
3,253,783

 
6.7
 
5.36

 
2,997,303

 
5.32

$6.45 - $9.78
2,431,132

 
7.4
 
7.30

 
1,614,677

 
7.23

$9.90- $10.99
106,000

 
8.2
 
10.43

 
35,326

 
10.43

 
12,962,168

 
5.8
 
$
3.65

 
11,818,559

 
$
3.30

 
Total unrecognized compensation expense related to granted stock options at September 30, 2016, was approximately $2,150,652 and will be charged to expense ratably through May 2017. 
The fair value of options granted by the Company is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.  Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.  The term of employee options granted is derived using the “simplified method,” which computes expected term as the mid point between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company's lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded.  The term for non-employee options is generally based upon the contractual term of the option.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.
The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:

16


 
Nine Months Ended September 30,
 
2016
 
2015
Expected volatility
n/a
 
54.4 - 58.1 %

Expected life (in years)
n/a
 
6.0

Expected dividend yield
n/a
 
—

Risk-free interest rate
n/a
 
1.51 - 1.68%

There were no options granted during the nine months ended September 30, 2016.
Restricted Stock Awards                                                    
Activity with respect to restricted stock awards for the nine months ended September 30, 2016 is summarized as follows: 
 
Number
of
Shares
 
Weighted-Average Grant Date
Fair Value
Unvested at January 1, 2016
2,613,267

 
$9.14
Granted
2,369,876

 
7.98
Vested
(952,910
)
 
8.75
Forfeited
(137,575
)
 
8.73

Unvested at September 30, 2016
3,892,658

 
$8.54
As of September 30, 2016, there was approximately $23,767,731 of total unrecognized stock-based compensation related to time-based, nonvested restricted stock.  That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.0 years, which approximates the remaining vesting period of these grants. All shares noted above as unvested are considered issued and outstanding at September 30, 2016.
For the three and nine months ended September 30, 2016 and 2015, the Company recognized stock-based compensation as follows (in thousands): 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Cost of sales
$
109

 
$
85

 
$
300

 
$
270

Research and development
159

 
202

 
520

 
591

Selling, general and administrative
4,433

 
4,091

 
13,006

 
11,703

 
$
4,701

 
$
4,378

 
$
13,826

 
$
12,564

Treasury Stock
On May 12, 2014, our Board of Directors authorized the repurchase of up to $10 million of our common stock from time to time, through December 31, 2014. The Board subsequently extended the program until December 31, 2016. In December 2014, the Board increased the authorization to $20 million and further increased the authorization in 2015 to $60 million. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.
For the nine months ended September 30, 2016, the Company purchased 1,338,616 shares of its common stock for a purchase price of approximately $10,338,000 before brokerage commissions of approximately $40,000. As of September 30, 2016, the Company had approximately $3,936,000 of availability remaining under the repurchase program.
Additionally, for the nine months ended September 30, 2016, the Company reissued 2,854,189 shares from the Treasury for restricted stock grants and stock option exercises, net of forfeitures, and as partial consideration to the shareholders of Stability, with an aggregate carrying value of approximately $23,257,728.


17


12. Income taxes 

The effective tax rates for continuing operations of 31.5% and 3.2% for the nine months ended September 30, 2016 and September 30, 2015, respectively, were determined using an estimated annual effective tax rate and include, in 2016, the impact of discrete items of approximately $900,000. The effective tax rate for the 2016 period increased approximately 28.3% when compared to the same period of 2015, primarily due to the $15.4 million valuation allowance release recorded in 2015 and discussed in our Annual Report on Form 10-K for the year ended December 31, 2015. Due to the valuation allowance previously recorded against the Company's U.S. deferred tax assets, the effective tax rate for the nine months ended September 30, 2015, did not include the expense of the current period U.S. taxable income. As of the end of September 2016, the projected annual effective tax rate for 2016 is approximately 41.0%.

13. Supplemental disclosure of cash flow and non-cash investing and financing activities:
    
Selected cash payments, receipts, and noncash activities are as follows (in thousands):
 
Nine Months Ended September 30,
 
2016
 
2015
Cash paid for interest
$
118

 
$
18

Income taxes paid
637

 
1,506

Stock issuance of 441,009 shares in connection with acquisition
3,346

 
—

Retirement of fixed assets
—

 
319

Stock issuances of 43,344 and 16,493 shares in exchange for services performed, respectively
346

 
164


14. Contractual Commitments and Contingencies
Contractual Commitments
In addition to the capital leases noted above in Note 7, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next eight years and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The Company also has commitments for meeting space and to various charitable organizations. The estimated annual lease payments, meeting space and charitable organization commitments are as follows (in thousands):
12-month period ended September 30,
2017
$
3,156

2018
3,103

2019
2,038

2020
957

Thereafter
550

 
$
9,804


Rent expense for the nine months ended September 30, 2016 and 2015, was approximately $1,311,000 and $956,000, respectively, and was approximately $453,000 and $363,000 for the three months ended September 30, 2016 and 2015, respectively, and is allocated among cost of sales, research and development, and selling, general and administrative expenses.

Letters of Credit
As a condition of the lease for the Company's main facility, the Company is obligated under standby letters of credit in the amount of approximately $103,000. These obligations are reduced at various times over the life of the lease.
FDA Untitled Letter and Draft Guidance
On August 28, 2013, the FDA issued an Untitled Letter alleging that the Company's micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, MiMedx would need a

18


biologics license to lawfully market those micronized products. Since the issuance of the Untitled Letter, the Company has been in discussions with the FDA to communicate its disagreement with the FDA's assertion that the Company's allografts are more than minimally manipulated. To date, the FDA has not changed its position that the Company's micronized products are not eligible for marketing solely under Section 361 of the Public Health Service Act, but discussions are continuing. The Company continues to market its micronized products but is also pursuing the Biologics License Application (“BLA”) process for certain of its micronized products.

On December 22, 2014, the FDA issued for comment “Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.” Essentially the Minimal Manipulation draft guidance takes the same position with respect to micronized amniotic tissue that the FDA took in the Untitled Letter to MiMedx 16 months earlier. The Company submitted comments asserting that the Minimal Manipulation draft guidance represents agency action that goes far beyond the FDA’s statutory authority, is inconsistent with existing HCT/P regulations and the FDA’s prior positions, and is internally inconsistent and scientifically unsound. On October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance as well. On September 12 and 13, 2016, the FDA held a public hearing to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The Company awaits further decision from FDA on the draft guidances, but anticipates this will be a lengthy process.

If the FDA does allow the Company to continue to market a micronized form of its sheet allografts without a biologics license either prior to or after finalization of the draft guidance documents, it may impose conditions, such as labeling restrictions and compliance with Current Good Manufacturing Practices (cGMP). Although the Company is preparing for these requirements in connection with its pursuit of a BLA for certain of its micronized products, earlier compliance with these conditions requires significant additional time and cost investments by the Company. It is also possible that the FDA will not allow the Company to market any form of a micronized product without a biologics license even prior to finalization of the draft guidance documents and could even require the Company to recall its micronized products. Revenues from micronized products comprised approximately 12% of the Company's revenues for the fiscal year ended December 31, 2015.

Patent Litigation

MiMedx continues to diligently enforce its intellectual property against several entities. Currently, there are four actions pending, as described below:

The Liventa Action

On April 22, 2014, the Company filed a patent infringement lawsuit in the United States District Court for the Northern District of Georgia against Liventa Bioscience, Inc. ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages (the "Liventa Action"). In addition to the allegations of infringement of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients, and in some cases, prospective investors. Though the terms of the agreement are confidential, the parties have reached an amicable settlement of the false advertising claims for an undisclosed sum. The patent infringement claims are still pending as described below.

MiMedx asserts that Liventa (formerly known as AFCell Medical, Inc.), Medline and MTF infringed and continue to infringe certain of the Company's patents relating to the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts. MTF is the tissue processor while Liventa and Medline are the distributors of the allegedly infringing products. On May 30, 2014, defendants filed answers to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement, invalidity, laches and estoppel. MTF and Medline also filed counterclaims seeking declaratory judgments of non-infringement and invalidity. Defendants filed parallel Inter Partes Review ("IPR") proceedings which are discussed below. We expect the case to go to trial in 2017.

The Bone Bank Action

On May 16, 2014, the Company also filed a patent infringement lawsuit against Transplant Technology, Inc. d/b/a Bone Bank Allografts ("Bone Bank") and Texas Human Biologics, Ltd. ("Biologics") for permanent injunctive relief and unspecified damages (the "Bone Bank Action"). The Bone Bank Action was filed in the United States District Court for the Western District of Texas. This lawsuit similarly asserts that Bone Bank and Biologics infringed certain of the Company's patents through the manufacturing and sale of their placental-derived tissue graft products. On July 10, 2014, Defendants filed an answer to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement and invalidity

19


and filed counterclaims seeking declaratory judgments of non-infringement and invalidity. Defendants also filed parallel IPR proceedings which are further discussed below. Discovery is closed and we expect the case to go to trial in the early part of 2017.

The NuTech Action

On March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. ("NuTech") and DCI Donor Services, Inc. ("DCI") for permanent injunctive relief and unspecified damages. This lawsuit was filed in the United States District Court for the Northern District of Alabama. The lawsuit alleges that NuTech and DCI have infringed and continue to infringe the Company's patents through the manufacture, use, sale, and/or offering of their tissue graft product. The lawsuit also asserts that NuTech knowingly and willfully made false and misleading representations about its products to customers and/or prospective customers. The case is currently in the discovery phase.

The Vivex Action

On April 1, 2016, the Company also filed a patent infringement lawsuit against Vivex BioMedical (“Vivex”) for permanent injunctive relief and unspecified damages (the "Vivex Action"). The lawsuit was filed in the United States District Court for the Northern District of Georgia. The patent at issue is the 8,709,494 patent (the "494" patent). Vivex answered MiMedx’s Complaint and filed Counterclaims of noninfringement and invalidity. 

Pending IPRs

In addition to defending the claims in the pending district court litigations, defendants in the Liventa and Bone Bank cases have challenged certain of the Company's patents in several IPR proceedings to avoid the high burden of proof of proving invalidity by "clear and convincing evidence" in the district court litigations. An inter partes review (or "IPR") is a request for a specialized group within the United States Patent and Trademark Office to review the validity of a plaintiff's patent claims. The defendants in the Bone Bank Action challenged the validity of the Company's 8,597,687 (the "687" patent) and the 494 patent; while the defendants in the Liventa Action challenged the validity of the Company's 8,372,437 and 8,323,701 patents (the "'437" and "'701" patents, respectively).

On June 29, 2015, the Patent Trial and Appeals Board ("PTAB") denied the Bone Bank defendants' request for institution of an IPR with respect to the '494 patent (EpiFix) on all seven challenged grounds. On August 18, 2015, the PTAB also denied the Liventa defendants' request for institution of an IPR with respect to the '701 patent (AmnioFix) on all six challenged grounds. That is, the PTAB decided in each case that the defendants failed to establish a reasonable likelihood that defendants would prevail in showing any of the challenged claims of the '494 or the '701 patent were unpatentable.

On July 10, 2015, the PTAB issued an opinion allowing a review of the '687 patent to proceed, although on only two of the five challenged grounds. The parties decided to forego oral arguments. On July 7, 2016, the PTAB issued an opinion finding that the challenged claims, which relate to embossment and not configuration, were invalid for obviousness. On August 18, 2015, the PTAB issued an opinion allowing a review of the '437 patent to proceed, although only on one of the seven challenged grounds. On August 16, 2016, the PTAB issued an opinion finding that the challenged claims were unpatentable.  MiMedx has filed a notice of appeal of the PTAB’s decision regarding the '437 patent.


15. Subsequent Events
None


20


Schedule II Valuation and Qualifying Accounts
MIMEDX GROUP, INC. AND SUBSIDIARIES
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS
 Three and Nine Months Ended September 30, 2016 and 2015 (in thousands)
 
 
 
 
 
 
 
 
Balance at
Beginning of Period
Additions charged to Expense or Revenue
Deductions
and write-offs
Balance at
End of Period
 
 
 
 
 
 
For the three months ended September 30, 2016
 
 
 
 
 
 Allowance for doubtful accounts
 
$
4,086

$
800

$
(536
)
$
4,350

 Allowance for product returns
 
2,191

2,591

(2,520
)
2,262

 Allowance for obsolescence
 
1,780

339

(1,411
)
708

 
 
 
 
 
 
For the three months ended September 30, 2015
 
 
 
 
 
 Allowance for doubtful accounts
 
$
2,504

$
800

$
(172
)
$
3,132

 Allowance for product returns
 
1,030

906

(407
)
1,529

 Allowance for obsolescence
 
553

227

(87
)
693

 
 
 
 
 
 
For the nine months ended September 30, 2016
 
 
 
 
 
 Allowance for doubtful accounts
 
$
3,270

$
1,635

$
(555
)
$
4,350

 Allowance for product returns
 
1,262

5,917

(4,917
)
2,262

 Allowance for obsolescence
 
397

1,910

(1,599
)
708


 
 
 
 
 
For the nine months ended September 30, 2015
 
 
 
 
 
 Allowance for doubtful accounts
 
$
1,750

$
1,560

$
(178
)
$
3,132

 Allowance for product returns
 
841

2,349

(1,661
)
1,529

 Allowance for obsolescence
 
527

447

(281
)
693



21


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Overview

MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  The MiMedx allograft product families include our: dHACM family with AmnioFix®, EpiFix® and EpiBurn® brands; Amniotic Fluid family with OrthoFlo brand; Umbilical family with EpiCord™ and AmnioCord™ brands; Placental Collagen family with CollaFix™ and AmnioFill™ brands; Bone family with Physio® brand; and Skin family with AlloBurn™ brand. AmnioFix,  EpiFix, and EpiBurn are our tissue technologies processed from human amniotic membrane; OrthoFlo is an amniotic fluid derived allograft;  EpiCord™ and AmnioCord™ are derived from the umbilical cord; Physio is a bone grafting material comprised of 100% bone tissue with no added carrier; AlloBurn is a skin product derived from human skin designed for the treatment of burns; and  CollaFix, our next brand we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.  We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.  MiMedx is the leading supplier of amniotic tissue, having supplied over 700,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. The Company distinguishes its revenue in two primary regenerative medicine specialties of "Wound Care" and "SSO."  The Company defines SSO as surgical, sports medicine and orthopedics with spinal procedures included in orthopedics and abdominal, and lower pelvic procedures included in surgical.

Recent Events

On December 22, 2014, the FDA issued for comment “Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.” Essentially the Minimal Manipulation draft guidance takes the same position with respect to micronized amniotic tissue that the FDA took in the Untitled Letter to MiMedx 16 months earlier. The Company submitted comments asserting that the Minimal Manipulation draft guidance represents agency action that goes far beyond the FDA’s statutory authority, is inconsistent with existing HCT/P regulations and the FDA’s prior positions, and is internally inconsistent and scientifically unsound. On October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance as well. On September 12 and 13, 2016, the FDA held a public hearing to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The Company awaits further decision from FDA on the draft guidances, but anticipates this will be a lengthy process.





22


Results of Operations Comparison for the Three Months Ended September 30, 2016, to the Three Months Ended September 30, 2015
Revenue
Total revenue increased approximately $15.4 million, or 31%, to $64.4 million for the three months ended September 30, 2016, as compared to $49.0 million for the three months ended September 30, 2015. Wound Care revenue for the three months ended September 30, 2016 grew by $14.0 million, or approximately 39%, to $49.8 million, compared to $35.8 million for the three months ended September 30, 2015. SSO revenue for the three months ended September 30, 2016 grew by $1.3 million, or approximately 10%, to $14.6 million compared to $13.3 million, for the three months ended September 30, 2015. The primary drivers for the increase in revenue for both categories was increased volume and the introduction of new products.
Tissue Processing Costs and Cost of Products Sold
Cost of products sold as a percentage of revenue increased to 12.4% from 10.2% compared to the prior year as a result of additional costs incurred in connection with the integration of Stability, an increase in the cost of sales related to the purchase accounting inventory step up of approximately $247,000 as well as changes in product mix. Cost of goods sold excluding the inventory step up was 12.0%.
Research and Development Expenses 
The Company's research and development expenses (“R&D expenses”) increased approximately $0.7 million, or 33%, to $2.9 million during the three months ended September 30, 2016, compared to approximately $2.2 million in the prior year. The increase is primarily related to increased investments in scientific studies, clinical trials and personnel costs.

R&D expenses consist primarily of internal personnel costs, expenses of clinical trials, fees paid to external consultants, and the cost of supplies and instruments used in the Company's laboratories.
Selling, General and Administrative Expenses
Selling, General and Administrative expenses for the three months ended September 30, 2016 increased approximately $13.3 million to $48.2 million, compared to $34.9 million for the three months ended September 30, 2015. Selling expense increases were driven by costs associated with expanding the Company's direct sales organization, increased commissions due to higher sales volume, an increase in share-based compensation, and the addition of staff and normal operating costs of Stability. Additional spending increases included one time costs of approximately $237,000 related to the acquisition of Stability, support costs related to medical reimbursement, accounting, information technology infrastructure to help manage the growth of the business, and legal costs due to patent litigation. Selling, General and Administrative expenses consist of personnel costs, professional fees, sales commissions, sales training costs, industry trade show fees and expenses, product promotion and product literature costs, facilities costs and other sales, marketing and administrative costs, depreciation and amortization, and share-based compensation.
Income Taxes
The effective tax rate increased approximately 26% when compared to the same period of 2015, primarily due to the valuation allowance release recorded in 2015 and discussed in our Annual Report on Form 10-K for the year ended December 31, 2015.
Results of Operations Comparison for the Nine Months Ended September 30, 2016, to the Nine Months Ended September 30, 2015
Revenue
Total revenue increased approximately $39.6 million, or 29%, to $175.1 million for the nine months ended September 30, 2016, as compared to $135.5 million for the nine months ended September 30, 2015. Wound Care revenue for the nine months ended September 30, 2016 grew by $30.0 million, or approximately 29.7%, to $131.2 million, compared to $101.2 million million for the nine months ended September 30, 2015. SSO revenue for the nine months ended September 30, 2016 grew by $9.6 million, or approximately 28%, to $43.9 million compared to $34.3 million for the nine months ended September 30, 2015. The primary drivers for the increase in revenue for both categories was increased volume and the introduction of new products.
Tissue Processing Costs and Cost of Products Sold
Cost of products sold as a percentage of revenue increased to 13.3% from 11.2% compared to the prior year as a result of additional costs incurred in connection with the integration of Stability, an increase in the cost of sales related to the purchase accounting inventory step up of approximately $1,578,000 as well as changes in product mix. Cost of goods sold excluding the inventory step up was 12.4%.


23


Research and Development Expenses 
The Company's R&D expenses increased approximately $2.5 million, or 41.3%, to $8.6 million during the nine months ended September 30, 2016, compared to approximately $6.1 million in the prior year. The increase is primarily related to increased investments in scientific studies, clinical trials and personnel costs.
Selling, General and Administrative Expenses
Selling, General and Administrative expenses for the nine months ended September 30, 2016, increased approximately $34.7 million to $131.6 million, compared to $96.9 million for the nine months ended September 30, 2015. Selling expense increases were driven by costs associated with expanding the Company's direct sales organization, increased commissions due to higher sales volume, an increase in share-based compensation, and the addition of staff and normal operating costs of Stability. Additional spending increases included one time costs of approximately $1,088,000 related to the acquisition of Stability, support costs related to medical reimbursement, accounting, information technology infrastructure to help manage the growth of the business, and legal costs due to patent litigation. Selling, General and Administrative expenses consist of personnel costs, professional fees, sales commissions, sales training costs, industry trade show fees and expenses, product promotion and product literature costs, facilities costs and other sales, marketing and administrative costs, depreciation and amortization, and share-based compensation.
Income Taxes
The nine month effective tax rate of 31.5% includes discrete items related to certain favorable provision to return adjustments resulting from the recently filed 2015 income tax returns and a deferred tax rate adjustment. This rate is an increase of approximately 28% when compared to the same period of 2015, primarily due to the valuation allowance release recorded in 2015 and discussed in our Annual Report on Form 10-K for the year ended December 31, 2015.

Liquidity and Capital Resources
As of September 30, 2016, the Company had approximately $18.3 million of cash and cash equivalents. The Company reported total current assets of approximately $106.3 million and total current liabilities of approximately $41.6 million at September 30, 2016, which represents a current ratio of 2.6 as of September 30, 2016.

On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain lenders and Bank of America, N.A., as administrative agent. The Credit Agreement established a senior secured revolving credit facility in favor of the Company, with an aggregate lender commitment of up to $50 million. As of the date hereof, there are no outstanding revolving loans under the Credit Agreement. The Credit Agreement also provides for an uncommitted incremental facility of up to $35 million, which can be exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and conditions set forth in the Credit Agreement. The Credit Agreement contains customary covenants and events of default for senior secured credit agreements of this type. The covenants include (a) a requirement for the Company to maintain a maximum consolidated leverage ratio of 2.50:1.00; (b) a requirement for the Company to maintain a minimum consolidated fixed charge coverage ratio of 2.00:1.00; and (c) a requirement for the Company to maintain minimum liquidity of $10 million. As of September 30, 2016, the Company was in compliance with all of its covenants.

For the nine months ended September 30, 2016, in connection with the acquisition of Stability, the Company paid approximately $6 million in cash for the initial purchase price, paid off debt of approximately $1.8 million and provided initial working capital of approximately $4 million.
For the nine months ended September 30, 2016, the Company repurchased 1,338,616 shares of its common stock for a purchase price of approximately $10,338,000, before brokerage commissions of approximately $40,000 bringing the total amount spent under the program to approximately $56,064,000 since inception. As of September 30, 2016, the Company had approximately $3,936,000 of availability remaining under the repurchase program. The timing and amount of future repurchases, if any, will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.
In addition, during the nine months ended September 30, 2016, the Company repurchased 109,394 shares surrendered by employees to satisfy tax withholding obligations upon vesting of restricted stock.
We believe that our anticipated cash from operating activities, existing cash and cash equivalents, and availability under the Credit Agreement will enable us to meet our operational liquidity needs and fund our planned investing activities for the next year.

24




Contingencies
See Note 14 to our Condensed Consolidated Financial Statements in Part I, Item 1 herein.
Contractual Obligations
Contractual obligations associated with ongoing business activities are expected to result in cash payments in future periods.  The table below summarizes the amounts and estimated timing of these future cash payments as of September 30, 2016 (in thousands):
 
 
 
Less than
 
 
 
 
 
 
Contractual Obligations
TOTAL
 
1 year
 
1-3 years
 
3-5 years
 
Thereafter
Capital lease obligations
$
41

 
$
32

 
$
9

 
$
—

 
$
—

Operating lease obligations
7,510

 
2,093

 
3,933

 
1,074

 
410

Charitable contribution obligations
325

 
325

 
—

 
—

 
 
Software license
308

 
95

 
189

 
24

 
 
Meeting space commitments
1,661

 
643

 
1,018

 
—

 
 
 
$
9,845

 
$
3,188

 
$
5,149

 
$
1,098

 
$
410

Discussion of cash flows
Net cash from operations during the nine months ended September 30, 2016 decreased approximately $5.4 million to approximately $9.1 million, compared to $14.5 million from operating activities for the nine months ended September 30, 2015, primarily attributable to a decrease in net income compared to the prior year, as well as post acquisition working capital costs for Stability. For the three months ended September 30, 2016, operating cash decreased approximately $4.5 million as compared to the three months ended September 30, 2015, primarily due to a decrease in net income compared to the prior year, as well as post acquisition working capital costs for Stability.
Net cash used in investing activities during the nine months ended September 30, 2016 was approximately $10.4 million, compared to approximately $2.3 million for 2015. Cash used for the acquisition of Stability totaled $7.6 million, and an additional $5.3 million was used for the purchase of equipment to expand production capacity, partially offset by maturing certificates of deposit of $3 million. For the three months ended September 30, 2016, cash utilized for investing activities increased approximately $600,000 as compared to the three months ended September 30, 2015, primarily due to maturing certificates of deposit which occurred in 2015.
Net cash used in financing activities during the nine months ended September 30, 2016 decreased approximately $8.9 million to $8.8 million compared to $17.7 million of cash used during the nine months ended September 30, 2015. Cash flows used in financing activities during the nine months ended September 30, 2016 included approximately $11.3 million for stock repurchases compared to $21.1 million in the prior year. Additionally, the Company received $2.5 million from the exercise of stock options compared to approximately $3.5 million in the prior year. For the three months ended September 30, 2016, cash utilized for financing activities increased by $2.8 million as compared to the three months ended September 30, 2015, primarily due to a greater amount of stock repurchases in 2016.
Non-GAAP Financial Measures
In addition to our GAAP results, we provide certain Non-GAAP metrics including Adjusted EBITDA, Adjusted Gross Margin, Adjusted Net Income and Adjusted Diluted Net Income per share. The Company believes that the presentation of these measures provides important supplemental information to management and investors regarding the Company's performance. These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company's on-going financial performance from quarter-to-quarter and year-to-year on a regular basis and for benchmarking against other medical technology companies. Adjusted EBITDA consists of GAAP Net Income excluding: (i) depreciation and amortization, (ii) other income (expense), (iii) interest income and expense, (iv) income taxes, (v) one time acquisition related costs, (vi) the effect of purchase accounting due to acquisitions and (vii) share-based compensation expense. Due to the impact of the acquisition of Stability in January 2016 and the release of the valuation allowance on the deferred tax asset on reported tax expense in 2015 on results, the Company has decided to provide additional adjusted non-GAAP measures to provide comparability of normal ongoing operating results. Beginning in 2016, the Company has reported Adjusted Gross Margin, Adjusted Net Income and Adjusted EPS to normalize results for comparison purposes. Adjusted Gross Margin consists of GAAP gross margin excluding amortization of inventory fair value step-up. Adjusted Net

25


Income and Adjusted Diluted Net Income per share consists of GAAP net income excluding: (i) one time acquisition related costs, (ii) amortization of inventory fair value step-up, (iii) amortization of intangible assets and (iv) share-based compensation. Reconciliations of GAAP net income to Adjusted EBITDA, GAAP Gross Margin to Adjusted Gross Margin and GAAP Net Income to Adjusted Net Income and Adjusted Diluted Net Income per share for the three months and nine months ended September 30, 2016 and 2015 appear in the tables below.
The Company's Adjusted EBITDA for the three months ended September 30, 2016, was approximately $11.4 million which is a reduction of $(0.4) million as compared to the three months ended September 30, 2015. The reduction was attributable to increased investments in support of growth of the business compared to the prior year. The Company's Adjusted EBITDA for the nine months ended September 30, 2016, was approximately $30.5 million which is a reduction of $(0.6) million as compared to the nine months ended September 30, 2015. The reduction was attributable to increased investments in support of growth of the business compared to the prior year.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Net Income (Per GAAP)
$
3,321

 
$
6,551

 
$
6,493

 
$
16,068

 
 
 
 
 
 
 
 
Add back:
 
 
 
 
 

 
 
Income taxes
1,295

 
158

 
2,984

 
527

One time costs incurred in connection with acquisition
237

 
—

 
1,088

 
—

One time inventory costs incurred in connection with acquisition
247

 
—

 
1,578

 
—

Other interest (income) expense, net
87

 
5

 
254

 
18

Depreciation expense
838

 
470

 
2,394

 
1,247

Amortization of intangible assets
631

 
234

 
1,889

 
699

Share-based compensation
4,701

 
4,378

 
13,826

 
12,564

Adjusted EBITDA
$
11,357

 
$
11,796

 
$
30,506

 
$
31,123


Reconciliation of "Adjusted Gross Margin" defined as Gross Margin before Amortization of inventory fair value step-up (in thousands):
 
Three months ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Gross Margin (Per GAAP)
$
56,432

 
$
44,036

 
$
151,801

 
$
120,244

 
 
 
 
 
 
 
 
Non-GAAP Adjustments:
 
 
 
 
 
 
 
One time inventory costs incurred in connection with acquisition
247

 
—

 
1,578

 
—

Gross Margin before Amortization of inventory fair value step-up
$
56,679

 
$
44,036

 
$
153,379

 
$
120,244

Adjusted Gross Margin
88.0
%
 
89.8
%
 
87.6
%
 
88.8
%







26




Reconciliation of "Adjusted Net Income" and "Adjusted Diluted Net Income" per share defined as Net Income less Amortization, One Time Costs and Share-Based Compensation (in thousands, except share and per share data):
 
Three months ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Net Income (Per GAAP)
$
3,321

 
$
6,551

 
$
6,493

 
$
16,068

 
 
 
 
 
 
 
 
Non-GAAP Adjustments:
 
 
 

 
 

 
 

Tax rate normalization*
(539
)
 
(2,662
)
 
(901
)
 
(6,450
)
One time costs incurred in connection with acquisition
237

 
—

 
1,088

 
—

One time inventory costs incurred in connection with acquisition
247

 
—

 
1,578

 
—

Amortization of intangible assets
631

 
234

 
1,889

 
699

Share - based compensation
4,701

 
4,378

 
13,826

 
12,564

Estimated income tax impact from adjustments
(2,384
)
 
(1,939
)
 
(7,686
)
 
(5,576
)
Adjusted Net Income
$
6,214

 
$
6,562

 
$
16,287

 
$
17,305

Adjusted Diluted Net Income per share
$
0.06

 
$
0.06

 
$
0.15

 
$
0.15

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
112,361,179

 
114,556,036

 
112,193,701

 
114,110,120

*Assumes a normalized tax rate of 42% for 2015 and 41% for 2016.
Critical Accounting Policies
In preparing financial statements, the Company follows accounting principles generally accepted in the United States, which require the Company to make certain estimates and apply judgments that affect its financial position and results of operations. Management continually reviews the Company's accounting policies and financial information disclosures. A summary of significant accounting policies that require the use of estimates and judgments in preparing the financial statements was provided in the Company's Annual Report on Form 10-K for the year ended December 31, 2015.  During the quarter covered by this report, there were no material changes to the accounting policies and assumptions previously disclosed.
Recent Accounting Pronouncements
For the effect of recent accounting pronouncements, see Note 2 to the Condensed Consolidated Financial Statements contained herein.
Off-Balance Sheet Arrangements
The Company has no off-balance sheet arrangements.
Item 3. Quantitative and Qualitative Disclosures about Market Risk

Based on our lack of market risk sensitive instruments outstanding at September 30, 2016, we have determined that there was no material market risk exposure to our consolidated financial position, results of operations or cash flows as of such date.

27


Item 4. Controls and Procedures
Disclosure Controls and Procedures
As required by Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the Company carried out an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of the end of the period covered by this report. This evaluation was carried out under the supervision and with the participation of Company management, including its Chief Executive Officer and Chief Financial Officer. Based upon that evaluation, the Company's Chief Executive Officer and Chief Financial Officer concluded that the Company's controls and procedures were effective as of the end of the period covered by this report.
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in the Company's reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in the Company's reports filed under the Exchange Act is accumulated and communicated to management, including the Company's Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding disclosures.
Changes in Internal Control over Financial Reporting
There was no change in the Company's internal control over financial reporting that occurred during the quarter ended September 30, 2016, that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.
Limitations on the Effectiveness of Controls
The Company has confidence in its internal controls and procedures. Nevertheless, management, including the Company's Chief Executive Officer and Chief Financial Officer, does not expect that the Company's disclosure procedures and controls or its internal controls will prevent all errors or intentional fraud. An internal control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of such internal controls are met. Further, the design of an internal control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all internal control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.
PART II – OTHER INFORMATION
Item 1. Legal Proceedings

We are a party to various legal claims and actions incidental to our business. These items are more fully discussed in Note 14 to our Condensed Consolidated Financial Statements.
Item 1A. Risk Factors
There have been no material changes to the risk factors previously disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2015.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Stock Repurchases 

The following table sets forth information regarding the purchases of the Company’s equity securities made by or on behalf of the Company or any affiliated purchaser (as defined in Exchange Act Rule 10b-18) during the three month period ended September 30, 2016:


28


 
Total number of
shares purchased (a)
 
Average price paid
per share
 
Total number of shares purchased under publicly announced plan(b)
 
Total amount spent under the plan
 
Remaining amount
to be spent
under the plan
Total amount remaining July 1, 2016
 
 
 
 
 
 
 
 
$
10,756,012

 
 
 
 
 
 
 
 
 
 
July 1, 2016 - July 31, 2016
143,621
 
$
7.48

 
116,964

 
$
874,431

 
$
9,881,581

 
 
 
 
 
 
 
 
 
 
August 1, 2016 - August 31, 2016
656,400
 
$
7.44

 
656,400

 
$
4,884,196

 
$
4,997,385

 
 
 
 
 
 
 
 
 
 
September 1 - September 30, 2016
151,143
 
$
7.08

 
150,000

 
$
1,061,596

 
$
3,935,789

 
 
 
 
 
 
 
 
 
 
    Total for the quarter
951,164
 
 
 
923,364

 
$
6,820,223

 
 

(a) Shares repurchased during the quarter include 27,800 shares surrendered by employees to satisfy tax withholding obligations upon vesting of restricted stock.

(b) On May 12, 2014, our Board of Directors authorized the repurchase of up to $10 million of our common stock from time to time, through December 31, 2014. The Board subsequently extended the program until December 31, 2016. In December 2014, the Board increased the authorization to a total of $20 million and further increased the authorization in 2015 to a total of $60 million. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time. The above table sets forth information regarding the purchases of the Company’s equity securities made under the repurchase program during the quarter prior to brokerage commissions of approximately $28,000.
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
None.

29


Item 6. Exhibits
Exhibit
Number
Reference
Description
 
 
 
2.1##
 
Agreement and Plan of Merger dated January 10, 2016, by and among MiMedx Group, Inc., Titan Acquisition Sub I, Inc., Titan Acquisition Sub II, LLC, Stability Inc., certain stockholders of Stability Inc. and Brian Martin as representative of the Stability stockholders (incorporated by reference to Exhibit 2.1 filed with Registrant's Form 8-K filed on January 13, 2016)
3.1
 
Articles of Incorporation as filed with the Secretary of State of Florida on March 31, 2008 (incorporated by reference to Exhibit 3.1 filed with the Registrant's Form 10-Q on August 8, 2013)
3.2
 
Articles of Amendment to Articles of Incorporation as filed with the Secretary of the State of Florida on May 14, 2010 (incorporated by reference to Exhibit 3.2 filed with the Registrant's Form 10-Q on August 8, 2013)
3.3
 
Articles of Amendment to Articles of Incorporation as filed with the Secretary of the State of Florida on August 8, 2012 (incorporated by reference to Exhibit 3.3 filed with the Registrant's Form 10-Q on August 8, 2013)
3.4
 
Articles of Amendment to Articles of Incorporation as filed with the Secretary of the State of Florida on November 8, 2012 (incorporated by reference to Exhibit 3.4 filed with the Registrant's Form 10-Q on August 8, 2013)
3.5
 
Articles of Amendment to Articles of Incorporation as filed with the Secretary of the State of Florida on May 15, 2015  (incorporated by reference to Exhibit 3.5 filed with the Registrant's Form 10-Q on August 7, 2015)
3.6
 
Bylaws of MiMedx Group, Inc. (incorporated by reference to Exhibit 3.2 filed with Registrant's Form 8-K filed on April 2, 2008)
3.7
 
Amendment to the Bylaws of MiMedx Group, Inc. adopted by the Board of Directors on May 11, 2010 (incorporated by reference to Exhibit 3.2 to the Registrant's Form 8-K filed on May 14, 2010)
31.1 #
 
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2 #
 
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 #
 
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2 #
 
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS
 
XBRL Instance Document
101.SCH
 
XBRL Taxonomy Extension Schema Document
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
 
XBRL Taxonomy Extension Label Linkbase Document
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document
 
#
Filed herewith
##
Certain exhibits and schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K, but a copy will be furnished supplementally to the Securities and Exchange Commission upon request





*
Indicates a management contract or compensatory plan or arrangement



30


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
November 8, 2016
 
 
 
By:
/s/ Michael J. Senken
 
 
Michael J. Senken
 
 
Chief Financial Officer
 
 
(principal financial and accounting officer)

31
 EX-31.1 2 exhibit311-certificationof.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO RULES 13a-14(A) AND 15d-14(A)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
I, Parker H. Petit, certify that:
 
1. I have reviewed this Form 10-Q for the quarter ended September 30, 2016, of MiMedx Group, Inc.;
 
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
November 8, 2016
/s/ Parker H. Petit
 
 
Parker H. Petit
 
 
Chief Executive Officer


 EX-31.2 3 exhibit312-certificationof.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO RULES 13a-14(A) AND 15d-14(A)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
I, Michael J. Senken, certify that:

1. I have reviewed this Form 10-Q for the quarter ended September 30, 2016, of MiMedx Group, Inc.;
 
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. The registrant’s other certifying officer  and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
November 8, 2016
/s/ Michael J. Senken
 
 
Michael J. Senken
 
 
Chief Financial Officer


 EX-32.1 4 exhibit321-certificationof.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
 
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of MiMedx Group, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Parker H. Petit, Chief Executive Officer of the Company, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify, that to the best of my knowledge:
 
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:
November 8, 2016
/s/ Parker H. Petit
 
 
Parker H. Petit
 
 
Chief Executive Officer


 EX-32.2 5 exhibit322-certificationof.htm EXHIBIT 32.2 Exhibit


 Exhibit 32.2
 
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of MiMedx Group, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael J. Senken, Chief Financial Officer of the Company, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify, that to the best of my knowledge:
 
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:
November 8, 2016
/s/ Michael J. Senken
 
 
Michael J. Senken
 
 
Chief Financial Officer


 EX-101.INS 6 mdxg-20160930.xml XBRL INSTANCE DOCUMENT 0001376339 2016-01-01 2016-09-30 0001376339 2016-10-15 0001376339 2015-12-31 0001376339 2016-09-30 0001376339 2016-07-01 2016-09-30 0001376339 2015-07-01 2015-09-30 0001376339 2015-01-01 2015-09-30 0001376339 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-09-30 0001376339 us-gaap:TreasuryStockMember 2016-01-01 2016-09-30 0001376339 us-gaap:CommonStockMember 2015-12-31 0001376339 us-gaap:RetainedEarningsMember 2015-12-31 0001376339 us-gaap:CommonStockMember 2016-01-01 2016-09-30 0001376339 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0001376339 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001376339 us-gaap:RetainedEarningsMember 2016-01-01 2016-09-30 0001376339 us-gaap:TreasuryStockMember 2016-09-30 0001376339 us-gaap:CommonStockMember 2016-09-30 0001376339 us-gaap:TreasuryStockMember 2015-12-31 0001376339 us-gaap:RetainedEarningsMember 2016-09-30 0001376339 2014-12-31 0001376339 2015-09-30 0001376339 us-gaap:FairValueAdjustmentToInventoryMember 2016-01-13 2016-01-13 0001376339 us-gaap:PatentsMember 2016-01-01 2016-09-30 0001376339 us-gaap:FairValueAdjustmentToInventoryMember 2016-01-01 2016-09-30 0001376339 us-gaap:PatentsMember 2015-01-01 2015-09-30 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:CustomerRelationshipsMember 2016-01-13 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:LicensingAgreementsMember 2016-01-13 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:NoncompeteAgreementsMember 2016-01-13 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:PatentsMember 2016-01-13 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:LoansPayableMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:PatentsMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember 2016-01-13 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:NoncompeteAgreementsMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember mdxg:ShareholderDebtMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:LineOfCreditMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:TrademarksAndTradeNamesMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:LicensingAgreementsMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:CustomerRelationshipsMember 2016-01-13 0001376339 us-gaap:FairValueAdjustmentToInventoryMember 2015-01-01 2015-09-30 0001376339 us-gaap:ProFormaMember 2015-01-01 2015-09-30 0001376339 mdxg:StabilityBiologicsLLCMember 2016-09-30 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-13 2016-01-13 0001376339 us-gaap:CertificatesOfDepositMember 2015-12-31 0001376339 us-gaap:FurnitureAndFixturesMember 2016-09-30 0001376339 us-gaap:ConstructionInProgressMember 2016-09-30 0001376339 us-gaap:EquipmentMember 2015-12-31 0001376339 us-gaap:LeaseholdImprovementsMember 2016-09-30 0001376339 us-gaap:FurnitureAndFixturesMember 2015-12-31 0001376339 us-gaap:LeaseholdImprovementsMember 2015-12-31 0001376339 us-gaap:ConstructionInProgressMember 2015-12-31 0001376339 us-gaap:EquipmentMember 2016-09-30 0001376339 us-gaap:AssetsHeldUnderCapitalLeasesMember 2016-09-30 0001376339 mdxg:LeaseholdImprovementsPaidbyOthersMember 2016-09-30 0001376339 mdxg:SurgicalBiologicsMember mdxg:TradeNamesAndTrademarksMember 2011-01-05 0001376339 mdxg:ShrinersHospitalsForChildrenAndUniversityOfSouthFloridaResearchFoundationInc.Member us-gaap:LicensingAgreementsMember 2007-01-29 0001376339 mdxg:SurgicalBiologicsMember us-gaap:InProcessResearchAndDevelopmentMember 2011-01-05 0001376339 mdxg:ShrinersHospitalsForChildrenAndUniversityOfSouthFloridaResearchFoundationInc.Member us-gaap:LicensingAgreementsMember 2007-01-28 2007-01-29 0001376339 mdxg:SurgicalBiologicsMember us-gaap:PatentsMember 2016-01-01 2016-09-30 0001376339 mdxg:StabilityBiologicsLLCMember mdxg:TradeNamesAndTrademarksMember 2016-01-13 0001376339 mdxg:SurgicalBiologicsMember us-gaap:LicensingAgreementsMember 2011-01-05 0001376339 mdxg:SurgicalBiologicsMember us-gaap:CustomerRelationshipsMember 2011-01-05 0001376339 mdxg:SurgicalBiologicsMember us-gaap:PatentsMember 2011-01-05 0001376339 mdxg:TradeNamesAndTrademarksMember 2015-12-31 0001376339 us-gaap:InProcessResearchAndDevelopmentMember 2015-12-31 0001376339 us-gaap:LicensingAgreementsMember 2015-12-31 0001376339 us-gaap:LicensingAgreementsMember 2016-09-30 0001376339 us-gaap:InProcessResearchAndDevelopmentMember 2016-09-30 0001376339 us-gaap:NoncompeteAgreementsMember 2016-01-01 2016-09-30 0001376339 us-gaap:NoncompeteAgreementsMember 2016-09-30 0001376339 us-gaap:NoncompeteAgreementsMember 2015-12-31 0001376339 mdxg:PatentsinProcessMember 2015-12-31 0001376339 us-gaap:LicensingAgreementsMember 2016-01-01 2016-09-30 0001376339 mdxg:TradeNamesAndTrademarksMember 2016-09-30 0001376339 us-gaap:CustomerRelationshipsMember 2016-01-01 2016-09-30 0001376339 us-gaap:CustomerRelationshipsMember 2016-09-30 0001376339 us-gaap:PatentsMember 2016-09-30 0001376339 us-gaap:PatentsMember 2015-12-31 0001376339 mdxg:PatentsinProcessMember 2016-09-30 0001376339 us-gaap:CustomerRelationshipsMember 2015-12-31 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember 2016-09-30 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember 2015-10-12 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember 2015-10-12 2015-10-12 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember us-gaap:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-10-12 2015-10-12 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember us-gaap:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-10-12 2015-10-12 0001376339 us-gaap:WarrantMember 2016-07-01 2016-09-30 0001376339 us-gaap:WarrantMember 2015-07-01 2015-09-30 0001376339 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001376339 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001376339 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0001376339 us-gaap:RestrictedStockMember 2016-01-01 2016-09-30 0001376339 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0001376339 us-gaap:WarrantMember 2015-01-01 2015-09-30 0001376339 us-gaap:RestrictedStockMember 2016-07-01 2016-09-30 0001376339 us-gaap:RestrictedStockMember 2015-01-01 2015-09-30 0001376339 us-gaap:RestrictedStockMember 2015-07-01 2015-09-30 0001376339 us-gaap:WarrantMember 2016-01-01 2016-09-30 0001376339 mdxg:PriceRange7Member 2016-01-01 2016-09-30 0001376339 mdxg:PriceRange2Member 2016-09-30 0001376339 mdxg:PriceRange4Member 2016-09-30 0001376339 mdxg:PriceRange7Member 2016-09-30 0001376339 mdxg:PriceRange5Member 2016-09-30 0001376339 mdxg:PriceRange3Member 2016-09-30 0001376339 mdxg:PriceRange6Member 2016-09-30 0001376339 mdxg:PriceRange5Member 2016-01-01 2016-09-30 0001376339 mdxg:PriceRange2Member 2016-01-01 2016-09-30 0001376339 mdxg:PriceRange1Member 2016-01-01 2016-09-30 0001376339 mdxg:PriceRange3Member 2016-01-01 2016-09-30 0001376339 mdxg:PriceRange1Member 2016-09-30 0001376339 mdxg:PriceRange4Member 2016-01-01 2016-09-30 0001376339 mdxg:PriceRange6Member 2016-01-01 2016-09-30 0001376339 us-gaap:RestrictedStockMember 2016-01-01 2016-09-30 0001376339 us-gaap:RestrictedStockMember 2016-09-30 0001376339 us-gaap:RestrictedStockMember 2015-12-31 0001376339 2014-05-12 0001376339 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0001376339 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-07-01 2015-09-30 0001376339 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-09-30 0001376339 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-09-30 0001376339 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-09-30 0001376339 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-07-01 2016-09-30 0001376339 us-gaap:CostOfSalesMember 2016-01-01 2016-09-30 0001376339 us-gaap:CostOfSalesMember 2015-07-01 2015-09-30 0001376339 us-gaap:ResearchAndDevelopmentExpenseMember 2016-07-01 2016-09-30 0001376339 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0001376339 us-gaap:CostOfSalesMember 2016-07-01 2016-09-30 0001376339 us-gaap:CostOfSalesMember 2015-01-01 2015-09-30 0001376339 us-gaap:ScenarioForecastMember 2016-01-01 2016-12-31 0001376339 2015-01-01 2015-12-31 0001376339 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2015-01-01 2015-12-31 0001376339 mdxg:BoneBankActionMember us-gaap:PendingLitigationMember 2015-07-10 0001376339 mdxg:BoneBankActionMember us-gaap:PendingLitigationMember 2015-06-29 0001376339 us-gaap:PendingLitigationMember 2016-06-30 0001376339 mdxg:LiventaAction701PatentMember us-gaap:PendingLitigationMember 2015-08-18 0001376339 mdxg:LiventaAction437PatentMember us-gaap:PendingLitigationMember 2015-08-18 0001376339 us-gaap:StandbyLettersOfCreditMember 2016-09-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2015-01-01 2015-09-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2015-06-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2016-07-01 2016-09-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2016-01-01 2016-09-30 0001376339 mdxg:AllowanceforObsolescenceMember 2016-07-01 2016-09-30 0001376339 mdxg:AllowanceforObsolescenceMember 2015-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2016-01-01 2016-09-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2015-07-01 2015-09-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2015-09-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2015-06-30 0001376339 mdxg:AllowanceforObsolescenceMember 2015-09-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2016-01-01 2016-09-30 0001376339 mdxg:AllowanceforObsolescenceMember 2015-07-01 2015-09-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2015-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2015-01-01 2015-09-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2016-09-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2014-12-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2014-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2016-09-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2015-09-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2016-07-01 2016-09-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2015-01-01 2015-09-30 0001376339 mdxg:AllowanceforObsolescenceMember 2014-12-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2015-07-01 2015-09-30 0001376339 mdxg:AllowanceforObsolescenceMember 2016-09-30 0001376339 mdxg:AllowanceforObsolescenceMember 2016-06-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2015-12-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2016-06-30 0001376339 mdxg:AllowanceforObsolescenceMember 2015-06-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2016-06-30 iso4217:USD xbrli:shares mdxg:plan xbrli:pure mdxg:segment iso4217:USD mdxg:claim xbrli:shares false --12-31 Q3 2016 2016-09-30 10-Q 0001376339 109514557 Large Accelerated Filer MIMEDX GROUP, INC. 2001000 28000 2179000 -4515000 408000 0.12 0.03 0.03 900000 0.283 4864000 6753000 35000000 1 2 4 594000 515000 P30D 40000 319000 0 6633000 11162000 53755000 63427000 4644000 6664000 4979000 7373000 P13Y P7Y P4Y P19Y 163133000 159940000 892000 892000 4378000 85000 202000 4091000 12564000 270000 591000 11703000 4701000 109000 159000 4433000 13826000 300000 520000 13006000 0 136000 234000 699000 1186000 631000 1889000 8044742 7320155 686564 38023 7931984 7366426 527738 37820 6369189 5704112 665077 0 6265811 5767469 498342 0 135913000 181665000 96310000 106290000 441009 0.04 0.11 0.03 0.06 9.07 4253000 12227000 1471000 3406000 7074000 52108000 148521000 64429000 175687000 1088000 1088000 36257000 3346000 1771000 25620000 200000 25620000 0 9642000 0 15978000 -480000 140000 100000 8815000 194000 8268000 830000 17860000 6090000 690000 1080000 9170000 8725000 85000 932000 560000 199000 1375000 36257000 46582000 41073000 28486000 18338000 -5509000 -10148000 0.001 0.001 150000000 150000000 109467416 110212547 107361471 109512781 109000 110000 0.12 9804000 550000 957000 3156000 3103000 2038000 4979000 15217000 7997000 23338000 0.0225 0.015 P3Y 487000 399000 500000 14838000 7019000 470000 1247000 838000 2394000 0.06 0.15 0.03 0.06 0.06 0.14 0.03 0.06 0.032 0.315 0.410 15034000 10812000 P2Y 23767731 2150652 P12Y P2Y P4Y P20Y 16396000 630000 1805000 2075000 2075000 2430000 3761000 1009000 0 8001000 9851000 1699000 1080000 17211000 3761000 13000 7690000 6090000 690000 1080000 9170000 25411000 594000 515000 40000 4040000 26951000 22912000 44036000 120244000 56432000 151801000 6709000 16595000 4616000 9477000 158000 527000 1295000 2984000 1506000 637000 3747000 -3941000 20106000 7671000 1592000 2020000 1474000 -4223000 2100000 520000 3599000 600000 26000 163000 -1087000 2539000 1201000 2023000 1823000 1008000 25000 2298000 1838000 25000 1008000 25000 830000 15627000 34002000 10763000 27249000 18000 118000 3405000 11118000 7857000 19021000 7460000 18313000 602000 1193000 397000 708000 3850000 6710000 0 1500000 1471000 363000 956000 453000 1311000 P8Y 103000 27925000 58388000 135913000 181665000 26777000 41578000 0 50000000 4 7 7 6 5 -17690000 -8849000 -2270000 -10447000 14451000 9148000 6551000 16068000 3321000 6493000 6493000 1 6714000 16613000 4703000 9731000 466000 3298000 1148000 832000 41000 -5000 -18000 -87000 -254000 10338000 0 106000 0 892000 6000000 0 7631000 87000 21000 996000 4176000 5301000 0.001 0.001 5000000 5000000 0 0 0 0 0 0 3609000 6212000 -21068000 -10378000 2500000 3000000 3465000 2548000 14454000 2629000 4564000 4577000 2684000 21130000 3629000 7971000 6271000 3259000 9475000 13757000 1000000 427000 2187000 6072000 2919000 8582000 -38130000 -31637000 50000 49015000 135461000 64429000 175139000 34901000 96860000 48179000 131599000 12564000 13826000 137575 8.73 2369876 7.98 2613267 3892658 9.14 8.54 952910 8.75 0 0.581 0.544 0.0168 0.0151 12937248 3.30 5283449 38354 93097 0 64153271 14019629 12962168 3.62 3.65 64120370 11818559 3.30 2.76 6.77 6.52 0.00 0.50 0.87 1.40 2.66 4.19 6.45 9.90 11818559 441429 4397970 1442424 889430 2997303 1614677 35326 12962168 441429 4397970 1442424 889430 3253783 2431132 106000 0.76 1.35 2.45 3.99 6.38 9.78 10.99 P6Y 62449678 P5Y7M13D P5Y7M13D 3.30 0.72 1.19 1.92 3.06 5.32 7.23 10.43 3.65 0.72 1.19 1.92 3.06 5.36 7.30 10.43 P5Y9M7D P2Y7M6D P4Y10M24D P4Y2M12D P6Y1M6D P6Y8M12D P7Y4M24D P8Y2M12D 109467416 2105945 110212547 699766 109394 3000000 3000000 0 441009 -441009 16493 43344 -43344 137575 501203 -1825329 926010 243928 -682082 2854189 0 3346000 -462000 3808000 164000 346000 6000 340000 0 -1070000 1070000 0 -14676000 1000 14675000 13826000 13826000 2548000 -2957000 5505000 23257728 20000000 60000000 10000000 3936000 107988000 163133000 109000 -38130000 -17124000 123277000 159940000 110000 -31637000 -5136000 2105945 699766 1338616 1338616 17124000 5136000 10378000 10378000 -15400000 527000 1750000 841000 553000 2504000 1030000 693000 3132000 1529000 397000 3270000 1262000 1780000 4086000 2191000 708000 4350000 2262000 227000 800000 906000 447000 1560000 2349000 339000 800000 2591000 1910000 1635000 5917000 87000 172000 407000 281000 178000 1661000 1411000 536000 2520000 1599000 555000 4917000 8044742 7931984 6369189 6265811 114556036 114110120 112361179 112193701 106511294 106178136 105991990 105927890 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Management&#8217;s Plans</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had approximately </font><font style="font-family:inherit;font-size:10pt;">$18,338,000</font><font style="font-family:inherit;font-size:10pt;"> of cash and cash equivalents.&#160;&#160;The Company reported total current assets of approximately </font><font style="font-family:inherit;font-size:10pt;">$106,290,000</font><font style="font-family:inherit;font-size:10pt;"> and current liabilities of approximately </font><font style="font-family:inherit;font-size:10pt;">$41,578,000</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The Company believes that its anticipated cash from operating and financing activities, existing cash and cash equivalents, and availability under its line of credit will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next year.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets are summarized as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted<br clear="none"/>Average<br clear="none"/>Amortization<br clear="none"/>Lives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses (a) (b) (c) (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,699</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents &amp; Know How (b) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,211</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer &amp; Supplier Relationships (b) (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,761</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tradenames &amp; Trademarks (b) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,838</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-compete agreements (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In Process Research &amp; Development (b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents in Process (c)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,298</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,823</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,002</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,627</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less Accumulated amortization and impairment charges</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,753</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,864</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,249</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,763</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of </font><font style="font-family:inherit;font-size:10pt;">$996,000</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Within </font><font style="font-family:inherit;font-size:10pt;">30 days</font><font style="font-family:inherit;font-size:10pt;"> after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;"> to the licensor.&#160;&#160;Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> on all commercial sales revenue from the licensed products. The Company is also obligated to pay a </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;"> minimum annual royalty payment over the life of the license.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 5, 2011, the Company acquired Surgical Biologics, LLC.&#160;&#160;As a result, the Company recorded intangible assets for Customer &amp; Supplier Relationships of </font><font style="font-family:inherit;font-size:10pt;">$3,761,000</font><font style="font-family:inherit;font-size:10pt;">, Patents &amp; Know-How of </font><font style="font-family:inherit;font-size:10pt;">$7,690,000</font><font style="font-family:inherit;font-size:10pt;">, Licenses of </font><font style="font-family:inherit;font-size:10pt;">$13,000</font><font style="font-family:inherit;font-size:10pt;">, Tradenames &amp; Trademarks of </font><font style="font-family:inherit;font-size:10pt;">$1,008,000</font><font style="font-family:inherit;font-size:10pt;"> and In-Process Research &amp; Development of </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;">. For the nine months ended September 30, 2016, approximately </font><font style="font-family:inherit;font-size:10pt;">$40,000</font><font style="font-family:inherit;font-size:10pt;"> of costs associated with patents granted during the period were capitalized and included in Patents &amp; Know-How subject to amortization.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents &amp; Know-How under intangible assets subject to amortization.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2016, the Company acquired Stability. As a result, the Company recorded intangible assets for Patents &amp; Know - How of </font><font style="font-family:inherit;font-size:10pt;">$9,170,000</font><font style="font-family:inherit;font-size:10pt;">, Customer Relationships of </font><font style="font-family:inherit;font-size:10pt;">$6,090,000</font><font style="font-family:inherit;font-size:10pt;">, Non - compete agreements of </font><font style="font-family:inherit;font-size:10pt;">$1,080,000</font><font style="font-family:inherit;font-size:10pt;">, Tradenames &amp; Trademarks of </font><font style="font-family:inherit;font-size:10pt;">$830,000</font><font style="font-family:inherit;font-size:10pt;"> and Licenses of </font><font style="font-family:inherit;font-size:10pt;">$690,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.&#160;&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.&#160;&#160;Changes to GAAP are established by the Financial Accounting Standards Board (&#8220;FASB&#8221;) in the form of Accounting Standards Updates (&#8220;ASU&#8217;&#8217;) to the FASB&#8217;s Accounting Standards Codification (&#8220;ASC&#8221;).&#160;&#160;In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.&#160;&#160;Operating results for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, are not necessarily indicative of the results that may be expected for the fiscal year.&#160;&#160;The balance sheet at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, included in the Company's Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, filed with the SEC on February 29, 2016.&#160;</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unaudited pro forma information for the three and nine months ended September 30, 2016 and 2015 (in thousands) is as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:598px;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:236px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:74px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:74px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:70px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:70px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three months ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,074</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per share, fully diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisition of Stability Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2016, the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics ("Stability"), a provider of human tissue products to surgeons, facilities, and distributors serving the surgical, spine, and orthopedic sectors of the healthcare</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">industry. As a result of this transaction, the Company acquired all of the outstanding shares of Stability in exchange for</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6,000,000</font><font style="font-family:inherit;font-size:10pt;"> cash, </font><font style="font-family:inherit;font-size:10pt;">$3,346,000</font><font style="font-family:inherit;font-size:10pt;"> in stock, represented by </font><font style="font-family:inherit;font-size:10pt;">441,009</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, and assumed debt of </font><font style="font-family:inherit;font-size:10pt;">$1,771,000</font><font style="font-family:inherit;font-size:10pt;">. Additional one time costs incurred in connection with the transaction totaled </font><font style="font-family:inherit;font-size:10pt;">$1,088,000</font><font style="font-family:inherit;font-size:10pt;"> and are included within selling, general and administrative expenses on the condensed consolidated statements of operations. Contingent consideration may be payable in a formula determined by sales less certain expenses for the years 2016 and 2017. As of September 30, 2016, the contingent consideration was valued at </font><font style="font-family:inherit;font-size:10pt;">$25,620,000</font><font style="font-family:inherit;font-size:10pt;"> and is shown in the schedule below as fair value of earn-out. The Company used a third party specialist to assist us with the valuation. The contingent consideration was classified as a liability.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has evaluated the contingent consideration for accounting purposes under GAAP and has determined that the</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">contingent consideration is within the scope of ASC 480 "Distinguishing Liabilities from Equity" whereby a financial instrument,</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other than an outstanding share, that embodies a conditional obligation that the issuer may settle by issuing a variable number</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of its equity shares shall be classified as a liability if, at inception, the monetary value of the obligation is based solely or</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">predominantly on variations in something other than the fair value of the issuer&#8217;s equity shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The actual purchase price was based on cash paid, the fair value of our stock on the date of the acquisition, and direct costs</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">associated with the combination. The actual purchase price has been preliminarily allocated as of September 30, 2016 (in</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">thousands) and is subject to change:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:602px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:458px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:119px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid at closing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(480</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock issued (441,009 shares valued at $9.07 per share)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,771</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of earn-out</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of purchase price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,257</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt-free working capital</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,268</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,090</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents and know-how</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,170</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade names and trademarks</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non compete agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,080</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses and permits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">690</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,860</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,912</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Assets Purchased</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,257</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital and other assets were composed of the following (in thousands):</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid Expenses and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal and state taxes receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,725</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt-free working capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,179</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(194</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Line of Credit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(932</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholder loan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net working capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">408</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long term assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The acquisition was accounted for as a purchase business combination as defined by FASB Topic 805 - "Business Combinations". The fair value of the contingent consideration is measured as a Level 3 instrument. The contingent consideration liability is recorded at fair value on the acquisition date and will be remeasured quarterly until purchase accounting is completed based on the assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measured is based on significant inputs that are not observable in the market, they are categorized as Level 3. The income valuation approach was applied in determining the fair value of the contingent consideration using a discounted cash flow valuation technique with significant unobservable inputs comprised of projected sales and certain expenses. The values assigned to intangible assets are subject to amortization. The intangible assets were assigned the following lives for amortization purposes:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:603px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:458px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:133px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated useful life (in years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible asset:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents and know-how</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade name and Trademarks</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non compete agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses and permits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill consists of the excess of the purchase price paid over the identifiable net assets and liabilities acquired at fair value.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill was determined using the residual method based on an independent appraisal of the assets and liabilities acquired in</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the transaction and is preliminary as of September 30, 2016 and is subject to change. Goodwill is tested for impairment on an annual basis as defined by FASB Topic 350 - "Intangibles - Goodwill and Other".</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following unaudited pro forma summary financial information presents the consolidated results of operations for the Company as if the acquisition had occurred on January 1, 2015. The pro forma results are shown for illustrative purposes only and do not purport to be indicative of the results that would have been reported if the acquisition had occurred on the date indicated or indicative of the results that may occur in the future.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unaudited pro forma information for the three and nine months ended September 30, 2016 and 2015 (in thousands) is as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:598px;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:236px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:74px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:74px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:70px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:70px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three months ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,074</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per share, fully diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 supplemental pro forma earnings were adjusted to exclude </font><font style="font-family:inherit;font-size:10pt;">$1,088,000</font><font style="font-family:inherit;font-size:10pt;"> of acquisition-related legal, audit and other</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs, net of tax. The 2015 supplemental pro forma earnings were adjusted to include </font><font style="font-family:inherit;font-size:10pt;">$1,186,000</font><font style="font-family:inherit;font-size:10pt;"> of amortization costs related to recorded intangible assets with defined useful lives, and </font><font style="font-family:inherit;font-size:10pt;">$1,471,000</font><font style="font-family:inherit;font-size:10pt;"> of inventory step-up charges as a result of the acquisition for comparability to 2016. The number of shares outstanding used in calculating the income per share for 2015 was adjusted to include </font><font style="font-family:inherit;font-size:10pt;">441,009</font><font style="font-family:inherit;font-size:10pt;"> shares issued as part of the purchase price and assumed to be issued on January 1, 2015.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisitions</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Results of operations of acquired companies are included in the Company&#8217;s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of an earn out based on sales less direct production costs, and are valued using discounted cash flow techniques. The fair value of these payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The acquisition was accounted for as a purchase business combination as defined by FASB Topic 805 - "Business Combinations". The fair value of the contingent consideration is measured as a Level 3 instrument. The contingent consideration liability is recorded at fair value on the acquisition date and will be remeasured quarterly until purchase accounting is completed based on the assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measured is based on significant inputs that are not observable in the market, they are categorized as Level 3. The income valuation approach was applied in determining the fair value of the contingent consideration using a discounted cash flow valuation technique with significant unobservable inputs comprised of projected sales and certain expenses. The values assigned to intangible assets are subject to amortization.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Short Term Investments</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short term investments consisted of approximately </font><font style="font-family:inherit;font-size:10pt;">$3,000,000</font><font style="font-family:inherit;font-size:10pt;"> of FDIC insured certificates of deposit held with various financial institutions as of December 31, 2015. The cost of these instruments approximated their fair market value at December 31, 2015.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental disclosure of cash flow and non-cash investing and financing activities:</font></div><div style="line-height:120%;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selected cash payments, receipts, and noncash activities are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes paid</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,506</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuance of 441,009 shares in connection with acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retirement of fixed assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuances of 43,344 and 16,493 shares in exchange for services performed, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contractual Commitments</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the capital leases noted above in Note 7, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next </font><font style="font-family:inherit;font-size:10pt;">eight years</font><font style="font-family:inherit;font-size:10pt;"> and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The Company also has commitments for meeting space and to various charitable organizations. The estimated annual lease payments, meeting space and charitable organization commitments are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12-month period ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,156</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,103</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">957</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,804</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, was approximately </font><font style="font-family:inherit;font-size:10pt;">$1,311,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$956,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, and was approximately </font><font style="font-family:inherit;font-size:10pt;">$453,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$363,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, respectively, and is allocated among cost of sales, research and development, and selling, general and administrative expenses.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Letters of Credit</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a condition of the lease for the Company's main facility, the Company is obligated under standby letters of credit in the amount of approximately </font><font style="font-family:inherit;font-size:10pt;">$103,000</font><font style="font-family:inherit;font-size:10pt;">. These obligations are reduced at various times over the life of the lease.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">FDA Untitled Letter and Draft Guidance</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 28, 2013, the FDA issued an Untitled Letter alleging that the Company's micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, MiMedx would need a biologics license to lawfully market those micronized products. Since the issuance of the Untitled Letter, the Company has been in discussions with the FDA to communicate its disagreement with the FDA's assertion that the Company's allografts are more than minimally manipulated. To date, the FDA has not changed its position that the Company's micronized products are not eligible for marketing solely under Section 361 of the Public Health Service Act, but discussions are continuing. The Company continues to market its micronized products but is also pursuing the Biologics License Application (&#8220;BLA&#8221;) process for certain of its micronized products.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2014, the FDA issued for comment &#8220;Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.&#8221; Essentially the Minimal Manipulation draft guidance takes the same position with respect to micronized amniotic tissue that the FDA took in the Untitled Letter to MiMedx 16 months earlier. The Company submitted comments asserting that the Minimal Manipulation draft guidance represents agency action that goes far beyond the FDA&#8217;s statutory authority, is inconsistent with existing HCT/P regulations and the FDA&#8217;s prior positions, and is internally inconsistent and scientifically unsound. On&#160;October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance as well. On September 12 and 13, 2016, the FDA held a public hearing to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The Company awaits further decision from FDA on the draft guidances, but anticipates this will be a lengthy process.</font></div><div style="line-height:120%;text-align:left;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the FDA does allow the Company to continue to market a micronized form of its sheet allografts without a biologics license either prior to or after finalization of the draft guidance documents, it may impose conditions, such as labeling restrictions and compliance with Current Good Manufacturing Practices (cGMP). Although the Company is preparing for these requirements in connection with its pursuit of a BLA for certain of its micronized products, earlier compliance with these conditions requires significant additional time and cost investments by the Company. It is also possible that the FDA will not allow the Company to market any form of a micronized product without a biologics license even prior to finalization of the draft guidance documents and could even require the Company to recall its micronized products. Revenues from micronized products comprised approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">12%</font><font style="font-family:inherit;font-size:10pt;">&#160;of the Company's revenues for the fiscal year ended December 31, 2015.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patent Litigation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MiMedx continues to diligently enforce its intellectual property against several entities. Currently, there are&#160;</font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">&#160;actions pending, as described below:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">The Liventa Action</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 22, 2014, the Company filed a patent infringement lawsuit in the United States District Court for the Northern District of Georgia against Liventa Bioscience, Inc. ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages (the "Liventa Action"). In addition to the allegations of infringement of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients, and in some cases, prospective investors. Though the terms of the agreement are confidential, the parties have reached an amicable settlement of the false advertising claims for an undisclosed sum. The patent infringement claims are still pending as described below.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MiMedx asserts that Liventa (formerly known as AFCell Medical, Inc.), Medline and MTF infringed and continue to infringe certain of the Company's patents relating to the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts. MTF is the tissue processor while Liventa and Medline are the distributors of the allegedly infringing products. On May 30, 2014, defendants filed answers to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement, invalidity, laches and estoppel. MTF and Medline also filed counterclaims seeking declaratory judgments of non-infringement and invalidity. Defendants filed parallel Inter Partes Review ("IPR") proceedings which are discussed below. We expect the case to go to trial in 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">The Bone Bank Action</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 16, 2014, the Company also filed a patent infringement lawsuit against Transplant Technology, Inc. d/b/a Bone Bank Allografts ("Bone Bank") and Texas Human Biologics, Ltd. ("Biologics") for permanent injunctive relief and unspecified damages (the "Bone Bank Action"). The Bone Bank Action was filed in the United States District Court for the Western District of Texas. This lawsuit similarly asserts that Bone Bank and Biologics infringed certain of the Company's patents through the manufacturing and sale of their placental-derived tissue graft products. On July 10, 2014, Defendants filed an answer to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement and invalidity and filed counterclaims seeking declaratory judgments of non-infringement and invalidity. Defendants also filed parallel IPR proceedings which are further discussed below. Discovery is closed and we expect the case to go to trial in the early part of 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">The NuTech Action</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. ("NuTech") and DCI Donor Services, Inc. ("DCI") for permanent injunctive relief and unspecified damages. This lawsuit was filed in the United States District Court for the Northern District of Alabama. The lawsuit alleges that NuTech and DCI have infringed and continue to infringe the Company's patents through the manufacture, use, sale, and/or offering of their tissue graft product. The lawsuit also asserts that NuTech knowingly and willfully made false and misleading representations about its products to customers and/or prospective customers. The case is currently in the discovery phase.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">The Vivex Action</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 1, 2016, the Company also filed a patent infringement lawsuit against Vivex BioMedical (&#8220;Vivex&#8221;) for permanent injunctive relief and unspecified damages (the "Vivex Action"). The lawsuit was filed in the United States District Court for the Northern District of Georgia. The patent at issue is the 8,709,494 patent (the "494" patent). Vivex answered MiMedx&#8217;s Complaint and filed Counterclaims of noninfringement and invalidity.</font><font style="font-family:inherit;font-size:10pt;color:#1f497d;">&#160; </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pending IPRs</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to defending the claims in the pending district court litigations, defendants in the Liventa and Bone Bank cases have challenged certain of the Company's patents in several IPR proceedings to avoid the high burden of proof of proving invalidity by "clear and convincing evidence" in the district court litigations. An inter partes review (or "IPR") is a request for a specialized group within the United States Patent and Trademark Office to review the validity of a plaintiff's patent claims. The defendants in the Bone Bank Action challenged the validity of the Company's 8,597,687 (the "687" patent) and the 494 patent; while the defendants in the Liventa Action challenged the validity of the Company's 8,372,437 and 8,323,701 patents (the "'437" and "'701" patents, respectively).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 29, 2015, the Patent Trial and Appeals Board ("PTAB") denied the Bone Bank defendants' request for institution of an IPR with respect to the '494 patent (EpiFix) on all&#160;</font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;">&#160;challenged grounds. On August 18, 2015, the PTAB also denied the Liventa defendants' request for institution of an IPR with respect to the '701 patent (AmnioFix) on all&#160;</font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">&#160;challenged grounds. That is, the PTAB decided in each case that the defendants failed to establish a reasonable likelihood that defendants would prevail in showing any of the challenged claims of the '494 or the '701 patent were unpatentable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 10, 2015, the PTAB issued an opinion allowing a review of the '687 patent to proceed, although on only&#160;</font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#160;of the&#160;</font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#160;challenged grounds. The parties decided to forego oral arguments. On July 7, 2016, the PTAB issued an opinion finding that the challenged claims, which relate to embossment and not configuration, were invalid for obviousness. On August 18, 2015, the PTAB issued an opinion allowing a review of the '437 patent to proceed, although only on&#160;</font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#160;of the&#160;</font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;">&#160;challenged grounds. On August 16, 2016, the PTAB issued an opinion finding that the challenged claims were unpatentable.&#160; MiMedx has filed a notice of appeal of the PTAB&#8217;s decision regarding the '437 patent.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated annual lease payments, meeting space and charitable organization commitments are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12-month period ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,156</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,103</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">957</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,804</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Credit Facility</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">lenders and Bank of America, N.A., as administrative agent. The Credit Agreement establishes a senior secured revolving</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">credit facility in favor of the Company with a maturity date of October 12, 2018 and an aggregate lender commitment of up to</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$50 million</font><font style="font-family:inherit;font-size:10pt;">. The Credit Agreement also provides for an uncommitted incremental facility of up to </font><font style="font-family:inherit;font-size:10pt;">$35 million</font><font style="font-family:inherit;font-size:10pt;">, which can be</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">conditions set forth in the Credit Agreement. Borrowings under the facility will bear interest at LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">1.5%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fees paid in connection with the initiation of the credit facility totaled approximately </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;">. These deferred financing costs</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">are being amortized to interest expense over the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year life of the facility. The Credit Agreement contains customary</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">representations, warranties, covenants, and events of default. As of September 30, 2016, there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> outstanding revolving loans under the credit facility.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Incentive Plans</font><font style="font-family:inherit;font-size:10pt;">&#160; </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">four</font><font style="font-family:inherit;font-size:10pt;"> share-based compensation plans which provide for the granting of equity awards, including qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors: the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan (the "2016 Plan"), which was approved by shareholders on May 18, 2016; the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the &#8220;Assumed 2006 Plan&#8221;); the MiMedx Inc. 2007 Assumed Stock Plan (the &#8220;Assumed 2007 Plan&#8221;); and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the &#8220;Assumed 2005 Plan&#8221;). The awards are subject to a vesting schedule as set forth in each individual agreement. The Company currently intends to use only the 2016 Plan to make future grants. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity with respect to the stock options is summarized as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Price</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,019,629</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(926,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested options forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(93,097</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.52</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested options expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,354</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,962,168</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.65</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.77</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,153,271</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested at September 30, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,818,559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,449,678</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested or expected to vest at September 30, 2016 (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,937,248</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.62</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,120,370</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes forfeiture adjusted unvested shares.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The intrinsic value of the options exercised during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, was approximately </font><font style="font-family:inherit;font-size:10pt;">$5,283,449</font><font style="font-family:inherit;font-size:10pt;">.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following is a summary of stock options outstanding and exercisable at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Price</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.50 - $0.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.87 - $1.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,397,970</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,397,970</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.40 - $2.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,442,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,442,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.66 - $3.99</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">889,430</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">889,430</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.19 - $6.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,253,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,997,303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6.45 - $9.78</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,431,132</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,614,677</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.90- $10.99</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,326</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,962,168</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.65</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,818,559</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total unrecognized compensation expense related to granted stock options at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, was approximately </font><font style="font-family:inherit;font-size:10pt;">$2,150,652</font><font style="font-family:inherit;font-size:10pt;"> and will be charged to expense ratably through May 2017.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of options granted by the Company is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.&#160;&#160;Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.&#160;&#160;The term of employee options granted is derived using the &#8220;simplified method,&#8221; which computes expected term as the mid point between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company's lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded.&#160;&#160;The term for non-employee options is generally based upon the contractual term of the option.&#160;&#160;The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54.4 - 58.1 %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.51 - 1.68%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> options granted during the nine months ended September 30, 2016.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Awards&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity with respect to restricted stock awards for the nine months ended September 30, 2016 is summarized as follows:&#160; </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of<br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average Grant Date<br clear="none"/> Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,613,267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.14</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,369,876</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.98</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(952,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.75</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,575</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.73</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,892,658</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.54</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, there was approximately </font><font style="font-family:inherit;font-size:10pt;">$23,767,731</font><font style="font-family:inherit;font-size:10pt;"> of total unrecognized stock-based compensation related to time-based, nonvested restricted stock.&#160;&#160;That expense is expected to be recognized on a straight-line basis over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">2.0</font><font style="font-family:inherit;font-size:10pt;"> years, which approximates the remaining vesting period of these grants. All shares noted above as unvested are considered issued and outstanding at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized stock-based compensation as follows (in thousands):&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">591</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,433</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,091</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,006</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,703</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,701</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,378</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,564</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Treasury Stock</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;padding-left:6px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> On May 12, 2014, our Board of Directors authorized the repurchase of up to </font><font style="font-family:inherit;font-size:10pt;">$10 million</font><font style="font-family:inherit;font-size:10pt;"> of our common stock from time to time, through December 31, 2014. The Board subsequently extended the program until December 31, 2016. In December 2014, the Board increased the authorization to </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;"> and further increased the authorization in 2015 to </font><font style="font-family:inherit;font-size:10pt;">$60 million</font><font style="font-family:inherit;font-size:10pt;">. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company purchased </font><font style="font-family:inherit;font-size:10pt;">1,338,616</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock for a purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$10,338,000</font><font style="font-family:inherit;font-size:10pt;"> before brokerage commissions of approximately </font><font style="font-family:inherit;font-size:10pt;">$40,000</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had approximately </font><font style="font-family:inherit;font-size:10pt;">$3,936,000</font><font style="font-family:inherit;font-size:10pt;"> of availability remaining under the repurchase program.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, for the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company reissued </font><font style="font-family:inherit;font-size:10pt;">2,854,189</font><font style="font-family:inherit;font-size:10pt;"> shares from the Treasury for restricted stock grants and stock option exercises, net of forfeitures, and as partial consideration to the shareholders of Stability, with an aggregate carrying value of approximately </font><font style="font-family:inherit;font-size:10pt;">$23,257,728</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Income (Loss) Per Share</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding during the period.&#160;&#160;Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, restricted stock, and warrants using the treasury stock method.&#160;</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Income (Loss) Per Share</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding during the period.&#160;&#160;Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, restricted stock, and warrants using the treasury stock method.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except share data):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.8515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for basic earnings per share - weighted average shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,991,990</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,511,294</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,927,890</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,178,136</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,369,189</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,044,742</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,265,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,931,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,361,179</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,556,036</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,193,701</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,110,120</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per common share - basic </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.15</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per common share - diluted</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.14</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding Stock Options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,704,112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,320,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,767,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,366,426</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,023</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,820</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted Stock Awards</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">665,077</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">686,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498,342</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">527,738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,369,189</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,044,742</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,265,811</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,931,984</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The intangible assets were assigned the following lives for amortization purposes:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:603px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:458px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:133px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated useful life (in years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible asset:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents and know-how</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade name and Trademarks</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non compete agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses and permits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income taxes</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effective tax rates for continuing operations of&#160;</font><font style="font-family:inherit;font-size:10pt;">31.5%</font><font style="font-family:inherit;font-size:10pt;"> and&#160;</font><font style="font-family:inherit;font-size:10pt;">3.2%</font><font style="font-family:inherit;font-size:10pt;"> for the nine months ended September 30, 2016 and September 30, 2015, respectively, were determined using an estimated annual effective tax rate and include, in 2016, the impact of discrete items of approximately </font><font style="font-family:inherit;font-size:10pt;">$900,000</font><font style="font-family:inherit;font-size:10pt;">. The effective tax rate for the 2016 period increased approximately </font><font style="font-family:inherit;font-size:10pt;">28.3%</font><font style="font-family:inherit;font-size:10pt;"> when compared to the same period of 2015, primarily due to the </font><font style="font-family:inherit;font-size:10pt;">$15.4 million</font><font style="font-family:inherit;font-size:10pt;"> valuation allowance release recorded in 2015 and discussed in our Annual Report on Form 10-K for the year ended December 31, 2015. Due to the valuation allowance previously recorded against the Company's U.S. deferred tax assets, the effective tax rate for the nine months ended September 30, 2015, did not include the expense of the current period U.S. taxable income. As of the end of September 2016, the projected annual effective tax rate for 2016 is approximately </font><font style="font-family:inherit;font-size:10pt;">41.0%</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible Assets and Royalty Agreement</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets are summarized as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted<br clear="none"/>Average<br clear="none"/>Amortization<br clear="none"/>Lives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses (a) (b) (c) (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,699</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents &amp; Know How (b) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,211</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer &amp; Supplier Relationships (b) (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,761</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tradenames &amp; Trademarks (b) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,838</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-compete agreements (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In Process Research &amp; Development (b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents in Process (c)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,298</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,823</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,002</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,627</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less Accumulated amortization and impairment charges</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,753</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,864</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,249</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,763</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of </font><font style="font-family:inherit;font-size:10pt;">$996,000</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Within </font><font style="font-family:inherit;font-size:10pt;">30 days</font><font style="font-family:inherit;font-size:10pt;"> after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;"> to the licensor.&#160;&#160;Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> on all commercial sales revenue from the licensed products. The Company is also obligated to pay a </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;"> minimum annual royalty payment over the life of the license.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 5, 2011, the Company acquired Surgical Biologics, LLC.&#160;&#160;As a result, the Company recorded intangible assets for Customer &amp; Supplier Relationships of </font><font style="font-family:inherit;font-size:10pt;">$3,761,000</font><font style="font-family:inherit;font-size:10pt;">, Patents &amp; Know-How of </font><font style="font-family:inherit;font-size:10pt;">$7,690,000</font><font style="font-family:inherit;font-size:10pt;">, Licenses of </font><font style="font-family:inherit;font-size:10pt;">$13,000</font><font style="font-family:inherit;font-size:10pt;">, Tradenames &amp; Trademarks of </font><font style="font-family:inherit;font-size:10pt;">$1,008,000</font><font style="font-family:inherit;font-size:10pt;"> and In-Process Research &amp; Development of </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;">. For the nine months ended September 30, 2016, approximately </font><font style="font-family:inherit;font-size:10pt;">$40,000</font><font style="font-family:inherit;font-size:10pt;"> of costs associated with patents granted during the period were capitalized and included in Patents &amp; Know-How subject to amortization.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents &amp; Know-How under intangible assets subject to amortization.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2016, the Company acquired Stability. As a result, the Company recorded intangible assets for Patents &amp; Know - How of </font><font style="font-family:inherit;font-size:10pt;">$9,170,000</font><font style="font-family:inherit;font-size:10pt;">, Customer Relationships of </font><font style="font-family:inherit;font-size:10pt;">$6,090,000</font><font style="font-family:inherit;font-size:10pt;">, Non - compete agreements of </font><font style="font-family:inherit;font-size:10pt;">$1,080,000</font><font style="font-family:inherit;font-size:10pt;">, Tradenames &amp; Trademarks of </font><font style="font-family:inherit;font-size:10pt;">$830,000</font><font style="font-family:inherit;font-size:10pt;"> and Licenses of </font><font style="font-family:inherit;font-size:10pt;">$690,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, was approximately </font><font style="font-family:inherit;font-size:10pt;">$1,889,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$699,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$631,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$234,000</font><font style="font-family:inherit;font-size:10pt;"> for </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, respectively.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected future amortization of intangible assets as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ending&#160;December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expense</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016 (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,430</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,075</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,075</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,396</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,411</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Estimated amortization expense for the year ending December 31, 2016, includes only amortization to be recorded after </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following items as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:64%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,710</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,118</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,405</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Inventory, gross</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,021</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,857</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reserve for obsolescence</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(708</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(397</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Inventory, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,313</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,460</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory is valued at the lower of cost or market value. The Company assesses the valuation of its inventory on a periodic basis and makes adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for the Company's excess inventory charge. The Company's excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patent Costs</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company and are included in Intangible Assets in the Condensed Consolidated Balance Sheets.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued, both effective and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">not yet effective. In May 2014, the FASB issued ASU 2014-09, &#8220;Revenue Recognition - Revenue from Contracts with</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customers&#8221; (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">is currently assessing the impact the adoption of ASU 2014-09 will have on our condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17, "Balance Sheet Classification of Deferred Taxes". ASU 2015-17</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">is permitted. The Company adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reporting with the release of the valuation allowance as disclosed in Note 12. Prior periods were not retrospectively adjusted.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)". The core principle of Topic 842 is that a lessee</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">should recognize the assets and liabilities that arise from both capital and operating leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718)". The standard is</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">intended to simplify several areas of accounting for share - based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. This ASU is effective for fiscal years beginning after December 15, 2016. The Company is currently assessing the impact the adoption of ASU 2016-09 will have on its consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15, &#8220;Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments&#8221;. The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company is currently assessing the impact of the adoption of ASU 2016-15 will have on its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other ASUs issued and not yet effective for the nine months ended September 30, 2016, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.&#160;&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.&#160;&#160;Changes to GAAP are established by the Financial Accounting Standards Board (&#8220;FASB&#8221;) in the form of Accounting Standards Updates (&#8220;ASU&#8217;&#8217;) to the FASB&#8217;s Accounting Standards Codification (&#8220;ASC&#8221;).&#160;&#160;In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.&#160;&#160;Operating results for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, are not necessarily indicative of the results that may be expected for the fiscal year.&#160;&#160;The balance sheet at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, included in the Company's Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, filed with the SEC on February 29, 2016.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The&#160;MiMedx&#160;allograft product families include our: dHACM family with AmnioFix&#174;, EpiFix&#174; and EpiBurn&#174; brands; Amniotic Fluid family with OrthoFlo brand; Umbilical family with EpiCord&#8482; and AmnioCord&#8482; brands; Placental Collagen family with CollaFix&#8482; and AmnioFill&#8482; brands; Bone family with Physio&#174; brand; and Skin family with AlloBurn&#8482; brand. AmnioFix,&#160; EpiFix, and EpiBurn are our tissue technologies processed from human amniotic membrane; OrthoFlo is an amniotic fluid derived allograft;&#160; EpiCord&#8482; and AmnioCord&#8482; are derived from the umbilical cord; Physio is a bone grafting material comprised of 100% bone tissue with no added carrier; AlloBurn is a skin product derived from human skin designed for the treatment of burns; and&#160;CollaFix, our next brand we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and Equipment</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> Property and equipment consisted of the following as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab and clean room equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,971</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and office equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,629</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,629</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,373</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,979</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,757</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in net property and equipment is approximately </font><font style="font-family:inherit;font-size:10pt;">$427,000</font><font style="font-family:inherit;font-size:10pt;"> of equipment covered under capital leases. The corresponding liability of approximately </font><font style="font-family:inherit;font-size:10pt;">$41,000</font><font style="font-family:inherit;font-size:10pt;"> is included in other liabilities in the accompanying Condensed Consolidated Balance Sheets. Interest rates for these leases range from approximately </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">12%</font><font style="font-family:inherit;font-size:10pt;"> with maturity dates to January 2018.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Also included in net property and equipment is approximately </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> in leasehold improvements paid for by the landlord of the Company's main facility with a corresponding liability included in other liabilities which is amortized over the term of the lease.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, was approximately </font><font style="font-family:inherit;font-size:10pt;">$2,394,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1,247,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, and approximately </font><font style="font-family:inherit;font-size:10pt;">$838,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$470,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment consisted of the following as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab and clean room equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,971</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and office equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,629</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,629</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,373</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,979</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,757</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The allowance for doubtful accounts is the Company&#8217;s best estimate of the amount of probable credit losses in the Company&#8217;s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.&#160;</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all other revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals, clinics and doctor's offices. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.&#160;&#160;</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The actual purchase price has been preliminarily allocated as of September 30, 2016 (in</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">thousands) and is subject to change:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:602px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:458px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:119px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid at closing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(480</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock issued (441,009 shares valued at $9.07 per share)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,771</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of earn-out</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of purchase price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,257</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt-free working capital</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,268</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,090</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents and know-how</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,170</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade names and trademarks</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non compete agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,080</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses and permits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">690</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,860</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,912</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Assets Purchased</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,257</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital and other assets were composed of the following (in thousands):</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid Expenses and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal and state taxes receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,725</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt-free working capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,179</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(194</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Line of Credit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(932</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholder loan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net working capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">408</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long term assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selected cash payments, receipts, and noncash activities are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes paid</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,506</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuance of 441,009 shares in connection with acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retirement of fixed assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuances of 43,344 and 16,493 shares in exchange for services performed, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except share data):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.8515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for basic earnings per share - weighted average shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,991,990</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,511,294</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,927,890</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,178,136</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,369,189</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,044,742</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,265,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,931,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,361,179</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,556,036</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,193,701</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,110,120</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per common share - basic </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.15</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per common share - diluted</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.14</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding Stock Options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,704,112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,320,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,767,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,366,426</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,023</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,820</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted Stock Awards</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">665,077</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">686,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498,342</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">527,738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,369,189</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,044,742</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,265,811</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,931,984</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized stock-based compensation as follows (in thousands):&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">591</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,433</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,091</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,006</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,703</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,701</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,378</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,564</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following items as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:64%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,710</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,118</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,405</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Inventory, gross</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,021</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,857</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reserve for obsolescence</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(708</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(397</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Inventory, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,313</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,460</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following is a summary of stock options outstanding and exercisable at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Price</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.50 - $0.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.87 - $1.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,397,970</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,397,970</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.40 - $2.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,442,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,442,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.66 - $3.99</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">889,430</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">889,430</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.19 - $6.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,253,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,997,303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6.45 - $9.78</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,431,132</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,614,677</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.90- $10.99</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,326</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,962,168</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.65</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,818,559</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity with respect to the stock options is summarized as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Price</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,019,629</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(926,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested options forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(93,097</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.52</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested options expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,354</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,962,168</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.65</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.77</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,153,271</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested at September 30, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,818,559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,449,678</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested or expected to vest at September 30, 2016 (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,937,248</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.62</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,120,370</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes forfeiture adjusted unvested shares.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54.4 - 58.1 %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.51 - 1.68%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity with respect to restricted stock awards for the nine months ended September 30, 2016 is summarized as follows:&#160; </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of<br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average Grant Date<br clear="none"/> Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,613,267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.14</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,369,876</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.98</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(952,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.75</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,575</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.73</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,892,658</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.54</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Schedule II Valuation and Qualifying Accounts</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MIMEDX GROUP, INC. AND SUBSIDIARIES</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS</font></div></td></tr><tr><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Three and Nine Months Ended September 30, 2016 and 2015 (in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at <br clear="none"/>Beginning of Period</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions charged to Expense or Revenue</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deductions <br clear="none"/>and write-offs</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at<br clear="none"/> End of Period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(536</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for product returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,191</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,591</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,520</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,262</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for obsolescence</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">708</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended September 30, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">800</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(172</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,132</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for product returns</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,030</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for obsolescence</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(87</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">693</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the nine months ended September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for product returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,262</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,917</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,917</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,262</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for obsolescence</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,599</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">708</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the nine months ended September 30, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(178</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,132</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for product returns</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,349</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,661</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Allowance for obsolescence</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">527</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">447</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(281</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">693</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected future amortization of intangible assets as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ending&#160;December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expense</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016 (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,430</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,075</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,075</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,396</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,411</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Estimated amortization expense for the year ending December 31, 2016, includes only amortization to be recorded after </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please see Note 2 to the Company's Consolidated Financial Statements included in the Company&#8217;s Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, for a description of all significant accounting policies.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The allowance for doubtful accounts is the Company&#8217;s best estimate of the amount of probable credit losses in the Company&#8217;s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory is valued at the lower of cost or market value. The Company assesses the valuation of its inventory on a periodic basis and makes adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for the Company's excess inventory charge. The Company's excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory. The value of inventory as of September 30, 2016 includes a fair value step - up connected with the January 2016 acquisition of Stability Inc. of approximately </font><font style="font-family:inherit;font-size:10pt;">$600,000</font><font style="font-family:inherit;font-size:10pt;">, which is comprised of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;"> as of the date of the acquisition less amortization of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> during the nine months ended September 30, 2016. Please see Note 4 contained herein.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all other revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals, clinics and doctor's offices. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.&#160;&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisitions</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Results of operations of acquired companies are included in the Company&#8217;s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of an earn out based on sales less direct production costs, and are valued using discounted cash flow techniques. The fair value of these payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patent Costs</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company and are included in Intangible Assets in the Condensed Consolidated Balance Sheets. The Company capitalized approximately </font><font style="font-family:inherit;font-size:10pt;">$515,000</font><font style="font-family:inherit;font-size:10pt;"> of patent costs during the first nine months of </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The Company capitalized approximately </font><font style="font-family:inherit;font-size:10pt;">$594,000</font><font style="font-family:inherit;font-size:10pt;"> of patent costs during the first nine months of 2015.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Treasury Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a first - in first - out (FIFO) basis.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued, both effective and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">not yet effective. In May 2014, the FASB issued ASU 2014-09, &#8220;Revenue Recognition - Revenue from Contracts with</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customers&#8221; (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">is currently assessing the impact the adoption of ASU 2014-09 will have on our condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17, "Balance Sheet Classification of Deferred Taxes". ASU 2015-17</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">is permitted. The Company adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reporting with the release of the valuation allowance as disclosed in Note 12. Prior periods were not retrospectively adjusted.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)". The core principle of Topic 842 is that a lessee</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">should recognize the assets and liabilities that arise from both capital and operating leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718)". The standard is</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">intended to simplify several areas of accounting for share - based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. This ASU is effective for fiscal years beginning after December 15, 2016. The Company is currently assessing the impact the adoption of ASU 2016-09 will have on its consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15, &#8220;Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments&#8221;. The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company is currently assessing the impact of the adoption of ASU 2016-15 will have on its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other ASUs issued and not yet effective for the nine months ended September 30, 2016, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Treasury Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a first - in first - out (FIFO) basis.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&#160;</font></div></div> EX-101.SCH 7 mdxg-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2104100 - Disclosure - Acquisition of Stability Inc. link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Acquisition of Stability Inc. - Intangible Assets Acquired as Part of Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Acquisition of Stability Inc. - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Acquisition of Stability Inc. - Preliminarily Allocation of Purchase Price (Details) link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - Acquisition of Stability Inc. - Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Acquisition of Stability Inc. (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Contractual Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Contractual Commitments and Contingencies - Estimated Annual Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Contractual Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Contractual Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Credit Facility link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - Credit Facility (Details) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Equity - Restricted Stock Awards (Details) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Equity - Stock Incentive Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Equity - Treasury Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Intangible Assets and Royalty Agreement link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Intangible Assets and Royalty Agreement - Estimated Future Amortization Expense for Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Intangible Assets and Royalty Agreement - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Intangible Assets and Royalty Agreement - Summary of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Intangible Assets and Royalty Agreement (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Liquidity and Management's Plans link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Liquidity and Management's Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Net Income (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Net Income (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Net Income (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Property and Equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Schedule - Schedule II - Valuation and Qualifying Accounts link:presentationLink link:calculationLink link:definitionLink 2417401 - Schedule - Schedule II - Valuation and Qualifying Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Short Term Investments link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Short Term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Supplemental disclosure of cash flow and non-cash investing and financing activities link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Supplemental disclosure of cash flow and non-cash investing and financing activities (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Supplemental disclosure of cash flow and non-cash investing and financing activities (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 mdxg-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 mdxg-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 mdxg-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document and Entity Information [Abstract] -- None. No documentation exists for this element. -- Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Amendment Flag Document Period End Date Debt Disclosure [Abstract] Credit Facility Debt Disclosure [Text Block] Supplemental Cash Flow Elements [Abstract] Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Business Combinations [Abstract] Revenue Business Acquisition, Pro Forma Revenue Net income Business Acquisition, Pro Forma Net Income (Loss) Income per share, fully diluted (in dollars per share) Business Acquisition, Pro Forma Earnings Per Share, Diluted Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Assets Held under Capital Leases Assets Held under Capital Leases [Member] Leasehold Improvements Paid by Others Leasehold Improvements Paid by Others [Member] Leasehold Improvements Paid by Others [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property and equipment, net of accumulated depreciation Property, Plant and Equipment, Net Other liabilities Other Liabilities, Noncurrent Capital leases interest rate effective percentage, minimum Capital Leases Interest Rate Effective Percentage Minimum Minimum effective interest rate for the capital lease. Capital leases interest rate effective percentage, maximum Capital Leases Interest Rate Effective Percentage Maximum Maximum effective interest rate for the capital lease. Depreciation Depreciation Accounting Policies [Abstract] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Nonrecurring Adjustment [Axis] Nonrecurring Adjustment [Axis] Nonrecurring Adjustment [Domain] Nonrecurring Adjustment [Domain] Fair Value Adjustment to Inventory Fair Value Adjustment to Inventory [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Patents Patents [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Increase (decrease) in inventories Increase (Decrease) in Inventories Amortization of inventory fair value step-up Inventory Write-down Intangible assets, net of accumulated amortization Finite-Lived Intangible Assets, Period Increase (Decrease) Equity [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Restricted Stock Awards Restricted Stock [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost of sales Cost of Sales [Member] Research and development Research and Development Expense [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Unvested, Beginning Balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Unvested, Ending Balance (in shares) Weighted- Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Unvested, Beginning Balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Unvested, Ending Balance (in dollars per share) Total unrecognized stock-based compensation related to time-based, nonvested restricted stock Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Expenses expected to be recognized over a weighted-average period (in years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Share-based Compensation [Abstract] Share-based Compensation [Abstract] Share-based compensation expense Allocated Share-based Compensation Expense Earnings Per Share [Abstract] Computation of Basic and Diluted Net Loss per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cash and Cash Equivalents [Abstract] Short Term Investments Cash, Cash Equivalents, and Short-term Investments [Text Block] Income Tax Disclosure [Abstract] Income taxes Income Tax Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] Estimated Annual Lease, Royalty and Employment Agreement Expenses Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Leasehold improvements Leasehold Improvements [Member] Lab and clean room equipment Equipment [Member] Furniture and office equipment Furniture and Fixtures [Member] Construction in progress Construction in Progress [Member] Property and equipment, gross Property, Plant and Equipment, Gross Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Inventory Disclosure [Abstract] Inventory Schedule of Inventory, Current [Table Text Block] Equity Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Investment [Table] Investment [Table] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Certificates of Deposit Certificates of Deposit [Member] Investment [Line Items] Investment [Line Items] Short term investments Short-term Investments Liquidity and management's plans [Abstract] -- None. No documentation exists for this element. -- Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Total current liabilities Liabilities, Current Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Stability Biologics, LLC Stability Biologics, LLC [Member] Stability Biologics, LLC Customer relationships Customer Relationships [Member] Patents and know-how Non compete agreements Noncompete Agreements [Member] Licenses and permits Licensing Agreements [Member] Estimated useful life (in years) Finite-Lived Intangible Asset, Useful Life Statement of Financial Position [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Treasury stock, shares (in shares) Treasury Stock, Shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Net Income (Loss) Attributable to Parent Adjustments to reconcile net income to net cash from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Amortization of intangible assets Amortization of Intangible Assets Amortization of deferred financing costs Amortization of Debt Issuance Costs and Discounts Share-based compensation Share-based Compensation Increase (decrease) in cash, net of effects of acquisition, resulting from changes in: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventory Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense Other assets Increase (Decrease) in Other Operating Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued compensation Increase (Decrease) in Deferred Compensation Accrued expenses Increase (Decrease) in Accrued Liabilities Other liabilities Increase (Decrease) in Other Operating Liabilities Net cash flows from operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of equipment Payments to Acquire Machinery and Equipment Purchase of Stability Inc., net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Fixed maturity securities redemption Proceeds from Sale and Maturity of Held-to-maturity Securities Patent application costs Payments for Application Costs, Patent Payments for Application Costs, Patent Net cash flows from investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Stock repurchase under repurchase plan Proceeds from (Repurchase of) Equity Stock repurchase for tax withholdings on vesting of restricted stock Payments Related to Tax Withholding for Share-based Compensation Deferred financing costs Payments of Debt Issuance Costs Payments under capital lease obligations Payments to Acquire Equipment on Lease Net cash flows from financing activities Net Cash Provided by (Used in) Financing Activities Net change in cash Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Credit Agreement Credit Agreement [Member] Credit Agreement [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Maximum borrowing capacity (up to) Line of Credit Facility, Maximum Borrowing Capacity Uncommitted incremental facility (up to) Line of Credit Facility, Uncommitted Incremental Facility Line of Credit Facility, Uncommitted Incremental Facility Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Debt issuance costs Debt Issuance Costs, Net Debt term Debt Instrument, Term Outstanding line of credit Long-term Line of Credit Income Statement [Abstract] Net sales Sales Revenue, Goods, Net Cost of sales Cost of Goods Sold Gross margin Gross Profit Operating expenses: Operating Expenses [Abstract] Research and development expenses Research and Development Expense Selling, general and administrative expenses Selling, General and Administrative Expense Operating income Operating Income (Loss) Other income (expense), net Nonoperating Income (Expense) [Abstract] Interest income (expense), net Other Nonoperating Income (Expense) Income before income tax provision Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income tax provision Income Tax Expense (Benefit) Net income Net income per common share - basic (in dollars per share) Earnings Per Share, Basic Net income per common share - diluted (in dollars per share) Earnings Per Share, Diluted Weighted average shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Weighted average shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Number of business segments Number of Operating Segments Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets and Royalty Agreement Intangible Assets Disclosure [Text Block] Raw materials Inventory, Raw Materials, Gross Work in process Inventory, Work in Process, Gross Finished goods Inventory, Finished Goods, Gross Inventory, gross Inventory, Gross Reserve for obsolescence Inventory Valuation Reserves Inventory, net Inventory, Net Stock Options Activity Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Stock Options Outstanding and Exercisable Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Fair Value of Options, Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Restricted Stock Awards Roll Forward Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Allocation of Share-based Compensation Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Segment Reporting Segment Reporting, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Accounts Receivable Receivables, Policy [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Revenue Recognition Revenue Recognition, Sales of Goods [Policy Text Block] Acquisitions Business Combinations Policy [Policy Text Block] Patent Costs Legal Costs, Policy [Policy Text Block] Treasury Stock Stockholders' Equity, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Net Income (Loss) Per Share Earnings Per Share, Policy [Policy Text Block] Contractual Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Exercise Price Range [Axis] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] $0.50 - $0.76 Price Range 1 [Member] Price Range 1 [Member] $0.87 - $1.35 Price Range 2 [Member] Price Range 2 [Member] $1.40 - $2.45 Price Range 3 [Member] Price Range 3 [Member] $2.66 - $3.99 Price Range 4 [Member] Price Range 4 [Member] $4.19 - $6.38 Price Range 5 [Member] Price Range 5 [Member] $6.45 - $9.78 Price Range 6 [Member] Price Range 6 [Member] $9.90- $10.99 Price Range 7 [Member] Price Range 7 [Member] Number of share-based compensation plans Number of share based compensation plans The number of share-based compensation the company maintains. Number of shares [Roll forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding, beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Unvested options forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Vested options expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Outstanding, end of period (in shares) Vested at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Exercisable options, vested and expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted-Average Exercise Price [Roll forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding, weighted average exercise price, beginning of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted, weighted average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised, weighted average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Unvested options forfeited, weighted-average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Vested options expired, weighted-average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Outstanding, weighted average exercise price, end of period (in dollars per share) Vested at end of period, weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Vested and expected to vest, weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Stock options, additional disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Outstanding Options, weighted average remaining contractual term (in years) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term Vested at end of period, weighted average remaining contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Vested and expected to vest, weighted average remaining contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Outstanding, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Vested at end of period, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Vested or expected to vest, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Exercised options, intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Exercise Price Range, lower range limit (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Exercise Price Range, upper range limit (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Number of outstanding options (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options Outstanding Options, weighted average remaining contractual term (in years) Outstanding Options, weighted average exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price Number of exercisable options (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Exercisable Options, weighted average exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price Total unrecognized compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Fair value options valuation assumptions [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Expected volatility Minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility Maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected life (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Risk-free interest rate Minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate Maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Estimated annual lease, royalty, and employment agreement expenses [Abstract] Contractual Obligation, Fiscal Year Maturity [Abstract] 2017 Contractual Obligation, Due in Next Fiscal Year 2018 Contractual Obligation, Due in Second Year 2019 Contractual Obligation, Due in Third Year 2020 Contractual Obligation, Due in Fourth Year Thereafter Contractual Obligation, Due after Fifth Year Total Contractual commitments Contractual Obligation Significant Accounting Policies Significant Accounting Policies [Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Pro Forma Pro Forma [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Cash paid at closing Payments to Acquire Businesses, Gross Common stock issued Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Common stock issued (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Assumed debt Business Combination, Consideration Transferred, Liabilities Incurred Acquisition related costs Business Combination, Acquisition Related Costs Fair value of earn-out Business Combination, Contingent Consideration, Liability Income Tax Contingency [Table] Income Tax Contingency [Table] Forecast Scenario, Forecast [Member] Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Effective income tax rate increase (decrease), amount Effective Income Tax Rate Reconciliation, Increase (Decrease) During Period, Amount Effective Income Tax Rate Reconciliation, Increase (Decrease) During Period, Amount Effective income tax rate increase (decrease), percent Effective Income Tax Rate Reconciliation, Increase (Decrease) During Period, Percent Effective Income Tax Rate Reconciliation, Increase (Decrease) During Period, Percent Decrease in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Trade names and trademarks Trademarks and Trade Names [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Long-term debt Loans Payable [Member] Line of Credit Line of Credit [Member] Shareholder loan Shareholder Debt [Member] Shareholder Debt [Member] Business Combination, Consideration Transferred [Abstract] Business Combination, Consideration Transferred [Abstract] Working capital adjustment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Common stock issued (441,009 shares valued at $9.07 per share) Common stock issued, price per share (in dollars per share) Business Acquisition, Share Price Total fair value of purchase price Business Combination, Consideration Transferred Net assets acquired: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Debt-free working capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Debt-free Working Capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Debt-free Working Capital Other assets, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent Subtotal Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets, Net Finite-Lived intangibles assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Indefinite-lived intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Subtotal Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Goodwill Goodwill Total Assets Purchased Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Prepaid Expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Accounts Receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Accounts Receivable Federal and state taxes receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Income Taxes Receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Income Taxes Receivable Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Accounts payable and accrued expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Debt-free working capital Current portion of long term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt Long-term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Net working capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Working Capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Working Capital Other long term assets Acquisition of Stability Inc. Business Combination Disclosure [Text Block] Net Income (Loss) Per Share Earnings Per Share [Text Block] Liquidity and Management's Plans Liquidity and management's plans [Text Block] The entire disclosure of management's assessment of funding needs and access to credit facilities to meet cash operational needs in the long term. Estimated future amortization expense [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] 2016 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year 2017 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2018 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Five Thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Net book value Finite-Lived Intangible Assets, Net Schedule of Acquisition of Stability Inc. Schedule of Business Acquisitions, by Acquisition [Table Text Block] Finite-Lived and Indefinite-Lived Intangible Assets Acquired Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Business Acquisition, Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Tradenames & trademarks Trade names and trademarks [Member] Rights acquired through registration of a business name to gain or protect exclusive use thereof and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style. In process research & development In Process Research and Development [Member] Patents in process Patents in Process [Member] Patents in Process Licenses Customer & supplier relationships Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. Shriners Hospitals For Children And University Of South Florida Research Foundation, Inc. [Member] Shriners Hospitals For Children And University Of South Florida Research Foundation, Inc. [Member] Surgical Biologics, LLC Surgical Biologics [Member] Represents Surgical Biologics, LLC ("Surgical Biologics"), a privately held company headquartered in Kennesaw, Georgia. which the Company acquired through an Agreement and Plan of Merger ("the Merger Agreement") with Membrane Products Holdings, LLC and Ramp Capital Investments, LLC on December 21, 2010. Weighted average amortization lives Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Gross carrying value Finite-Lived Intangible Assets, Gross Gross carrying value, indefinite lived Indefinite-Lived Intangible Assets (Excluding Goodwill) Total Intangible Assets, Gross (Excluding Goodwill) Less Accumulated amortization and impairment charges Intangible Assets, Accumulated Amortization And Impairment Charges Intangible Assets, Accumulated Amortization And Impairment Charges Net Intangible Assets, Net (Excluding Goodwill) Acquisition price Payments to Acquire Intangible Assets Maximum time of approval Period of approval, maximum The maximum amount of time the entity has to obtain approval by the FDA to allow the sale of the product. Contingent royalty to be paid to licensor Contingent royalty to be paid to licensor Royalty payment percentage on all commercial sales revenue from the licensed products. Annual royalty payment, minimum Royalty Expense Finite lived intangible assets Finite-lived Intangible Assets Acquired Loss Contingencies Loss Contingencies [Table] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Standby Letters of Credit Standby Letters of Credit [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Sales Revenue, Net Sales Revenue, Net [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Product Concentration Risk Product Concentration Risk [Member] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Pending Litigation Pending Litigation [Member] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Bone Bank Action Bone Bank Action [Member] Bone Bank Action [Member] Liventa Action, 701 Patent Liventa Action, 701 Patent [Member] Liventa Action, 701 Patent [Member] Liventa Action, 437 Patent Liventa Action, 437 Patent [Member] Liventa Action, 437 Patent [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Lease expiration period Lessee Leasing Arrangements, Operating Leases, Term of Contract Rent expense Operating Leases, Rent Expense Standby letters of credit Letters of Credit Outstanding, Amount Percentage of revenue Concentration Risk, Percentage Number of patent challenged grounds Loss Contingency, Pending Claims, Number Opinion allowing a review of patent Loss Contingency, Pending Claims, Allowed for Review, Number Loss Contingency Pending Claims Number Allowed for Review Valuation and Qualifying Accounts [Abstract] Valuation and Qualifying Accounts Disclosure [Table] Valuation and Qualifying Accounts Disclosure [Table] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves [Domain] Valuation Allowances and Reserves [Domain] Allowance for doubtful accounts Allowance for Doubtful Accounts [Member] Allowance for product returns Allowance for Sales Returns [Member] Allowance for obsolescence Allowance for Obsolescence [Member] Allowance for Obsolescence [Member] Valuation and Qualifying Accounts Disclosure [Line Items] Valuation and Qualifying Accounts Disclosure [Line Items] Movement in Valuation Allowances and Reserves [Roll Forward] Movement in Valuation Allowances and Reserves [Roll Forward] Balance at Beginning of Period Valuation Allowances and Reserves, Balance Additions charged to Expense or Revenue Valuation Allowances and Reserves, Additions for Charges to Cost and Expense Deductions and write-offs Valuation Allowances and Reserves, Deductions Balance at End of Period Intangible Assets Activity Summary Schedule of Intangible assets activity [Table Text Block] Tabular disclosure of intangible assets activity, which may be broken down by segment or major class. Estimated Future Amortization Expense for Intangible Assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Inventories Inventory Disclosure [Text Block] Authorized share amount for repurchase (up to) Stock Repurchase Program, Authorized Amount Stock repurchase (in shares) Treasury Stock, Shares, Acquired Shares repurchased, value Payments for Repurchase of Common Stock Brokerage commissions Treasury Stock, Brokerage Commissions Treasury Stock, Brokerage Commissions Remaining authorizations under the repurchase program Stock Repurchase Program, Remaining Authorized Repurchase Amount Shares reissued from the treasury (in shares) Stock Issued During Period, Shares, Treasury Stock Reissued Shares reissued from the treasury, value Stock Issued During Period, Value, Treasury Stock Reissued Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Accounts receivable, net Accounts Receivable, Net, Current Inventory, net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Intangible assets, net of accumulated amortization Deferred tax asset, net Deferred Income Tax Assets, Net Deferred financing costs and other assets Deferred Costs and Other Assets Total assets Assets Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued compensation Employee-related Liabilities, Current Accrued expenses Accrued Liabilities, Current Current portion of earn out liability Business Combination, Contingent Consideration, Liability, Current Other current liabilities Other Liabilities, Current Total current liabilities Earn out liability Business Combination, Contingent Consideration, Liability, Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Stockholders' equity: Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding Preferred Stock, Value, Issued Common stock; $.001 par value; 150,000,000 shares authorized; 110,212,547 issued and 109,512,781 outstanding at September 30, 2016 and 109,467,416 issued and 107,361,471 outstanding at December 31, 2015 Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Treasury stock at cost: 699,766 shares at September 30, 2016 and 2,105,945 shares at December 31, 2015 Treasury Stock, Value Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders' equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity Liabilities and Equity Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid - in Capital Additional Paid-in Capital [Member] Treasury Stock Treasury Stock [Member] Accumulated Deficit Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance, beginning of period Balance (in shares) Shares, Outstanding Share-based compensation expense Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options (in shares) Issuance of restricted stock Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Issuance of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Restricted stock shares cancelled/forfeited Stock Issued During Period, Value, Restricted Stock Award, Forfeitures Restricted stock shares cancelled/forfeited (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Shares issued for services performed Stock Issued During Period, Value, Issued for Services Shares issued for services performed (in shares) Stock Issued During Period, Shares, Issued for Services Stock repurchase Treasury Stock, Value, Acquired, Cost Method Shares repurchased for tax withholding Adjustments Related to Tax Withholding for Share-based Compensation Shares repurchased for tax withholding (in shares) Shares Paid for Tax Withholding for Share Based Compensation Shares issued in conjunction with acquisition Stock Issued During Period, Value, Acquisitions Shares issued in conjunction with acquisition (in shares) Stock Issued During Period, Shares, Acquisitions Balance, end of period Balance (in shares) Supplemental disclosure of cash flow and non-cash investing and financing activities [Abstract] Supplemental disclosure of cash flow and non cash investing and financing activities [Abstract] -- None. No documentation exists for this element. -- Cash paid for interest Interest Paid Income taxes paid Income Taxes Paid Stock issuance of 441,009 shares in connection with acquisition Retirement of fixed assets Write-off of Fixed Assets Write-off of Fixed Assets Stock issuances of 43,344 and 16,493 shares in exchange for services performed, respectively Supplemental disclosure of cash flow and non-cash investing and financing activities Cash Flow, Supplemental Disclosures [Text Block] Schedule II - Valuation and Qualifying Accounts Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Computation of basic and diluted net loss per share [Abstract] Computation of basic and diluted net loss per share [Abstract] -- None. No documentation exists for this element. -- Net income Denominator for basic earnings per share - weighted average shares (in shares) Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities (in shares) Income per common share - basic (in dollars per share) Income per common share - diluted (in dollars per share) Summary of Antidilutive Securities [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Outstanding Stock Options Employee Stock Option [Member] Outstanding Warrants Warrant [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Summary of Property and Equipment Property, Plant and Equipment [Table Text Block] EX-101.PRE 11 mdxg-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2016
Oct. 15, 2016
Document and Entity Information [Abstract]    
Entity Registrant Name MIMEDX GROUP, INC.  
Entity Central Index Key 0001376339  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   109,514,557
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q3  
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2016  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 18,338 $ 28,486
Short term investments 0 3,000
Accounts receivable, net 63,427 53,755
Inventory, net 18,313 7,460
Prepaid expenses and other current assets 6,212 3,609
Total current assets 106,290 96,310
Property and equipment, net of accumulated depreciation 13,757 9,475
Goodwill 26,951 4,040
Intangible assets, net of accumulated amortization 27,249 10,763
Deferred tax asset, net 7,019 14,838
Deferred financing costs and other assets 399 487
Total assets 181,665 135,913
Current liabilities:    
Accounts payable 11,162 6,633
Accrued compensation 10,812 15,034
Accrued expenses 6,664 4,644
Current portion of earn out liability 9,642 0
Other current liabilities 3,298 466
Total current liabilities 41,578 26,777
Earn out liability 15,978 0
Other liabilities 832 1,148
Total liabilities 58,388 27,925
Commitments and contingencies
Stockholders' equity:    
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding 0 0
Common stock; $.001 par value; 150,000,000 shares authorized; 110,212,547 issued and 109,512,781 outstanding at September 30, 2016 and 109,467,416 issued and 107,361,471 outstanding at December 31, 2015 110 109
Additional paid-in capital 159,940 163,133
Treasury stock at cost: 699,766 shares at September 30, 2016 and 2,105,945 shares at December 31, 2015 (5,136) (17,124)
Accumulated deficit (31,637) (38,130)
Total stockholders' equity 123,277 107,988
Total liabilities and stockholders' equity $ 181,665 $ 135,913
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Sep. 30, 2016
Dec. 31, 2015
Stockholders' equity:    
Preferred stock par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 150,000,000 150,000,000
Common stock, shares issued (in shares) 110,212,547 109,467,416
Common stock, shares outstanding (in shares) 109,512,781 107,361,471
Treasury stock, shares (in shares) 699,766 2,105,945
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Income Statement [Abstract]        
Net sales $ 64,429 $ 49,015 $ 175,139 $ 135,461
Cost of sales 7,997 4,979 23,338 15,217
Gross margin 56,432 44,036 151,801 120,244
Operating expenses:        
Research and development expenses 2,919 2,187 8,582 6,072
Selling, general and administrative expenses 48,179 34,901 131,599 96,860
Amortization of intangible assets 631 234 1,889 699
Operating income 4,703 6,714 9,731 16,613
Other income (expense), net        
Interest income (expense), net (87) (5) (254) (18)
Income before income tax provision 4,616 6,709 9,477 16,595
Income tax provision (1,295) (158) (2,984) (527)
Net income $ 3,321 $ 6,551 $ 6,493 $ 16,068
Net income per common share - basic (in dollars per share) $ 0.03 $ 0.06 $ 0.06 $ 0.15
Net income per common share - diluted (in dollars per share) $ 0.03 $ 0.06 $ 0.06 $ 0.14
Weighted average shares outstanding - basic (in shares) 105,991,990 106,511,294 105,927,890 106,178,136
Weighted average shares outstanding - diluted (in shares) 112,361,179 114,556,036 112,193,701 114,110,120
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - 9 months ended Sep. 30, 2016 - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid - in Capital
Treasury Stock
Accumulated Deficit
Balance, beginning of period at Dec. 31, 2015 $ 107,988 $ 109 $ 163,133 $ (17,124) $ (38,130)
Balance (in shares) at Dec. 31, 2015   109,467,416   2,105,945  
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Share-based compensation expense 13,826   13,826    
Exercise of stock options $ 2,548   (2,957) $ 5,505  
Exercise of stock options (in shares) 926,010 243,928   (682,082)  
Issuance of restricted stock $ 0 $ 1 (14,676) $ 14,675  
Issuance of restricted stock (in shares)   501,203   (1,825,329)  
Restricted stock shares cancelled/forfeited 0   1,070 $ (1,070)  
Restricted stock shares cancelled/forfeited (in shares)       137,575  
Shares issued for services performed $ 346   6 $ 340  
Shares issued for services performed (in shares) 43,344     (43,344)  
Stock repurchase $ (10,378)     $ (10,378)  
Stock repurchase (in shares) 1,338,616     1,338,616  
Shares repurchased for tax withholding $ (892)     $ (892)  
Shares repurchased for tax withholding (in shares)       109,394  
Shares issued in conjunction with acquisition $ 3,346   (462) $ 3,808  
Shares issued in conjunction with acquisition (in shares) 441,009     (441,009)  
Net income $ 6,493       6,493
Balance, end of period at Sep. 30, 2016 $ 123,277 $ 110 $ 159,940 $ (5,136) $ (31,637)
Balance (in shares) at Sep. 30, 2016   110,212,547   699,766  
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Cash flows from operating activities:    
Net income $ 6,493 $ 16,068
Adjustments to reconcile net income to net cash from operating activities:    
Depreciation 2,394 1,247
Amortization of intangible assets 1,889 699
Amortization of inventory fair value step-up 1,471 0
Amortization of deferred financing costs 136 0
Share-based compensation 13,826 12,564
Increase (decrease) in cash, net of effects of acquisition, resulting from changes in:    
Accounts receivable (7,671) (20,106)
Inventory (3,599) (520)
Prepaid expenses and other current assets (2,023) (1,201)
Other assets (163) (26)
Accounts payable (3,941) 3,747
Accrued compensation (4,223) 1,474
Accrued expenses 2,020 1,592
Other liabilities 2,539 (1,087)
Net cash flows from operating activities 9,148 14,451
Cash flows from investing activities:    
Purchases of equipment (5,301) (4,176)
Purchase of Stability Inc., net of cash acquired (7,631) 0
Fixed maturity securities redemption 3,000 2,500
Patent application costs (515) (594)
Net cash flows from investing activities (10,447) (2,270)
Cash flows from financing activities:    
Proceeds from exercise of stock options 2,548 3,465
Stock repurchase under repurchase plan (10,378) (21,068)
Stock repurchase for tax withholdings on vesting of restricted stock (892) 0
Deferred financing costs (106) 0
Payments under capital lease obligations (21) (87)
Net cash flows from financing activities (8,849) (17,690)
Net change in cash (10,148) (5,509)
Cash and cash equivalents, beginning of period 28,486 46,582
Cash and cash equivalents, end of period $ 18,338 $ 41,073
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
Basis of Presentation
 9 Months Ended
Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASU’’) to the FASB’s Accounting Standards Codification (“ASC”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the nine months ended September 30, 2016 and 2015, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at December 31, 2015, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. 
You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2015, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on February 29, 2016. 
The Company operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The MiMedx allograft product families include our: dHACM family with AmnioFix®, EpiFix® and EpiBurn® brands; Amniotic Fluid family with OrthoFlo brand; Umbilical family with EpiCord™ and AmnioCord™ brands; Placental Collagen family with CollaFix™ and AmnioFill™ brands; Bone family with Physio® brand; and Skin family with AlloBurn™ brand. AmnioFix,  EpiFix, and EpiBurn are our tissue technologies processed from human amniotic membrane; OrthoFlo is an amniotic fluid derived allograft;  EpiCord™ and AmnioCord™ are derived from the umbilical cord; Physio is a bone grafting material comprised of 100% bone tissue with no added carrier; AlloBurn is a skin product derived from human skin designed for the treatment of burns; and CollaFix, our next brand we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
Significant Accounting Policies
 9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Significant Accounting Policies
Significant Accounting Policies
Please see Note 2 to the Company's Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2015, for a description of all significant accounting policies. 
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. 
Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay. 
Inventories
Inventory is valued at the lower of cost or market value. The Company assesses the valuation of its inventory on a periodic basis and makes adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for the Company's excess inventory charge. The Company's excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory. The value of inventory as of September 30, 2016 includes a fair value step - up connected with the January 2016 acquisition of Stability Inc. of approximately $600,000, which is comprised of approximately $2.1 million as of the date of the acquisition less amortization of approximately $1.5 million during the nine months ended September 30, 2016. Please see Note 4 contained herein.


Revenue Recognition
The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all other revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals, clinics and doctor's offices. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.  
Acquisitions
Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.

Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of an earn out based on sales less direct production costs, and are valued using discounted cash flow techniques. The fair value of these payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.
Patent Costs
The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company and are included in Intangible Assets in the Condensed Consolidated Balance Sheets. The Company capitalized approximately $515,000 of patent costs during the first nine months of 2016. The Company capitalized approximately $594,000 of patent costs during the first nine months of 2015.
Treasury Stock
The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a first - in first - out (FIFO) basis.
Recent Accounting Pronouncements 
The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued, both effective and
not yet effective. In May 2014, the FASB issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with
Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when
companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting
periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company
is currently assessing the impact the adoption of ASU 2014-09 will have on our condensed consolidated financial statements.

In November 2015, the FASB issued ASU No. 2015-17, "Balance Sheet Classification of Deferred Taxes". ASU 2015-17
simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the
balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016,
and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption
is permitted. The Company adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify
reporting with the release of the valuation allowance as disclosed in Note 12. Prior periods were not retrospectively adjusted.

In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)". The core principle of Topic 842 is that a lessee
should recognize the assets and liabilities that arise from both capital and operating leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718)". The standard is
intended to simplify several areas of accounting for share - based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. This ASU is effective for fiscal years beginning after December 15, 2016. The Company is currently assessing the impact the adoption of ASU 2016-09 will have on its consolidated financial statements.

In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments”. The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company is currently assessing the impact of the adoption of ASU 2016-15 will have on its consolidated financial statements.
All other ASUs issued and not yet effective for the nine months ended September 30, 2016, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
Liquidity and Management's Plans
 9 Months Ended
Sep. 30, 2016
Liquidity and management's plans [Abstract]  
Liquidity and Management's Plans
Liquidity and Management’s Plans
As of September 30, 2016, the Company had approximately $18,338,000 of cash and cash equivalents.  The Company reported total current assets of approximately $106,290,000 and current liabilities of approximately $41,578,000 as of September 30, 2016.  The Company believes that its anticipated cash from operating and financing activities, existing cash and cash equivalents, and availability under its line of credit will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next year.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisition of Stability Inc.
 9 Months Ended
Sep. 30, 2016
Business Combinations [Abstract]  
Acquisition of Stability Inc.
Acquisition of Stability Inc.

On January 13, 2016, the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics ("Stability"), a provider of human tissue products to surgeons, facilities, and distributors serving the surgical, spine, and orthopedic sectors of the healthcare
industry. As a result of this transaction, the Company acquired all of the outstanding shares of Stability in exchange for
$6,000,000 cash, $3,346,000 in stock, represented by 441,009 shares of our common stock, and assumed debt of $1,771,000. Additional one time costs incurred in connection with the transaction totaled $1,088,000 and are included within selling, general and administrative expenses on the condensed consolidated statements of operations. Contingent consideration may be payable in a formula determined by sales less certain expenses for the years 2016 and 2017. As of September 30, 2016, the contingent consideration was valued at $25,620,000 and is shown in the schedule below as fair value of earn-out. The Company used a third party specialist to assist us with the valuation. The contingent consideration was classified as a liability.

The Company has evaluated the contingent consideration for accounting purposes under GAAP and has determined that the
contingent consideration is within the scope of ASC 480 "Distinguishing Liabilities from Equity" whereby a financial instrument,
other than an outstanding share, that embodies a conditional obligation that the issuer may settle by issuing a variable number
of its equity shares shall be classified as a liability if, at inception, the monetary value of the obligation is based solely or
predominantly on variations in something other than the fair value of the issuer’s equity shares.

The actual purchase price was based on cash paid, the fair value of our stock on the date of the acquisition, and direct costs
associated with the combination. The actual purchase price has been preliminarily allocated as of September 30, 2016 (in
thousands) and is subject to change:

Cash paid at closing
 
$
6,000

Working capital adjustment
 
(480
)
Common stock issued (441,009 shares valued at $9.07 per share)
 
3,346

Assumed debt
 
1,771

Fair value of earn-out
 
25,620

Total fair value of purchase price
 
$
36,257

 
 
 
Net assets acquired:
 

Debt-free working capital
 
$
2,179

Other assets, net
 
199

Property, plant and equipment
 
1,375

Deferred tax liability
 
(8,268
)
Subtotal
 
(4,515
)
Intangible assets:
 
 
Customer relationships
 
6,090

Patents and know-how
 
9,170

Trade names and trademarks
 
830

Non compete agreements
 
1,080

Licenses and permits
 
690

Subtotal
 
17,860

Goodwill
 
22,912

Total Assets Purchased
 
$
36,257

 
 
 
Working capital and other assets were composed of the following (in thousands):
 
 
Working capital
 
 
Cash
 
$
140

Prepaid Expenses and other current assets
 
100

Accounts receivable
 
2,001

Federal and state taxes receivable
 
28

Inventory
 
8,725

Accounts payable and accrued expenses
 
(8,815
)
Debt-free working capital
 
$
2,179

 
 
 
Current portion of long term debt
 
$
(194
)
Long-term debt
 
(560
)
Line of Credit
 
(932
)
Shareholder loan
 
(85
)
Net working capital
 
$
408

 
 

Other assets:
 
 
Other long term assets
 
$
199



The acquisition was accounted for as a purchase business combination as defined by FASB Topic 805 - "Business Combinations". The fair value of the contingent consideration is measured as a Level 3 instrument. The contingent consideration liability is recorded at fair value on the acquisition date and will be remeasured quarterly until purchase accounting is completed based on the assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measured is based on significant inputs that are not observable in the market, they are categorized as Level 3. The income valuation approach was applied in determining the fair value of the contingent consideration using a discounted cash flow valuation technique with significant unobservable inputs comprised of projected sales and certain expenses. The values assigned to intangible assets are subject to amortization. The intangible assets were assigned the following lives for amortization purposes:

 
 
Estimated useful life (in years)
Intangible asset:
 
 
Customer relationships
 
12
Patents and know-how
 
20
Trade name and Trademarks
 
Indefinite
Non compete agreements
 
4
Licenses and permits
 
2


Goodwill consists of the excess of the purchase price paid over the identifiable net assets and liabilities acquired at fair value.
Goodwill was determined using the residual method based on an independent appraisal of the assets and liabilities acquired in
the transaction and is preliminary as of September 30, 2016 and is subject to change. Goodwill is tested for impairment on an annual basis as defined by FASB Topic 350 - "Intangibles - Goodwill and Other".

The following unaudited pro forma summary financial information presents the consolidated results of operations for the Company as if the acquisition had occurred on January 1, 2015. The pro forma results are shown for illustrative purposes only and do not purport to be indicative of the results that would have been reported if the acquisition had occurred on the date indicated or indicative of the results that may occur in the future.

Unaudited pro forma information for the three and nine months ended September 30, 2016 and 2015 (in thousands) is as follows:

 
 
Three months ended September 30,
 
Nine Months Ended September 30,
 
 
2016
2015
 
2016
2015
Revenue
 
$
64,429

$
52,108

 
$
175,687

$
148,521

 
 
 
 
 
 
 
Net income
 
$
3,406

$
4,253

 
$
7,074

$
12,227

 
 
 
 
 
 
 
Income per share, fully diluted
 
$
0.03

$
0.04

 
$
0.06

$
0.11



The 2016 supplemental pro forma earnings were adjusted to exclude $1,088,000 of acquisition-related legal, audit and other
costs, net of tax. The 2015 supplemental pro forma earnings were adjusted to include $1,186,000 of amortization costs related to recorded intangible assets with defined useful lives, and $1,471,000 of inventory step-up charges as a result of the acquisition for comparability to 2016. The number of shares outstanding used in calculating the income per share for 2015 was adjusted to include 441,009 shares issued as part of the purchase price and assumed to be issued on January 1, 2015.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
Short Term Investments
 9 Months Ended
Sep. 30, 2016
Cash and Cash Equivalents [Abstract]  
Short Term Investments
Short Term Investments
Short term investments consisted of approximately $3,000,000 of FDIC insured certificates of deposit held with various financial institutions as of December 31, 2015. The cost of these instruments approximated their fair market value at December 31, 2015.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
Inventories
 9 Months Ended
Sep. 30, 2016
Inventory Disclosure [Abstract]  
Inventories
Inventories
Inventories consisted of the following items as of September 30, 2016, and December 31, 2015 (in thousands):
 
September 30, 2016
 
December 31, 2015
Raw materials
$
1,193

 
$
602

Work in process
6,710

 
3,850

Finished goods
11,118

 
3,405

 Inventory, gross
19,021

 
7,857

Reserve for obsolescence
(708
)
 
(397
)
 Inventory, net
$
18,313

 
$
7,460
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment
 9 Months Ended
Sep. 30, 2016
Property, Plant and Equipment [Abstract]  
Property and Equipment
Property and Equipment 
Property and equipment consisted of the following as of September 30, 2016, and December 31, 2015 (in thousands):
 
September 30,
2016
 
December 31,
2015
Leasehold improvements
$
3,259

 
$
2,684

Lab and clean room equipment
7,971

 
4,564

Furniture and office equipment
6,271

 
4,577

Construction in progress
3,629

 
2,629

   Property and equipment, gross
21,130

 
14,454

Less accumulated depreciation
(7,373
)
 
(4,979
)
   Property and equipment, net
$
13,757

 
$
9,475


Included in net property and equipment is approximately $427,000 of equipment covered under capital leases. The corresponding liability of approximately $41,000 is included in other liabilities in the accompanying Condensed Consolidated Balance Sheets. Interest rates for these leases range from approximately 3% to 12% with maturity dates to January 2018.
Also included in net property and equipment is approximately $1.0 million in leasehold improvements paid for by the landlord of the Company's main facility with a corresponding liability included in other liabilities which is amortized over the term of the lease.
Depreciation expense for the nine months ended September 30, 2016 and 2015, was approximately $2,394,000 and $1,247,000, respectively, and approximately $838,000 and $470,000 for the three months ended September 30, 2016 and 2015, respectively.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangible Assets and Royalty Agreement
 9 Months Ended
Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Royalty Agreement
Intangible Assets and Royalty Agreement
Intangible assets are summarized as follows (in thousands):
 
Weighted
Average
Amortization
Lives
 
September 30, 2016
 
December 31, 2015
 
 
 
Cost
 
Cost
Licenses (a) (b) (c) (d)
7 years
 
$
1,699

 
$
1,009

Patents & Know How (b) (d)
19 years
 
17,211

 
8,001

Customer & Supplier Relationships (b) (d)
13 years
 
9,851

 
3,761

Tradenames & Trademarks (b) (d)
indefinite
 
1,838

 
1,008

Non-compete agreements (d)
4 years
 
1,080

 
—

In Process Research & Development (b)
n/a
 
25

 
25

Patents in Process (c)
n/a
 
2,298

 
1,823

Total
 
 
34,002

 
15,627

Less Accumulated amortization and impairment charges
 
 
(6,753
)
 
(4,864
)
Net
 
 
$
27,249

 
$
10,763

(a)
On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000.  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license.
(b)
On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Tradenames & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the nine months ended September 30, 2016, approximately $40,000 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization.
(c)
Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
(d)
On January 13, 2016, the Company acquired Stability. As a result, the Company recorded intangible assets for Patents & Know - How of $9,170,000, Customer Relationships of $6,090,000, Non - compete agreements of $1,080,000, Tradenames & Trademarks of $830,000 and Licenses of $690,000.
Amortization expense for the nine months ended September 30, 2016 and 2015, was approximately $1,889,000 and $699,000, respectively, and $631,000 and $234,000 for three months ended September 30, 2016 and 2015, respectively.
Expected future amortization of intangible assets as of September 30, 2016, is as follows (in thousands):
Year ending December 31,
Estimated
Amortization
Expense
2016 (a)
$
630

2017
2,430

2018
2,075

2019
2,075

2020
1,805

Thereafter
16,396

 
$
25,411

(a) Estimated amortization expense for the year ending December 31, 2016, includes only amortization to be recorded after September 30, 2016.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
Credit Facility
 9 Months Ended
Sep. 30, 2016
Debt Disclosure [Abstract]  
Credit Facility
Credit Facility

On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain
lenders and Bank of America, N.A., as administrative agent. The Credit Agreement establishes a senior secured revolving
credit facility in favor of the Company with a maturity date of October 12, 2018 and an aggregate lender commitment of up to
$50 million. The Credit Agreement also provides for an uncommitted incremental facility of up to $35 million, which can be
exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and
conditions set forth in the Credit Agreement. Borrowings under the facility will bear interest at LIBOR plus 1.5% to 2.25%.
Fees paid in connection with the initiation of the credit facility totaled approximately $500,000. These deferred financing costs
are being amortized to interest expense over the three-year life of the facility. The Credit Agreement contains customary
representations, warranties, covenants, and events of default. As of September 30, 2016, there were no outstanding revolving loans under the credit facility.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
Net Income (Loss) Per Share
 9 Months Ended
Sep. 30, 2016
Earnings Per Share [Abstract]  
Net Income (Loss) Per Share
Net Income (Loss) Per Share
Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, restricted stock, and warrants using the treasury stock method. 
The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except share data):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Net income
$
3,321

 
$
6,551

 
$
6,493

 
$
16,068

Denominator for basic earnings per share - weighted average shares
105,991,990

 
106,511,294

 
105,927,890

 
106,178,136

Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)
6,369,189

 
8,044,742

 
6,265,811

 
7,931,984

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
112,361,179

 
114,556,036

 
112,193,701

 
114,110,120

Income per common share - basic
$
0.03

 
$
0.06

 
$
0.06

 
$
0.15

Income per common share - diluted
$
0.03

 
$
0.06


$
0.06


$
0.14

(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Outstanding Stock Options
5,704,112

 
7,320,155

 
5,767,469

 
7,366,426

Outstanding Warrants
—

 
38,023

 
—

 
37,820

Restricted Stock Awards
665,077

 
686,564

 
498,342

 
527,738

 
6,369,189

 
8,044,742

 
6,265,811

 
7,931,984
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity
 9 Months Ended
Sep. 30, 2016
Equity [Abstract]  
Equity
Equity
Stock Incentive Plans 
The Company has four share-based compensation plans which provide for the granting of equity awards, including qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors: the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan (the "2016 Plan"), which was approved by shareholders on May 18, 2016; the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “Assumed 2006 Plan”); the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”); and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”). The awards are subject to a vesting schedule as set forth in each individual agreement. The Company currently intends to use only the 2016 Plan to make future grants.

Activity with respect to the stock options is summarized as follows:
 
Number
 of
Shares
 
Weighted-
Average
Exercise
Price
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic
Value
Outstanding at January 1, 2016
14,019,629

 
$
3.62

 
 
 
 
Granted
—

 
$
—

 
 
 
 
Exercised
(926,010
)
 
$
2.76

 
 
 
 
Unvested options forfeited
(93,097
)
 
$
6.52

 
 
 
 
Vested options expired
(38,354
)
 
$
6.77

 
 
 
 

Outstanding at September 30, 2016
12,962,168

 
$
3.65

 
5.77
 
$
64,153,271

Vested at September 30, 2016
11,818,559

 
$
3.30

 
5.62
 
$
62,449,678

Vested or expected to vest at September 30, 2016 (a)
12,937,248

 
$
3.30

 
5.62
 
$
64,120,370

(a)
Includes forfeiture adjusted unvested shares.
The intrinsic value of the options exercised during the nine months ended September 30, 2016, was approximately $5,283,449. 
Following is a summary of stock options outstanding and exercisable at September 30, 2016:
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
Number outstanding
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Weighted-
Average
Exercise
Price
 
Number Exercisable
 
Weighted-
Average
Exercise Price
$0.50 - $0.76
441,429

 
2.6
 
$
0.72

 
441,429

 
$
0.72

$0.87 - $1.35
4,397,970

 
4.9
 
1.19

 
4,397,970

 
1.19

$1.40 - $2.45
1,442,424

 
4.2
 
1.92

 
1,442,424

 
1.92

$2.66 - $3.99
889,430

 
6.1
 
3.06

 
889,430

 
3.06

$4.19 - $6.38
3,253,783

 
6.7
 
5.36

 
2,997,303

 
5.32

$6.45 - $9.78
2,431,132

 
7.4
 
7.30

 
1,614,677

 
7.23

$9.90- $10.99
106,000

 
8.2
 
10.43

 
35,326

 
10.43

 
12,962,168

 
5.8
 
$
3.65

 
11,818,559

 
$
3.30

 
Total unrecognized compensation expense related to granted stock options at September 30, 2016, was approximately $2,150,652 and will be charged to expense ratably through May 2017. 
The fair value of options granted by the Company is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.  Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.  The term of employee options granted is derived using the “simplified method,” which computes expected term as the mid point between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company's lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded.  The term for non-employee options is generally based upon the contractual term of the option.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.
The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:
 
Nine Months Ended September 30,
 
2016
 
2015
Expected volatility
n/a
 
54.4 - 58.1 %

Expected life (in years)
n/a
 
6.0

Expected dividend yield
n/a
 
—

Risk-free interest rate
n/a
 
1.51 - 1.68%


There were no options granted during the nine months ended September 30, 2016.
Restricted Stock Awards                                                    
Activity with respect to restricted stock awards for the nine months ended September 30, 2016 is summarized as follows: 
 
Number
of
Shares
 
Weighted-Average Grant Date
Fair Value
Unvested at January 1, 2016
2,613,267

 
$9.14
Granted
2,369,876

 
7.98
Vested
(952,910
)
 
8.75
Forfeited
(137,575
)
 
8.73

Unvested at September 30, 2016
3,892,658

 
$8.54

As of September 30, 2016, there was approximately $23,767,731 of total unrecognized stock-based compensation related to time-based, nonvested restricted stock.  That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.0 years, which approximates the remaining vesting period of these grants. All shares noted above as unvested are considered issued and outstanding at September 30, 2016.
For the three and nine months ended September 30, 2016 and 2015, the Company recognized stock-based compensation as follows (in thousands): 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Cost of sales
$
109

 
$
85

 
$
300

 
$
270

Research and development
159

 
202

 
520

 
591

Selling, general and administrative
4,433

 
4,091

 
13,006

 
11,703

 
$
4,701

 
$
4,378

 
$
13,826

 
$
12,564


Treasury Stock
On May 12, 2014, our Board of Directors authorized the repurchase of up to $10 million of our common stock from time to time, through December 31, 2014. The Board subsequently extended the program until December 31, 2016. In December 2014, the Board increased the authorization to $20 million and further increased the authorization in 2015 to $60 million. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.
For the nine months ended September 30, 2016, the Company purchased 1,338,616 shares of its common stock for a purchase price of approximately $10,338,000 before brokerage commissions of approximately $40,000. As of September 30, 2016, the Company had approximately $3,936,000 of availability remaining under the repurchase program.
Additionally, for the nine months ended September 30, 2016, the Company reissued 2,854,189 shares from the Treasury for restricted stock grants and stock option exercises, net of forfeitures, and as partial consideration to the shareholders of Stability, with an aggregate carrying value of approximately $23,257,728.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income taxes
 9 Months Ended
Sep. 30, 2016
Income Tax Disclosure [Abstract]  
Income taxes
Income taxes 

The effective tax rates for continuing operations of 31.5% and 3.2% for the nine months ended September 30, 2016 and September 30, 2015, respectively, were determined using an estimated annual effective tax rate and include, in 2016, the impact of discrete items of approximately $900,000. The effective tax rate for the 2016 period increased approximately 28.3% when compared to the same period of 2015, primarily due to the $15.4 million valuation allowance release recorded in 2015 and discussed in our Annual Report on Form 10-K for the year ended December 31, 2015. Due to the valuation allowance previously recorded against the Company's U.S. deferred tax assets, the effective tax rate for the nine months ended September 30, 2015, did not include the expense of the current period U.S. taxable income. As of the end of September 2016, the projected annual effective tax rate for 2016 is approximately 41.0%.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Supplemental disclosure of cash flow and non-cash investing and financing activities
 9 Months Ended
Sep. 30, 2016
Supplemental Cash Flow Elements [Abstract]  
Supplemental disclosure of cash flow and non-cash investing and financing activities
Supplemental disclosure of cash flow and non-cash investing and financing activities:
    
Selected cash payments, receipts, and noncash activities are as follows (in thousands):
 
Nine Months Ended September 30,
 
2016
 
2015
Cash paid for interest
$
118

 
$
18

Income taxes paid
637

 
1,506

Stock issuance of 441,009 shares in connection with acquisition
3,346

 
—

Retirement of fixed assets
—

 
319

Stock issuances of 43,344 and 16,493 shares in exchange for services performed, respectively
346

 
164
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
Contractual Commitments and Contingencies
 9 Months Ended
Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]  
Contractual Commitments and Contingencies
Contractual Commitments and Contingencies
Contractual Commitments
In addition to the capital leases noted above in Note 7, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next eight years and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The Company also has commitments for meeting space and to various charitable organizations. The estimated annual lease payments, meeting space and charitable organization commitments are as follows (in thousands):
12-month period ended September 30,
2017
$
3,156

2018
3,103

2019
2,038

2020
957

Thereafter
550

 
$
9,804



Rent expense for the nine months ended September 30, 2016 and 2015, was approximately $1,311,000 and $956,000, respectively, and was approximately $453,000 and $363,000 for the three months ended September 30, 2016 and 2015, respectively, and is allocated among cost of sales, research and development, and selling, general and administrative expenses.

Letters of Credit
As a condition of the lease for the Company's main facility, the Company is obligated under standby letters of credit in the amount of approximately $103,000. These obligations are reduced at various times over the life of the lease.
FDA Untitled Letter and Draft Guidance
On August 28, 2013, the FDA issued an Untitled Letter alleging that the Company's micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, MiMedx would need a biologics license to lawfully market those micronized products. Since the issuance of the Untitled Letter, the Company has been in discussions with the FDA to communicate its disagreement with the FDA's assertion that the Company's allografts are more than minimally manipulated. To date, the FDA has not changed its position that the Company's micronized products are not eligible for marketing solely under Section 361 of the Public Health Service Act, but discussions are continuing. The Company continues to market its micronized products but is also pursuing the Biologics License Application (“BLA”) process for certain of its micronized products.

On December 22, 2014, the FDA issued for comment “Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.” Essentially the Minimal Manipulation draft guidance takes the same position with respect to micronized amniotic tissue that the FDA took in the Untitled Letter to MiMedx 16 months earlier. The Company submitted comments asserting that the Minimal Manipulation draft guidance represents agency action that goes far beyond the FDA’s statutory authority, is inconsistent with existing HCT/P regulations and the FDA’s prior positions, and is internally inconsistent and scientifically unsound. On October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance as well. On September 12 and 13, 2016, the FDA held a public hearing to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The Company awaits further decision from FDA on the draft guidances, but anticipates this will be a lengthy process.

If the FDA does allow the Company to continue to market a micronized form of its sheet allografts without a biologics license either prior to or after finalization of the draft guidance documents, it may impose conditions, such as labeling restrictions and compliance with Current Good Manufacturing Practices (cGMP). Although the Company is preparing for these requirements in connection with its pursuit of a BLA for certain of its micronized products, earlier compliance with these conditions requires significant additional time and cost investments by the Company. It is also possible that the FDA will not allow the Company to market any form of a micronized product without a biologics license even prior to finalization of the draft guidance documents and could even require the Company to recall its micronized products. Revenues from micronized products comprised approximately 12% of the Company's revenues for the fiscal year ended December 31, 2015.

Patent Litigation

MiMedx continues to diligently enforce its intellectual property against several entities. Currently, there are four actions pending, as described below:

The Liventa Action

On April 22, 2014, the Company filed a patent infringement lawsuit in the United States District Court for the Northern District of Georgia against Liventa Bioscience, Inc. ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages (the "Liventa Action"). In addition to the allegations of infringement of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients, and in some cases, prospective investors. Though the terms of the agreement are confidential, the parties have reached an amicable settlement of the false advertising claims for an undisclosed sum. The patent infringement claims are still pending as described below.

MiMedx asserts that Liventa (formerly known as AFCell Medical, Inc.), Medline and MTF infringed and continue to infringe certain of the Company's patents relating to the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts. MTF is the tissue processor while Liventa and Medline are the distributors of the allegedly infringing products. On May 30, 2014, defendants filed answers to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement, invalidity, laches and estoppel. MTF and Medline also filed counterclaims seeking declaratory judgments of non-infringement and invalidity. Defendants filed parallel Inter Partes Review ("IPR") proceedings which are discussed below. We expect the case to go to trial in 2017.

The Bone Bank Action

On May 16, 2014, the Company also filed a patent infringement lawsuit against Transplant Technology, Inc. d/b/a Bone Bank Allografts ("Bone Bank") and Texas Human Biologics, Ltd. ("Biologics") for permanent injunctive relief and unspecified damages (the "Bone Bank Action"). The Bone Bank Action was filed in the United States District Court for the Western District of Texas. This lawsuit similarly asserts that Bone Bank and Biologics infringed certain of the Company's patents through the manufacturing and sale of their placental-derived tissue graft products. On July 10, 2014, Defendants filed an answer to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement and invalidity and filed counterclaims seeking declaratory judgments of non-infringement and invalidity. Defendants also filed parallel IPR proceedings which are further discussed below. Discovery is closed and we expect the case to go to trial in the early part of 2017.

The NuTech Action

On March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. ("NuTech") and DCI Donor Services, Inc. ("DCI") for permanent injunctive relief and unspecified damages. This lawsuit was filed in the United States District Court for the Northern District of Alabama. The lawsuit alleges that NuTech and DCI have infringed and continue to infringe the Company's patents through the manufacture, use, sale, and/or offering of their tissue graft product. The lawsuit also asserts that NuTech knowingly and willfully made false and misleading representations about its products to customers and/or prospective customers. The case is currently in the discovery phase.

The Vivex Action

On April 1, 2016, the Company also filed a patent infringement lawsuit against Vivex BioMedical (“Vivex”) for permanent injunctive relief and unspecified damages (the "Vivex Action"). The lawsuit was filed in the United States District Court for the Northern District of Georgia. The patent at issue is the 8,709,494 patent (the "494" patent). Vivex answered MiMedx’s Complaint and filed Counterclaims of noninfringement and invalidity. 

Pending IPRs

In addition to defending the claims in the pending district court litigations, defendants in the Liventa and Bone Bank cases have challenged certain of the Company's patents in several IPR proceedings to avoid the high burden of proof of proving invalidity by "clear and convincing evidence" in the district court litigations. An inter partes review (or "IPR") is a request for a specialized group within the United States Patent and Trademark Office to review the validity of a plaintiff's patent claims. The defendants in the Bone Bank Action challenged the validity of the Company's 8,597,687 (the "687" patent) and the 494 patent; while the defendants in the Liventa Action challenged the validity of the Company's 8,372,437 and 8,323,701 patents (the "'437" and "'701" patents, respectively).

On June 29, 2015, the Patent Trial and Appeals Board ("PTAB") denied the Bone Bank defendants' request for institution of an IPR with respect to the '494 patent (EpiFix) on all seven challenged grounds. On August 18, 2015, the PTAB also denied the Liventa defendants' request for institution of an IPR with respect to the '701 patent (AmnioFix) on all six challenged grounds. That is, the PTAB decided in each case that the defendants failed to establish a reasonable likelihood that defendants would prevail in showing any of the challenged claims of the '494 or the '701 patent were unpatentable.

On July 10, 2015, the PTAB issued an opinion allowing a review of the '687 patent to proceed, although on only two of the five challenged grounds. The parties decided to forego oral arguments. On July 7, 2016, the PTAB issued an opinion finding that the challenged claims, which relate to embossment and not configuration, were invalid for obviousness. On August 18, 2015, the PTAB issued an opinion allowing a review of the '437 patent to proceed, although only on one of the seven challenged grounds. On August 16, 2016, the PTAB issued an opinion finding that the challenged claims were unpatentable.  MiMedx has filed a notice of appeal of the PTAB’s decision regarding the '437 patent.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Subsequent Events
 9 Months Ended
Sep. 30, 2016
Subsequent Events [Abstract]  
Subsequent Events
Subsequent Events
None
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Schedule II - Valuation and Qualifying Accounts
 9 Months Ended
Sep. 30, 2016
Valuation and Qualifying Accounts [Abstract]  
Schedule II - Valuation and Qualifying Accounts
Schedule II Valuation and Qualifying Accounts
MIMEDX GROUP, INC. AND SUBSIDIARIES
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS
 Three and Nine Months Ended September 30, 2016 and 2015 (in thousands)
 
 
 
 
 
 
 
 
Balance at
Beginning of Period
Additions charged to Expense or Revenue
Deductions
and write-offs
Balance at
End of Period
 
 
 
 
 
 
For the three months ended September 30, 2016
 
 
 
 
 
 Allowance for doubtful accounts
 
$
4,086

$
800

$
(536
)
$
4,350

 Allowance for product returns
 
2,191

2,591

(2,520
)
2,262

 Allowance for obsolescence
 
1,780

339

(1,411
)
708

 
 
 
 
 
 
For the three months ended September 30, 2015
 
 
 
 
 
 Allowance for doubtful accounts
 
$
2,504

$
800

$
(172
)
$
3,132

 Allowance for product returns
 
1,030

906

(407
)
1,529

 Allowance for obsolescence
 
553

227

(87
)
693

 
 
 
 
 
 
For the nine months ended September 30, 2016
 
 
 
 
 
 Allowance for doubtful accounts
 
$
3,270

$
1,635

$
(555
)
$
4,350

 Allowance for product returns
 
1,262

5,917

(4,917
)
2,262

 Allowance for obsolescence
 
397

1,910

(1,599
)
708


 
 
 
 
 
For the nine months ended September 30, 2015
 
 
 
 
 
 Allowance for doubtful accounts
 
$
1,750

$
1,560

$
(178
)
$
3,132

 Allowance for product returns
 
841

2,349

(1,661
)
1,529

 Allowance for obsolescence
 
527

447

(281
)
693
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASU’’) to the FASB’s Accounting Standards Codification (“ASC”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the nine months ended September 30, 2016 and 2015, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at December 31, 2015, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. 
You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2015, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on February 29, 2016. 
Segment Reporting
The Company operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. 
Accounts Receivable
Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay. 
Inventories
Inventories
Inventory is valued at the lower of cost or market value. The Company assesses the valuation of its inventory on a periodic basis and makes adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for the Company's excess inventory charge. The Company's excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory.
Revenue Recognition
Revenue Recognition
The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all other revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals, clinics and doctor's offices. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.  
Acquisitions
Acquisitions
Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.

Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of an earn out based on sales less direct production costs, and are valued using discounted cash flow techniques. The fair value of these payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.
The acquisition was accounted for as a purchase business combination as defined by FASB Topic 805 - "Business Combinations". The fair value of the contingent consideration is measured as a Level 3 instrument. The contingent consideration liability is recorded at fair value on the acquisition date and will be remeasured quarterly until purchase accounting is completed based on the assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measured is based on significant inputs that are not observable in the market, they are categorized as Level 3. The income valuation approach was applied in determining the fair value of the contingent consideration using a discounted cash flow valuation technique with significant unobservable inputs comprised of projected sales and certain expenses. The values assigned to intangible assets are subject to amortization.
Patent Costs
Patent Costs
The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company and are included in Intangible Assets in the Condensed Consolidated Balance Sheets.
Treasury Stock
Treasury Stock
The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a first - in first - out (FIFO) basis.
Recent Accounting Pronouncements
Recent Accounting Pronouncements 
The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued, both effective and
not yet effective. In May 2014, the FASB issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with
Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when
companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting
periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company
is currently assessing the impact the adoption of ASU 2014-09 will have on our condensed consolidated financial statements.

In November 2015, the FASB issued ASU No. 2015-17, "Balance Sheet Classification of Deferred Taxes". ASU 2015-17
simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the
balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016,
and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption
is permitted. The Company adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify
reporting with the release of the valuation allowance as disclosed in Note 12. Prior periods were not retrospectively adjusted.

In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)". The core principle of Topic 842 is that a lessee
should recognize the assets and liabilities that arise from both capital and operating leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718)". The standard is
intended to simplify several areas of accounting for share - based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. This ASU is effective for fiscal years beginning after December 15, 2016. The Company is currently assessing the impact the adoption of ASU 2016-09 will have on its consolidated financial statements.

In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments”. The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company is currently assessing the impact of the adoption of ASU 2016-15 will have on its consolidated financial statements.
All other ASUs issued and not yet effective for the nine months ended September 30, 2016, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.
Net Income (Loss) Per Share
Net Income (Loss) Per Share
Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, restricted stock, and warrants using the treasury stock method. 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisition of Stability Inc. (Tables)
 9 Months Ended
Sep. 30, 2016
Business Combinations [Abstract]  
Schedule of Acquisition of Stability Inc.
The actual purchase price has been preliminarily allocated as of September 30, 2016 (in
thousands) and is subject to change:

Cash paid at closing
 
$
6,000

Working capital adjustment
 
(480
)
Common stock issued (441,009 shares valued at $9.07 per share)
 
3,346

Assumed debt
 
1,771

Fair value of earn-out
 
25,620

Total fair value of purchase price
 
$
36,257

 
 
 
Net assets acquired:
 

Debt-free working capital
 
$
2,179

Other assets, net
 
199

Property, plant and equipment
 
1,375

Deferred tax liability
 
(8,268
)
Subtotal
 
(4,515
)
Intangible assets:
 
 
Customer relationships
 
6,090

Patents and know-how
 
9,170

Trade names and trademarks
 
830

Non compete agreements
 
1,080

Licenses and permits
 
690

Subtotal
 
17,860

Goodwill
 
22,912

Total Assets Purchased
 
$
36,257

 
 
 
Working capital and other assets were composed of the following (in thousands):
 
 
Working capital
 
 
Cash
 
$
140

Prepaid Expenses and other current assets
 
100

Accounts receivable
 
2,001

Federal and state taxes receivable
 
28

Inventory
 
8,725

Accounts payable and accrued expenses
 
(8,815
)
Debt-free working capital
 
$
2,179

 
 
 
Current portion of long term debt
 
$
(194
)
Long-term debt
 
(560
)
Line of Credit
 
(932
)
Shareholder loan
 
(85
)
Net working capital
 
$
408

 
 

Other assets:
 
 
Other long term assets
 
$
199
Finite-Lived and Indefinite-Lived Intangible Assets Acquired
The intangible assets were assigned the following lives for amortization purposes:

 
 
Estimated useful life (in years)
Intangible asset:
 
 
Customer relationships
 
12
Patents and know-how
 
20
Trade name and Trademarks
 
Indefinite
Non compete agreements
 
4
Licenses and permits
 
2
Business Acquisition, Pro Forma Information
Unaudited pro forma information for the three and nine months ended September 30, 2016 and 2015 (in thousands) is as follows:

 
 
Three months ended September 30,
 
Nine Months Ended September 30,
 
 
2016
2015
 
2016
2015
Revenue
 
$
64,429

$
52,108

 
$
175,687

$
148,521

 
 
 
 
 
 
 
Net income
 
$
3,406

$
4,253

 
$
7,074

$
12,227

 
 
 
 
 
 
 
Income per share, fully diluted
 
$
0.03

$
0.04

 
$
0.06

$
0.11
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
Inventories (Tables)
 9 Months Ended
Sep. 30, 2016
Inventory Disclosure [Abstract]  
Inventory
Inventories consisted of the following items as of September 30, 2016, and December 31, 2015 (in thousands):
 
September 30, 2016
 
December 31, 2015
Raw materials
$
1,193

 
$
602

Work in process
6,710

 
3,850

Finished goods
11,118

 
3,405

 Inventory, gross
19,021

 
7,857

Reserve for obsolescence
(708
)
 
(397
)
 Inventory, net
$
18,313

 
$
7,460
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment (Tables)
 9 Months Ended
Sep. 30, 2016
Property, Plant and Equipment [Abstract]  
Summary of Property and Equipment
Property and equipment consisted of the following as of September 30, 2016, and December 31, 2015 (in thousands):
 
September 30,
2016
 
December 31,
2015
Leasehold improvements
$
3,259

 
$
2,684

Lab and clean room equipment
7,971

 
4,564

Furniture and office equipment
6,271

 
4,577

Construction in progress
3,629

 
2,629

   Property and equipment, gross
21,130

 
14,454

Less accumulated depreciation
(7,373
)
 
(4,979
)
   Property and equipment, net
$
13,757

 
$
9,475
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangible Assets and Royalty Agreement (Tables)
 9 Months Ended
Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Activity Summary
Intangible assets are summarized as follows (in thousands):
 
Weighted
Average
Amortization
Lives
 
September 30, 2016
 
December 31, 2015
 
 
 
Cost
 
Cost
Licenses (a) (b) (c) (d)
7 years
 
$
1,699

 
$
1,009

Patents & Know How (b) (d)
19 years
 
17,211

 
8,001

Customer & Supplier Relationships (b) (d)
13 years
 
9,851

 
3,761

Tradenames & Trademarks (b) (d)
indefinite
 
1,838

 
1,008

Non-compete agreements (d)
4 years
 
1,080

 
—

In Process Research & Development (b)
n/a
 
25

 
25

Patents in Process (c)
n/a
 
2,298

 
1,823

Total
 
 
34,002

 
15,627

Less Accumulated amortization and impairment charges
 
 
(6,753
)
 
(4,864
)
Net
 
 
$
27,249

 
$
10,763

(a)
On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000.  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license.
(b)
On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Tradenames & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the nine months ended September 30, 2016, approximately $40,000 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization.
(c)
Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
(d)
On January 13, 2016, the Company acquired Stability. As a result, the Company recorded intangible assets for Patents & Know - How of $9,170,000, Customer Relationships of $6,090,000, Non - compete agreements of $1,080,000, Tradenames & Trademarks of $830,000 and Licenses of $690,000.
Estimated Future Amortization Expense for Intangible Assets
Expected future amortization of intangible assets as of September 30, 2016, is as follows (in thousands):
Year ending December 31,
Estimated
Amortization
Expense
2016 (a)
$
630

2017
2,430

2018
2,075

2019
2,075

2020
1,805

Thereafter
16,396

 
$
25,411

(a) Estimated amortization expense for the year ending December 31, 2016, includes only amortization to be recorded after September 30, 2016.
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Net Income (Loss) Per Share (Tables)
 9 Months Ended
Sep. 30, 2016
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Net Loss per Share
The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except share data):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Net income
$
3,321

 
$
6,551

 
$
6,493

 
$
16,068

Denominator for basic earnings per share - weighted average shares
105,991,990

 
106,511,294

 
105,927,890

 
106,178,136

Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)
6,369,189

 
8,044,742

 
6,265,811

 
7,931,984

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
112,361,179

 
114,556,036

 
112,193,701

 
114,110,120

Income per common share - basic
$
0.03

 
$
0.06

 
$
0.06

 
$
0.15

Income per common share - diluted
$
0.03

 
$
0.06


$
0.06


$
0.14

(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Outstanding Stock Options
5,704,112

 
7,320,155

 
5,767,469

 
7,366,426

Outstanding Warrants
—

 
38,023

 
—

 
37,820

Restricted Stock Awards
665,077

 
686,564

 
498,342

 
527,738

 
6,369,189

 
8,044,742

 
6,265,811

 
7,931,984
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity (Tables)
 9 Months Ended
Sep. 30, 2016
Equity [Abstract]  
Stock Options Activity
Activity with respect to the stock options is summarized as follows:
 
Number
 of
Shares
 
Weighted-
Average
Exercise
Price
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic
Value
Outstanding at January 1, 2016
14,019,629

 
$
3.62

 
 
 
 
Granted
—

 
$
—

 
 
 
 
Exercised
(926,010
)
 
$
2.76

 
 
 
 
Unvested options forfeited
(93,097
)
 
$
6.52

 
 
 
 
Vested options expired
(38,354
)
 
$
6.77

 
 
 
 

Outstanding at September 30, 2016
12,962,168

 
$
3.65

 
5.77
 
$
64,153,271

Vested at September 30, 2016
11,818,559

 
$
3.30

 
5.62
 
$
62,449,678

Vested or expected to vest at September 30, 2016 (a)
12,937,248

 
$
3.30

 
5.62
 
$
64,120,370

(a)
Includes forfeiture adjusted unvested shares.
Stock Options Outstanding and Exercisable
Following is a summary of stock options outstanding and exercisable at September 30, 2016:
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
Number outstanding
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Weighted-
Average
Exercise
Price
 
Number Exercisable
 
Weighted-
Average
Exercise Price
$0.50 - $0.76
441,429

 
2.6
 
$
0.72

 
441,429

 
$
0.72

$0.87 - $1.35
4,397,970

 
4.9
 
1.19

 
4,397,970

 
1.19

$1.40 - $2.45
1,442,424

 
4.2
 
1.92

 
1,442,424

 
1.92

$2.66 - $3.99
889,430

 
6.1
 
3.06

 
889,430

 
3.06

$4.19 - $6.38
3,253,783

 
6.7
 
5.36

 
2,997,303

 
5.32

$6.45 - $9.78
2,431,132

 
7.4
 
7.30

 
1,614,677

 
7.23

$9.90- $10.99
106,000

 
8.2
 
10.43

 
35,326

 
10.43

 
12,962,168

 
5.8
 
$
3.65

 
11,818,559

 
$
3.30
Fair Value of Options, Valuation Assumptions
The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:
 
Nine Months Ended September 30,
 
2016
 
2015
Expected volatility
n/a
 
54.4 - 58.1 %

Expected life (in years)
n/a
 
6.0

Expected dividend yield
n/a
 
—

Risk-free interest rate
n/a
 
1.51 - 1.68%
Restricted Stock Awards Roll Forward
Activity with respect to restricted stock awards for the nine months ended September 30, 2016 is summarized as follows: 
 
Number
of
Shares
 
Weighted-Average Grant Date
Fair Value
Unvested at January 1, 2016
2,613,267

 
$9.14
Granted
2,369,876

 
7.98
Vested
(952,910
)
 
8.75
Forfeited
(137,575
)
 
8.73

Unvested at September 30, 2016
3,892,658

 
$8.54
Allocation of Share-based Compensation
For the three and nine months ended September 30, 2016 and 2015, the Company recognized stock-based compensation as follows (in thousands): 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Cost of sales
$
109

 
$
85

 
$
300

 
$
270

Research and development
159

 
202

 
520

 
591

Selling, general and administrative
4,433

 
4,091

 
13,006

 
11,703

 
$
4,701

 
$
4,378

 
$
13,826

 
$
12,564
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
Supplemental disclosure of cash flow and non-cash investing and financing activities (Tables)
 9 Months Ended
Sep. 30, 2016
Supplemental Cash Flow Elements [Abstract]  
Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities
Selected cash payments, receipts, and noncash activities are as follows (in thousands):
 
Nine Months Ended September 30,
 
2016
 
2015
Cash paid for interest
$
118

 
$
18

Income taxes paid
637

 
1,506

Stock issuance of 441,009 shares in connection with acquisition
3,346

 
—

Retirement of fixed assets
—

 
319

Stock issuances of 43,344 and 16,493 shares in exchange for services performed, respectively
346

 
164
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
Contractual Commitments and Contingencies (Tables)
 9 Months Ended
Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]  
Estimated Annual Lease, Royalty and Employment Agreement Expenses
The estimated annual lease payments, meeting space and charitable organization commitments are as follows (in thousands):
12-month period ended September 30,
2017
$
3,156

2018
3,103

2019
2,038

2020
957

Thereafter
550

 
$
9,804
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Basis of Presentation (Details)
 9 Months Ended
Sep. 30, 2016
segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of business segments 1
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
Significant Accounting Policies (Details) - USD ($)
$ in Thousands
 9 Months Ended
Jan. 13, 2016
Sep. 30, 2016
Sep. 30, 2015
Finite-Lived Intangible Assets [Line Items]      
Increase (decrease) in inventories   $ 3,599 $ 520
Amortization of inventory fair value step-up   1,471 0
Patents      
Finite-Lived Intangible Assets [Line Items]      
Intangible assets, net of accumulated amortization   515 $ 594
Fair Value Adjustment to Inventory      
Finite-Lived Intangible Assets [Line Items]      
Increase (decrease) in inventories $ 2,100 $ 600  
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
Liquidity and Management's Plans (Details) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Sep. 30, 2015
Dec. 31, 2014
Liquidity and management's plans [Abstract]        
Cash and cash equivalents $ 18,338 $ 28,486 $ 41,073 $ 46,582
Total current assets 106,290 96,310    
Total current liabilities $ 41,578 $ 26,777    
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisition of Stability Inc. - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jan. 13, 2016
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Business Acquisition [Line Items]          
Amortization of intangible assets   $ 631 $ 234 $ 1,889 $ 699
Net income   3,406 $ 4,253 7,074 12,227
Fair Value Adjustment to Inventory          
Business Acquisition [Line Items]          
Net income         1,471
Pro Forma          
Business Acquisition [Line Items]          
Amortization of intangible assets         $ 1,186
Stability Biologics, LLC          
Business Acquisition [Line Items]          
Cash paid at closing $ 6,000        
Common stock issued $ 3,346        
Common stock issued (in shares) 441,009        
Assumed debt $ 1,771        
Acquisition related costs 1,088        
Fair value of earn-out 25,620 $ 25,620   $ 25,620  
Stability Biologics, LLC | Selling, general and administrative          
Business Acquisition [Line Items]          
Acquisition related costs $ 1,088        
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisition of Stability Inc. - Preliminarily Allocation of Purchase Price (Details) - USD ($)
$ / shares in Units, $ in Thousands
Jan. 13, 2016
Sep. 30, 2016
Dec. 31, 2015
Net assets acquired:      
Goodwill   $ 26,951 $ 4,040
Stability Biologics, LLC      
Business Combination, Consideration Transferred [Abstract]      
Cash paid at closing $ 6,000    
Working capital adjustment (480)    
Common stock issued (441,009 shares valued at $9.07 per share) $ 3,346    
Common stock issued (in shares) 441,009    
Common stock issued, price per share (in dollars per share) $ 9.07    
Assumed debt $ 1,771    
Fair value of earn-out 25,620 $ 25,620  
Total fair value of purchase price 36,257    
Net assets acquired:      
Debt-free working capital 2,179    
Other assets, net 199    
Property, plant and equipment 1,375    
Deferred tax liability (8,268)    
Subtotal (4,515)    
Subtotal 17,860    
Goodwill 22,912    
Total Assets Purchased 36,257    
Cash 140    
Prepaid Expenses and other current assets 100    
Accounts receivable 2,001    
Federal and state taxes receivable 28    
Inventory 8,725    
Accounts payable and accrued expenses (8,815)    
Debt-free working capital 2,179    
Current portion of long term debt (194)    
Net working capital 408    
Other long term assets 199    
Stability Biologics, LLC | Long-term debt      
Net assets acquired:      
Long-term debt (560)    
Stability Biologics, LLC | Line of Credit      
Net assets acquired:      
Long-term debt (932)    
Stability Biologics, LLC | Shareholder loan      
Net assets acquired:      
Long-term debt (85)    
Stability Biologics, LLC | Trade names and trademarks      
Net assets acquired:      
Indefinite-lived intangible assets 830    
Stability Biologics, LLC | Customer relationships      
Net assets acquired:      
Finite-Lived intangibles assets 6,090    
Stability Biologics, LLC | Patents and know-how      
Net assets acquired:      
Finite-Lived intangibles assets 9,170    
Stability Biologics, LLC | Non compete agreements      
Net assets acquired:      
Finite-Lived intangibles assets 1,080    
Stability Biologics, LLC | Licenses and permits      
Net assets acquired:      
Finite-Lived intangibles assets $ 690    
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisition of Stability Inc. - Intangible Assets Acquired as Part of Acquisition (Details) - Stability Biologics, LLC
Jan. 13, 2016
Customer relationships  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful life (in years) 12 years
Patents and know-how  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful life (in years) 20 years
Non compete agreements  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful life (in years) 4 years
Licenses and permits  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful life (in years) 2 years
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisition of Stability Inc. - Pro Forma Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Business Combinations [Abstract]        
Revenue $ 64,429 $ 52,108 $ 175,687 $ 148,521
Net income $ 3,406 $ 4,253 $ 7,074 $ 12,227
Income per share, fully diluted (in dollars per share) $ 0.03 $ 0.04 $ 0.06 $ 0.11
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.5.0.2
Short Term Investments (Details) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Investment [Line Items]    
Short term investments $ 0 $ 3,000
Certificates of Deposit    
Investment [Line Items]    
Short term investments   $ 3,000
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.5.0.2
Inventories (Details) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Inventory Disclosure [Abstract]    
Raw materials $ 1,193 $ 602
Work in process 6,710 3,850
Finished goods 11,118 3,405
Inventory, gross 19,021 7,857
Reserve for obsolescence (708) (397)
Inventory, net $ 18,313 $ 7,460
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment - Summary of Property and Equipment (Details) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 21,130 $ 14,454
Less accumulated depreciation (7,373) (4,979)
Property and equipment, net 13,757 9,475
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 3,259 2,684
Lab and clean room equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 7,971 4,564
Furniture and office equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 6,271 4,577
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 3,629 $ 2,629
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Property, Plant and Equipment [Line Items]          
Property and equipment, net of accumulated depreciation $ 13,757   $ 13,757   $ 9,475
Other liabilities $ 832   $ 832   $ 1,148
Capital leases interest rate effective percentage, minimum 3.00%   3.00%    
Capital leases interest rate effective percentage, maximum 12.00%   12.00%    
Depreciation $ 838 $ 470 $ 2,394 $ 1,247  
Assets Held under Capital Leases          
Property, Plant and Equipment [Line Items]          
Property and equipment, net of accumulated depreciation 427   427    
Other liabilities 41   41    
Leasehold Improvements Paid by Others          
Property, Plant and Equipment [Line Items]          
Property and equipment, net of accumulated depreciation $ 1,000   $ 1,000    
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangible Assets and Royalty Agreement - Summary of Intangible Assets (Details) - USD ($)
 9 Months Ended
Jan. 29, 2007
Sep. 30, 2016
Jan. 13, 2016
Dec. 31, 2015
Jan. 05, 2011
Finite-Lived Intangible Assets [Line Items]          
Total   $ 34,002,000   $ 15,627,000  
Less Accumulated amortization and impairment charges   (6,753,000)   (4,864,000)  
Net   27,249,000   10,763,000  
Stability Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Fair value of earn-out   $ 25,620,000 $ 25,620,000    
Licenses          
Finite-Lived Intangible Assets [Line Items]          
Weighted average amortization lives   7 years      
Gross carrying value   $ 1,699,000   1,009,000  
Licenses | Stability Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value     690,000    
Licenses | Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.          
Finite-Lived Intangible Assets [Line Items]          
Acquisition price $ 996,000        
Maximum time of approval 30 days        
Fair value of earn-out $ 200,000        
Contingent royalty to be paid to licensor 3.00%        
Annual royalty payment, minimum $ 50,000        
Licenses | Surgical Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value         $ 13,000
Patents and know-how          
Finite-Lived Intangible Assets [Line Items]          
Weighted average amortization lives   19 years      
Gross carrying value   $ 17,211,000   8,001,000  
Patents and know-how | Stability Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value     9,170,000    
Patents and know-how | Surgical Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value         7,690,000
Finite lived intangible assets   $ 40,000      
Customer & supplier relationships          
Finite-Lived Intangible Assets [Line Items]          
Weighted average amortization lives   13 years      
Gross carrying value   $ 9,851,000   3,761,000  
Customer & supplier relationships | Stability Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value     6,090,000    
Customer & supplier relationships | Surgical Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value         3,761,000
Non compete agreements          
Finite-Lived Intangible Assets [Line Items]          
Weighted average amortization lives   4 years      
Gross carrying value   $ 1,080,000   0  
Non compete agreements | Stability Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value     1,080,000    
Tradenames & trademarks          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value, indefinite lived   1,838,000   1,008,000  
Tradenames & trademarks | Stability Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value, indefinite lived     $ 830,000    
Tradenames & trademarks | Surgical Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value, indefinite lived         1,008,000
In process research & development          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value, indefinite lived   25,000   25,000  
In process research & development | Surgical Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value, indefinite lived         $ 25,000
Patents in process          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value, indefinite lived   $ 2,298,000   $ 1,823,000  
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangible Assets and Royalty Agreement - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]        
Amortization of intangible assets $ 631 $ 234 $ 1,889 $ 699
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangible Assets and Royalty Agreement - Estimated Future Amortization Expense for Intangible Assets (Details)
$ in Thousands
Sep. 30, 2016
USD ($)
Estimated future amortization expense [Abstract]  
2016 $ 630
2017 2,430
2018 2,075
2019 2,075
2020 1,805
Thereafter 16,396
Net book value $ 25,411
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.5.0.2
Credit Facility (Details) - Credit Agreement - Revolving Credit Facility - USD ($)
Oct. 12, 2015
Sep. 30, 2016
Debt Instrument [Line Items]    
Maximum borrowing capacity (up to) $ 50,000,000  
Uncommitted incremental facility (up to) 35,000,000  
Debt issuance costs $ 500,000  
Debt term 3 years  
Outstanding line of credit   $ 0
London Interbank Offered Rate (LIBOR) | Minimum    
Debt Instrument [Line Items]    
Basis spread on variable rate 1.50%  
London Interbank Offered Rate (LIBOR) | Maximum    
Debt Instrument [Line Items]    
Basis spread on variable rate 2.25%  
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.5.0.2
Net Income (Loss) Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Computation of basic and diluted net loss per share [Abstract]        
Net income $ 3,321 $ 6,551 $ 6,493 $ 16,068
Denominator for basic earnings per share - weighted average shares (in shares) 105,991,990 106,511,294 105,927,890 106,178,136
Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding (in shares) 6,369,189 8,044,742 6,265,811 7,931,984
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities (in shares) 112,361,179 114,556,036 112,193,701 114,110,120
Income per common share - basic (in dollars per share) $ 0.03 $ 0.06 $ 0.06 $ 0.15
Income per common share - diluted (in dollars per share) $ 0.03 $ 0.06 $ 0.06 $ 0.14
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share (in shares) 6,369,189 8,044,742 6,265,811 7,931,984
Outstanding Stock Options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share (in shares) 5,704,112 7,320,155 5,767,469 7,366,426
Outstanding Warrants        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share (in shares) 0 38,023 0 37,820
Restricted Stock Awards        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share (in shares) 665,077 686,564 498,342 527,738
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity - Stock Incentive Plans (Details)
 9 Months Ended
Sep. 30, 2016
USD ($)
plan
$ / shares
shares
Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of share-based compensation plans | plan 4  
Number of shares [Roll forward]    
Outstanding, beginning of period (in shares) | shares 14,019,629  
Granted (in shares) | shares 0  
Exercised (in shares) | shares (926,010)  
Unvested options forfeited (in shares) | shares (93,097)  
Vested options expired (in shares) | shares (38,354)  
Outstanding, end of period (in shares) | shares 12,962,168  
Vested at end of period (in shares) | shares 11,818,559  
Exercisable options, vested and expected to vest (in shares) | shares 12,937,248  
Weighted-Average Exercise Price [Roll forward]    
Outstanding, weighted average exercise price, beginning of period (in dollars per share) $ 3.62  
Granted, weighted average exercise price (in dollars per share) 0.00  
Exercised, weighted average exercise price (in dollars per share) 2.76  
Unvested options forfeited, weighted-average exercise price (in dollars per share) 6.52  
Vested options expired, weighted-average exercise price (in dollars per share) 6.77  
Outstanding, weighted average exercise price, end of period (in dollars per share) 3.65  
Vested at end of period, weighted average exercise price (in dollars per share) 3.30  
Vested and expected to vest, weighted average exercise price (in dollars per share) $ 3.30  
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 5 years 9 months 7 days  
Vested at end of period, weighted average remaining contractual term (in years) 5 years 7 months 13 days  
Vested and expected to vest, weighted average remaining contractual term (in years) 5 years 7 months 13 days  
Outstanding, aggregate intrinsic value | $ $ 64,153,271  
Vested at end of period, aggregate intrinsic value | $ 62,449,678  
Vested or expected to vest, aggregate intrinsic value | $ 64,120,370  
Exercised options, intrinsic value | $ $ 5,283,449  
Number of outstanding options (in shares) | shares 12,962,168  
Outstanding Options, weighted average remaining contractual term (in years) 5 years 9 months 7 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 3.65  
Number of exercisable options (in shares) | shares 11,818,559  
Exercisable Options, weighted average exercise price (in dollars per share) $ 3.30  
Total unrecognized compensation expense | $ $ 2,150,652  
Fair value options valuation assumptions [Abstract]    
Expected volatility Minimum   54.40%
Expected volatility Maximum   58.10%
Expected life (in years)   6 years
Expected dividend yield   0.00%
Risk-free interest rate Minimum   1.51%
Risk-free interest rate Maximum   1.68%
$0.50 - $0.76    
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 2 years 7 months 6 days  
Exercise Price Range, lower range limit (in dollars per share) $ 0.50  
Exercise Price Range, upper range limit (in dollars per share) $ 0.76  
Number of outstanding options (in shares) | shares 441,429  
Outstanding Options, weighted average remaining contractual term (in years) 2 years 7 months 6 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 0.72  
Number of exercisable options (in shares) | shares 441,429  
Exercisable Options, weighted average exercise price (in dollars per share) $ 0.72  
$0.87 - $1.35    
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 4 years 10 months 24 days  
Exercise Price Range, lower range limit (in dollars per share) $ 0.87  
Exercise Price Range, upper range limit (in dollars per share) $ 1.35  
Number of outstanding options (in shares) | shares 4,397,970  
Outstanding Options, weighted average remaining contractual term (in years) 4 years 10 months 24 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 1.19  
Number of exercisable options (in shares) | shares 4,397,970  
Exercisable Options, weighted average exercise price (in dollars per share) $ 1.19  
$1.40 - $2.45    
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 4 years 2 months 12 days  
Exercise Price Range, lower range limit (in dollars per share) $ 1.40  
Exercise Price Range, upper range limit (in dollars per share) $ 2.45  
Number of outstanding options (in shares) | shares 1,442,424  
Outstanding Options, weighted average remaining contractual term (in years) 4 years 2 months 12 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 1.92  
Number of exercisable options (in shares) | shares 1,442,424  
Exercisable Options, weighted average exercise price (in dollars per share) $ 1.92  
$2.66 - $3.99    
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 6 years 1 month 6 days  
Exercise Price Range, lower range limit (in dollars per share) $ 2.66  
Exercise Price Range, upper range limit (in dollars per share) $ 3.99  
Number of outstanding options (in shares) | shares 889,430  
Outstanding Options, weighted average remaining contractual term (in years) 6 years 1 month 6 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 3.06  
Number of exercisable options (in shares) | shares 889,430  
Exercisable Options, weighted average exercise price (in dollars per share) $ 3.06  
$4.19 - $6.38    
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 6 years 8 months 12 days  
Exercise Price Range, lower range limit (in dollars per share) $ 4.19  
Exercise Price Range, upper range limit (in dollars per share) $ 6.38  
Number of outstanding options (in shares) | shares 3,253,783  
Outstanding Options, weighted average remaining contractual term (in years) 6 years 8 months 12 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 5.36  
Number of exercisable options (in shares) | shares 2,997,303  
Exercisable Options, weighted average exercise price (in dollars per share) $ 5.32  
$6.45 - $9.78    
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 7 years 4 months 24 days  
Exercise Price Range, lower range limit (in dollars per share) $ 6.45  
Exercise Price Range, upper range limit (in dollars per share) $ 9.78  
Number of outstanding options (in shares) | shares 2,431,132  
Outstanding Options, weighted average remaining contractual term (in years) 7 years 4 months 24 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 7.30  
Number of exercisable options (in shares) | shares 1,614,677  
Exercisable Options, weighted average exercise price (in dollars per share) $ 7.23  
$9.90- $10.99    
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 8 years 2 months 12 days  
Exercise Price Range, lower range limit (in dollars per share) $ 9.90  
Exercise Price Range, upper range limit (in dollars per share) $ 10.99  
Number of outstanding options (in shares) | shares 106,000  
Outstanding Options, weighted average remaining contractual term (in years) 8 years 2 months 12 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 10.43  
Number of exercisable options (in shares) | shares 35,326  
Exercisable Options, weighted average exercise price (in dollars per share) $ 10.43  
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity - Restricted Stock Awards (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Dec. 31, 2015
Share-based Compensation [Abstract]            
Share-based compensation expense $ 4,701,000 $ 4,378,000 $ 13,826,000 $ 12,564,000    
Cost of sales            
Share-based Compensation [Abstract]            
Share-based compensation expense 109,000 85,000 300,000 270,000    
Research and development            
Share-based Compensation [Abstract]            
Share-based compensation expense 159,000 202,000 520,000 591,000    
Selling, general and administrative            
Share-based Compensation [Abstract]            
Share-based compensation expense $ 4,433,000 $ 4,091,000 $ 13,006,000 $ 11,703,000    
Restricted Stock Awards            
Number of Shares            
Unvested, Beginning Balance (in shares)     2,613,267      
Granted (in shares)     2,369,876      
Vested (in shares)     (952,910)      
Forfeited (in shares)     (137,575)      
Unvested, Ending Balance (in shares) 3,892,658   3,892,658      
Weighted- Average Grant Date Fair Value            
Unvested, Beginning Balance (in dollars per share) $ 8.54   $ 8.54   $ 8.54 $ 9.14
Granted (in dollars per share)     7.98      
Vested (in dollars per share)     8.75      
Forfeited (in dollars per share)     8.73      
Unvested, Ending Balance (in dollars per share) $ 8.54   $ 8.54      
Total unrecognized stock-based compensation related to time-based, nonvested restricted stock         $ 23,767,731  
Expenses expected to be recognized over a weighted-average period (in years)     2 years      
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity - Treasury Stock (Details) - USD ($)
 9 Months Ended
Sep. 30, 2016
Dec. 31, 2015
Dec. 31, 2014
May 12, 2014
Equity [Abstract]        
Authorized share amount for repurchase (up to)   $ 60,000,000 $ 20,000,000 $ 10,000,000
Stock repurchase (in shares) 1,338,616      
Shares repurchased, value $ 10,338,000      
Brokerage commissions 40,000      
Remaining authorizations under the repurchase program $ 3,936,000      
Shares reissued from the treasury (in shares) 2,854,189      
Shares reissued from the treasury, value $ 23,257,728      
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income taxes (Details) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2016
Dec. 31, 2015
Income Tax Contingency [Line Items]        
Effective tax rate 31.50% 3.20%    
Effective income tax rate increase (decrease), amount $ 900      
Effective income tax rate increase (decrease), percent 28.30%      
Decrease in valuation allowance       $ 15,400
Forecast        
Income Tax Contingency [Line Items]        
Effective tax rate     41.00%  
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.5.0.2
Supplemental disclosure of cash flow and non-cash investing and financing activities (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Supplemental disclosure of cash flow and non-cash investing and financing activities [Abstract]    
Cash paid for interest $ 118 $ 18
Income taxes paid 637 1,506
Stock issuance of 441,009 shares in connection with acquisition $ 3,346 0
Shares issued in conjunction with acquisition (in shares) 441,009  
Retirement of fixed assets $ 0 319
Stock issuances of 43,344 and 16,493 shares in exchange for services performed, respectively $ 346 $ 164
Shares issued for services performed (in shares) 43,344 16,493
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.5.0.2
Contractual Commitments and Contingencies - Narrative (Details)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
Dec. 31, 2015
Jun. 30, 2016
claim
Aug. 18, 2015
claim
Jul. 10, 2015
claim
Jun. 29, 2015
claim
Loss Contingencies [Line Items]                  
Lease expiration period     8 years            
Rent expense | $ $ 453 $ 363 $ 1,311 $ 956          
Pending Litigation                  
Loss Contingencies [Line Items]                  
Number of patent challenged grounds           4      
Pending Litigation | Bone Bank Action                  
Loss Contingencies [Line Items]                  
Number of patent challenged grounds               5 7
Opinion allowing a review of patent               2  
Pending Litigation | Liventa Action, 701 Patent                  
Loss Contingencies [Line Items]                  
Number of patent challenged grounds             6    
Pending Litigation | Liventa Action, 437 Patent                  
Loss Contingencies [Line Items]                  
Number of patent challenged grounds             7    
Opinion allowing a review of patent             1    
Sales Revenue, Net | Product Concentration Risk                  
Loss Contingencies [Line Items]                  
Percentage of revenue         12.00%        
Standby Letters of Credit                  
Loss Contingencies [Line Items]                  
Standby letters of credit | $ $ 103   $ 103            
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.5.0.2
Contractual Commitments and Contingencies - Estimated Annual Lease Payments (Details)
$ in Thousands
Sep. 30, 2016
USD ($)
Estimated annual lease, royalty, and employment agreement expenses [Abstract]  
2017 $ 3,156
2018 3,103
2019 2,038
2020 957
Thereafter 550
Total Contractual commitments $ 9,804
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.5.0.2
Schedule II - Valuation and Qualifying Accounts (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Allowance for doubtful accounts        
Movement in Valuation Allowances and Reserves [Roll Forward]        
Balance at Beginning of Period $ 4,086 $ 2,504 $ 3,270 $ 1,750
Additions charged to Expense or Revenue 800 800 1,635 1,560
Deductions and write-offs (536) (172) (555) (178)
Balance at End of Period 4,350 3,132 4,350 3,132
Allowance for product returns        
Movement in Valuation Allowances and Reserves [Roll Forward]        
Balance at Beginning of Period 2,191 1,030 1,262 841
Additions charged to Expense or Revenue 2,591 906 5,917 2,349
Deductions and write-offs (2,520) (407) (4,917) (1,661)
Balance at End of Period 2,262 1,529 2,262 1,529
Allowance for obsolescence        
Movement in Valuation Allowances and Reserves [Roll Forward]        
Balance at Beginning of Period 1,780 553 397 527
Additions charged to Expense or Revenue 339 227 1,910 447
Deductions and write-offs (1,411) (87) (1,599) (281)
Balance at End of Period $ 708 $ 693 $ 708 $ 693
EXCEL 67 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO=V]R:W-H965T&UL4$L! A0#% @ _(%H2:#. M8VRD 0 L0, !D ( !D%$ 'AL+W=O&PO=V]R:W-H965T-HP$ +$# 9 " 4]5 !X;"]W;W)K&UL4$L! A0#% @ _(%H22H(2\/6 0 104 !D M ( !*5< 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ _(%H25$JE">F 0 L0, !D ( ! MYUP 'AL+W=O&PO=V]R:W-H965TEKZT^P$ , % 9 M " 0UA !X;"]W;W)K&UL4$L! A0#% M @ _(%H2;!1B K. @ U@L !D ( !/V, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ _(%H2?UZ9'YI @ %PD !D M ( !G', 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ _(%H24XZ$Y'Z 0 :P4 !D ( !0GX M 'AL+W=OHTW M\N0! "D!0 &0 @ %S@ >&PO=V]R:W-H965T&UL4$L! A0#% @ M_(%H2<)QY_*$ P *@\ !D ( !T80 'AL+W=O&PO=V]R:W-H965TF/ !X;"]W M;W)K&UL4$L! A0#% @ _(%H23Z\B^E5 @ M@ < !D ( !T), 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ _(%H20^I(14L P 5@X !D M ( !4YL 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ _(%H25W6VIJ69 ^&\! !0 ( !@*0 'AL H+W-H87)E9%-T&UL4$L%!@ ! $ XML 68 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 69 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 71 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 166 286 1 false 57 0 false 7 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://mimedx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://mimedx.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://mimedx.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 2101100 - Disclosure - Basis of Presentation Sheet http://mimedx.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 2102100 - Disclosure - Significant Accounting Policies Sheet http://mimedx.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 2103100 - Disclosure - Liquidity and Management's Plans Sheet http://mimedx.com/role/LiquidityAndManagementsPlans Liquidity and Management's Plans Notes 9 false false R10.htm 2104100 - Disclosure - Acquisition of Stability Inc. Sheet http://mimedx.com/role/AcquisitionOfStabilityInc Acquisition of Stability Inc. Notes 10 false false R11.htm 2105100 - Disclosure - Short Term Investments Sheet http://mimedx.com/role/ShortTermInvestments Short Term Investments Notes 11 false false R12.htm 2106100 - Disclosure - Inventories Sheet http://mimedx.com/role/Inventories Inventories Notes 12 false false R13.htm 2107100 - Disclosure - Property and Equipment Sheet http://mimedx.com/role/PropertyAndEquipment Property and Equipment Notes 13 false false R14.htm 2108100 - Disclosure - Intangible Assets and Royalty Agreement Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreement Intangible Assets and Royalty Agreement Notes 14 false false R15.htm 2109100 - Disclosure - Credit Facility Sheet http://mimedx.com/role/CreditFacility Credit Facility Notes 15 false false R16.htm 2110100 - Disclosure - Net Income (Loss) Per Share Sheet http://mimedx.com/role/NetIncomeLossPerShare Net Income (Loss) Per Share Notes 16 false false R17.htm 2111100 - Disclosure - Equity Sheet http://mimedx.com/role/Equity Equity Notes 17 false false R18.htm 2112100 - Disclosure - Income taxes Sheet http://mimedx.com/role/IncomeTaxes Income taxes Notes 18 false false R19.htm 2114100 - Disclosure - Supplemental disclosure of cash flow and non-cash investing and financing activities Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivities Supplemental disclosure of cash flow and non-cash investing and financing activities Notes 19 false false R20.htm 2115100 - Disclosure - Contractual Commitments and Contingencies Sheet http://mimedx.com/role/ContractualCommitmentsAndContingencies Contractual Commitments and Contingencies Notes 20 false false R21.htm 2116100 - Disclosure - Subsequent Events Sheet http://mimedx.com/role/SubsequentEvents Subsequent Events Notes 21 false false R22.htm 2117100 - Schedule - Schedule II - Valuation and Qualifying Accounts Sheet http://mimedx.com/role/ScheduleIiValuationAndQualifyingAccounts Schedule II - Valuation and Qualifying Accounts Uncategorized 22 false false R23.htm 2202201 - Disclosure - Significant Accounting Policies (Policies) Sheet http://mimedx.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Uncategorized 23 false false R24.htm 2304301 - Disclosure - Acquisition of Stability Inc. (Tables) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncTables Acquisition of Stability Inc. (Tables) Uncategorized 24 false false R25.htm 2306301 - Disclosure - Inventories (Tables) Sheet http://mimedx.com/role/InventoriesTables Inventories (Tables) Uncategorized 25 false false R26.htm 2307301 - Disclosure - Property and Equipment (Tables) Sheet http://mimedx.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Uncategorized 26 false false R27.htm 2308301 - Disclosure - Intangible Assets and Royalty Agreement (Tables) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementTables Intangible Assets and Royalty Agreement (Tables) Uncategorized 27 false false R28.htm 2310301 - Disclosure - Net Income (Loss) Per Share (Tables) Sheet http://mimedx.com/role/NetIncomeLossPerShareTables Net Income (Loss) Per Share (Tables) Uncategorized 28 false false R29.htm 2311301 - Disclosure - Equity (Tables) Sheet http://mimedx.com/role/EquityTables Equity (Tables) Uncategorized 29 false false R30.htm 2314301 - Disclosure - Supplemental disclosure of cash flow and non-cash investing and financing activities (Tables) Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesTables Supplemental disclosure of cash flow and non-cash investing and financing activities (Tables) Uncategorized 30 false false R31.htm 2315301 - Disclosure - Contractual Commitments and Contingencies (Tables) Sheet http://mimedx.com/role/ContractualCommitmentsAndContingenciesTables Contractual Commitments and Contingencies (Tables) Uncategorized 31 false false R32.htm 2401401 - Disclosure - Basis of Presentation (Details) Sheet http://mimedx.com/role/BasisOfPresentationDetails Basis of Presentation (Details) Uncategorized 32 false false R33.htm 2402402 - Disclosure - Significant Accounting Policies (Details) Sheet http://mimedx.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Uncategorized 33 false false R34.htm 2403401 - Disclosure - Liquidity and Management's Plans (Details) Sheet http://mimedx.com/role/LiquidityAndManagementsPlansDetails Liquidity and Management's Plans (Details) Uncategorized 34 false false R35.htm 2404402 - Disclosure - Acquisition of Stability Inc. - Narrative (Details) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncNarrativeDetails Acquisition of Stability Inc. - Narrative (Details) Uncategorized 35 false false R36.htm 2404403 - Disclosure - Acquisition of Stability Inc. - Preliminarily Allocation of Purchase Price (Details) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncPreliminarilyAllocationOfPurchasePriceDetails Acquisition of Stability Inc. - Preliminarily Allocation of Purchase Price (Details) Uncategorized 36 false false R37.htm 2404404 - Disclosure - Acquisition of Stability Inc. - Intangible Assets Acquired as Part of Acquisition (Details) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncIntangibleAssetsAcquiredAsPartOfAcquisitionDetails Acquisition of Stability Inc. - Intangible Assets Acquired as Part of Acquisition (Details) Uncategorized 37 false false R38.htm 2404405 - Disclosure - Acquisition of Stability Inc. - Pro Forma Information (Details) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncProFormaInformationDetails Acquisition of Stability Inc. - Pro Forma Information (Details) Uncategorized 38 false false R39.htm 2405401 - Disclosure - Short Term Investments (Details) Sheet http://mimedx.com/role/ShortTermInvestmentsDetails Short Term Investments (Details) Uncategorized 39 false false R40.htm 2406402 - Disclosure - Inventories (Details) Sheet http://mimedx.com/role/InventoriesDetails Inventories (Details) Uncategorized 40 false false R41.htm 2407402 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details) Sheet http://mimedx.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails Property and Equipment - Summary of Property and Equipment (Details) Uncategorized 41 false false R42.htm 2407403 - Disclosure - Property and Equipment - Narrative (Details) Sheet http://mimedx.com/role/PropertyAndEquipmentNarrativeDetails Property and Equipment - Narrative (Details) Uncategorized 42 false false R43.htm 2408402 - Disclosure - Intangible Assets and Royalty Agreement - Summary of Intangible Assets (Details) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementSummaryOfIntangibleAssetsDetails Intangible Assets and Royalty Agreement - Summary of Intangible Assets (Details) Uncategorized 43 false false R44.htm 2408403 - Disclosure - Intangible Assets and Royalty Agreement - Narrative (Details) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementNarrativeDetails Intangible Assets and Royalty Agreement - Narrative (Details) Uncategorized 44 false false R45.htm 2408404 - Disclosure - Intangible Assets and Royalty Agreement - Estimated Future Amortization Expense for Intangible Assets (Details) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails Intangible Assets and Royalty Agreement - Estimated Future Amortization Expense for Intangible Assets (Details) Uncategorized 45 false false R46.htm 2409401 - Disclosure - Credit Facility (Details) Sheet http://mimedx.com/role/CreditFacilityDetails Credit Facility (Details) Uncategorized 46 false false R47.htm 2410402 - Disclosure - Net Income (Loss) Per Share (Details) Sheet http://mimedx.com/role/NetIncomeLossPerShareDetails Net Income (Loss) Per Share (Details) Uncategorized 47 false false R48.htm 2411402 - Disclosure - Equity - Stock Incentive Plans (Details) Sheet http://mimedx.com/role/EquityStockIncentivePlansDetails Equity - Stock Incentive Plans (Details) Uncategorized 48 false false R49.htm 2411403 - Disclosure - Equity - Restricted Stock Awards (Details) Sheet http://mimedx.com/role/EquityRestrictedStockAwardsDetails Equity - Restricted Stock Awards (Details) Uncategorized 49 false false R50.htm 2411404 - Disclosure - Equity - Treasury Stock (Details) Sheet http://mimedx.com/role/EquityTreasuryStockDetails Equity - Treasury Stock (Details) Uncategorized 50 false false R51.htm 2412401 - Disclosure - Income taxes (Details) Sheet http://mimedx.com/role/IncomeTaxesDetails Income taxes (Details) Uncategorized 51 false false R52.htm 2414402 - Disclosure - Supplemental disclosure of cash flow and non-cash investing and financing activities (Details) Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesDetails Supplemental disclosure of cash flow and non-cash investing and financing activities (Details) Uncategorized 52 false false R53.htm 2415402 - Disclosure - Contractual Commitments and Contingencies - Narrative (Details) Sheet http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails Contractual Commitments and Contingencies - Narrative (Details) Uncategorized 53 false false R54.htm 2415403 - Disclosure - Contractual Commitments and Contingencies - Estimated Annual Lease Payments (Details) Sheet http://mimedx.com/role/ContractualCommitmentsAndContingenciesEstimatedAnnualLeasePaymentsDetails Contractual Commitments and Contingencies - Estimated Annual Lease Payments (Details) Uncategorized 54 false false R55.htm 2417401 - Schedule - Schedule II - Valuation and Qualifying Accounts (Details) Sheet http://mimedx.com/role/ScheduleIiValuationAndQualifyingAccountsDetails Schedule II - Valuation and Qualifying Accounts (Details) Uncategorized 55 false false All Reports Book All Reports mdxg-20160930.xml mdxg-20160930.xsd mdxg-20160930_cal.xml mdxg-20160930_def.xml mdxg-20160930_lab.xml mdxg-20160930_pre.xml true true ZIP 73 0001376339-16-000213-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001376339-16-000213-xbrl.zip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